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Several of the multitude of functions attributed to Vascular Endothelial Growth Factor-A 
(VEGF-A)  are  coordinated by  its  various isoforms,  which  are  generated  as  a result of 
alternative splicing from a single gene. Despite the fact that the VEGF isoforms exhibit 
distinct biochemical properties,  little has been done to  clarify their  functions  and their 
contributions to physiological and pathological processes.
In this thesis  I  describe the biochemical  and biological  characterization of the heparin- 
binding domain of mouse VEGF 164 through structure-function analysis. To investigate the 
functional  significance  of heparin  binding,  mutations  were  introduced  into  exon  7  of 
VEGF 164  to  identify  essential  residues  for  heparin  binding.  Three  key  amino  acids 
involved in this interaction were identified. Mutants with alterations in these amino acids 
were unable to bind heparin and were compromised in their ability to bind to cell-surface 
heparan  sulfate.  These  mutants,  however,  retained  wild-type  like  potency  in  inducing 
tissue  factor  expression  in  vitro  and  micro  vessel  growth  ex  vivo,  and  maintained  the 
capacity to bind to the receptors neuropilin-1, VEGFR-1, and VEGFR-2.
A  second  goal  of this  work  was  to  better  define  the  role  of VEGF 164  in  mediating 
inflammatory  processes  during  pathological  vascularization  of the  retina.  Analysis  of
i on/iso
VEGF 164-deficient  (VEGF  )  mice  subjected  to  neovascularization-inducing 
conditions and rats injected intravitreally with recombinant VEGF variants demonstrated 
that  endogenous  and  exogenous  VEGF 164  increases  leukocyte  adhesiveness  to  retinal 
vessels compared to the non-heparin-binding isoform, VEGF 120.  Interestingly, the three 
basic residues that confer heparin binding of VEGF 164, appear to be critical for its pro- 
inflammatory activity, but not for its angiogenic activity.  In addition, both mutants (and 
VEGF 120) exhibited a reduced affinity for VEGFR-1, a leukocyte-expressed receptor that 
mediates VEGF-induced migration. Results of in vivo experiments using P1GF, VEGF-E, 
as well as a VEGFR-1 neutralizing antibody, further demonstrate a role for VEGFR-1  in 
retinal leukostasis.
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1.1 Vascular structure and development
The endothelium-lined vasculature is the first functional organ to form during embryonic 
development  of  vertebrates.  A  complex  network  of  endothelial  and  supporting  peri- 
endothelial cells perfuses all tissues in the body, satisfying the essential need for exchange 
of  oxygen,  nutrients  and  metabolic  wastes  between  blood  and  tissues.  Dysregulated 
formation of the vascular network is often lethal early in embryonic development, while 
abnormal  vessel  growth,  particularly  excessive  angiogenesis,  in  the  adult  organism 
contributes to the pathogenesis of many disorders.
All  blood  vessels  consist  of  at  least  two  different  cell  types,  endothelial  cells  and 
supporting mural cells. Endothelial cells form a single layer that lines the entire length of 
the  vessel  lumen  and  therefore  serve  as  an  interface  between  blood  and  the  tissues. 
Because  most  of  the  exchange  of particles  between  blood  and  tissue  occurs  in  the 
capillaries,  the  capillary  endothelial  cells  often  exhibit  remarkable  morphological  and 
functional heterogeneity in order to accommodate local physiological requirements [1]. For 
example, endothelial cells in the brain interact with astroglial cells, and the presence of 
tight junctions between continuous endothelial cells is  essential  for maintenance of the 
blood-brain barrier. On the other hand, capillaries of certain organs are discontinuous and 
highly fenestrated.  This  ensures  efficient  filtration  in the kidney  glomeruli,  and  allows 
exchange of metabolites and processing of toxins in the liver [2-5].
Vessel heterogeneity is also evident with regard to vessel wall coverage. Once endothelial 
cells have formed patent tubes, mural cells -  that is, pericytes or smooth muscle cells -  are
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recruited to form the vascular wall. In large vessels, such as arteries and veins, multiple 
layers of vascular smooth muscle cells surround the endothelial tubes to provide structural 
support and contractile ability. In capillary beds, small vessels are covered by a single layer 
of specialized mural cells called pericytes.  The association of smooth muscle cells and 
pericytes  with  newly  formed  vessels  is  essential  for  vascular  maturation.  These  peri- 
endothelial cells control  blood flow,  regulate vascular branching  and permeability,  and 
protect vessels against rupture and regression [6]. Indeed, insufficient recruitment of mural 
cells results in leaky and fragile vessels, which are prone to bleeding and ultimately regress
[7]-
The endothelium is supported by a basal lamina, which separates the endothelial cell layer 
from  the  mural  cells.  The  extracellular  matrix  provides  necessary  contacts  between 
endothelial  cells  and  the  surrounding  tissues  and  consists  mainly  of  proteoglycans, 
collagen fibers, and multiadhesive matrix proteins. Remodeling of the extracellular matrix 
by proteinases plays a key role in regulating vessel sprouting and pruning. Matrix-bound 
growth  factors  and  chemokines  are  released  that  can promote  or  inhibit  angiogenesis. 
Furthermore,  proteinases  are  able  to  expose  cryptic  epitopes  or  generate  fragments  of 
extracellular matrix components, which then regulate angiogenesis [8]. The endothelium 
and mural cells, together with the basement membrane, form the basic architecture of the 
vessel. Through reciprocal interactions between the cells of the vasculature and their local 
environment,  including  the  extracellular matrix  and parenchymal  cells,  vessels  acquire 
specialized functions in different vascular beds [9].
The assembly of blood vessels is commonly thought to occur through two mechanisms: 
vasculogenesis,  the  de  novo  formation  of blood  vessels  from  angioblasts,  which  are
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mesoderm-derived endothelial cell precursors that differentiate into endothelial cells and 
assemble a primary capillary plexus [10], and angiogenesis, the generation of new blood 
vessels via sprouting and branching from pre-existing capillaries [2,  11]. Vasculogenesis 
describes the establishment of the primary, albeit immature and poorly functional, vascular 
network,  whereas  the  expansion  and  remodeling  of this  network  is  accomplished  by 
angiogenesis.  Because the vasculature is usually quiescent in the  adult,  growth of new 
blood vessels rarely occurs at this stage.  The few adult tissues that do require ongoing 
angiogenesis  include  the  female  reproductive  organs  and  injured  tissues.  In  addition, 
physiological organ growth and increases in vascular density in cardiac and skeletal muscle 
also depend on angiogenesis [12-15]. As a whole, physiological angiogenesis in the adult 
is a highly regulated process in which the new vessels rapidly mature, becoming stable and 
quiescent. By contrast, uncontrolled angiogenesis often occurs in pathological conditions, 
with  abnormal  vessel  patterns  and  morphology  due  to  an  imbalance  of  pro-  and 
antiangiogenic signals [16]. Well-known examples of pathological angiogenesis occur in 
cancer,  psoriasis,  arthritis  and  diseases  in  the  back  of the  eye,  often  associated  with 
blindness [17].
While in humans most organs are vascularized before birth, vascularization of the mouse 
retina occurs postnatally and can therefore be used to model physiological angiogenesis. 
Immediately after birth the superficial vascular system starts to develop, originating from 
the optic nerve and extending radially along the vitreoretinal interface to fill the peripheral 
avascular  retina.  This  vascularization  is  guided  by  vascular  endothelial  growth  factor 
(VEGF)-secreting astrocytes [18]. Around postnatal day (P) 7, vessels then invade into the 
retina by sprouting to form the intermediary and deep capillary beds. This creates a three­
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dimensional network consisting of three horizontal microvessel layers, as well as vertical 
connecting  capillaries.  Finally,  selective  pruning  of  retinal  capillaries  immediately 
following formation of the primary vascular plexus, in response to various factors such as 
hyperoxia and immune cells, leaves behind a remodeled, smaller-caliber vasculature with 
distinct hierarchy of vessel size [19, 20]. Because of its accessibility for manipulation, the 
neonatal retina has been increasingly used as a model for studying molecular and cellular 
mechanisms of blood vessel development,  both during normal development and during 
progression of retinopathies [21, 22] (and references therein).
1.2 The multifunctional role of VEGF
VEGF  and  its receptors  (VEGFR-1-3)  form  a paracrine  system that  is  likely the most 
important  in  controlling  vascular  development  and  neovascularization.  This  system 
controls physiological and pathological vascularization, in both the embryo and the adult 
[23].  Several  lines  of evidence  can  be  put  forward  in  support  of this  view.  Firstly, 
expression patterns of VEGF and its receptors correlate both temporally and spatially with 
areas of vascular growth in developing embryos [24-26]. Secondly, embryos lacking either 
VEGF or one of its receptors fail to develop functional vessels [27-31]. Thirdly, VEGF is 
haplo-insufficient;  the  lack  of  even  one  allele  results  in  severe  disruption  of  vessel 
development  and  embryonic  lethality,  suggesting  that  the  correct  dosage  of VEGF  is 
critical for normal vascular development [27, 28, 32]. Fourthly, VEGF levels are increased 
in conditions involving pathological angiogenesis [33]. Lastly, antagonists of VEGF or its 
receptors are potent inhibitors of pathological angiogenesis [34-38].
19Chapter 1 Introduction
1.2.1 VEGF: history of the angiogenic “Factor X”
The quest for angiogenic factors in the last decades was mainly driven by the observation 
that neovascularization is involved in the progression of many pathologies,  and by the 
hope  that  identification  of angiogenic  factors  could  lead  to  new  treatments  for  these 
diseases. Based on early observations that some human tumors are highly vascularized and 
that  the  tumor  environment has  an  influence  on  tumor  vessel  characteristics,  Ide  and 
coworkers  found that  the transplantation  of tumors  into  the  rabbit  ear causes a  strong 
neovascular response, which led them to propose that tumor cells release growth factors 
that promote blood vessel formation [33]. In 1945, this hypothesis was advanced in a study 
led by Glenn Algire, who for the first time used a quantitative approach to assess blood 
vessel growth in mice [39]. By counting blood vessels and comparing them to tumor size, 
Algire  and colleagues found that rapid growth in  size of transplanted tumors  followed 
vascular growth; they concluded that the ability to promote vascular proliferation gives the 
tumor increased autonomy compared to normal tissues [39]. Isaac Michaelson was the first 
to hypothesize the existence of an angiogenic ‘Factor X’, which he thought was causal for 
pathologic neovascularization in the retina [39]. Efforts to find this factor culminated in the 
isolation  of highly  purified  protein  from  conditioned  medium  and  subsequent  cDNA 
cloning of VEGF and vascular permeability factor (VPF) by two independent groups in 
1989  [40, 41].  It soon became apparent that VEGF  and VPF were the  same molecule, 
which  was  able  to  mediate  such  seemingly  unrelated  activities  as  endothelial  cell 
mitogenesis  and  vascular permeability.  It  is  now  clear that  VEGF  elicits  an  array  of 
responses by vascular endothelial cells,  including proliferation,  migration, permeability, 
survival, and upregulation of proinflammatory gene expression [33].
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1.2.2 The activities of VEGF
From  the  year  of  its  discovery,  the  role  of  VEGF  in  regulating  angiogenesis  and 
vasculogenesis has been the subject of intense investigation.  Studies have concentrated 
primarily on the roles of this factor during vascular development and in the etiology of 
diseases  that  are  associated  with  abnormal  angiogenesis.  VEGF  promotes  both 
proliferation  and survival  of cultured  endothelial cells  [33].  It  also  induces  growth  and 
sprouting  of  blood  vessels  in  a  number  of  in  vivo  models,  including  the  chick 
chorioallantoic  membrane  assay  [40],  the  Matrigel  plug  in  mice  [42]  and  the  corneal 
pocket assay [43]. Mitogenic signaling is mediated by the ERK/MAPK cascade, which can 
be activated in two ways:  via Ras-dependent induction of the Raf-l/MEK/ERK cascade 
[44,  45]  and  via  Ras-independent  phosphorylation  of  phospholipase  C  (PLC)-y  and 
subsequent activation of the ERK pathway [46-48].
In cell culture assays, the prosurvival effects of VEGF are transduced via VEGFR-2, also 
known as Flk-1,  and mediated mainly by the phosphatidylinositol  (PI)-3  kinase/protein 
kinase B  (Akt) pathway [49,  50].  Akt is highly expressed in endothelial cells,  where it 
inhibits proapoptotic proteins such as Bad and caspase-9 [51]. In vivo, VEGF is essential 
for growth and survival in early postnatal life, but its role in endothelial cell survival in the 
adult animal has been controversial. One group recently reported that depletion of VEGF 
in  adult mice by administration of a neutralizing  antibody or soluble VEGFR-1  causes 
proteinuria  and  glomerular  endothelial  cell  detachment  [52].  However,  other  studies 
suggest  that VEGF  inhibition has  no  significant  effect on  glomerular function  in  fully 
developed  healthy  mice,  though  it  may  be  important  for  the  regeneration  of  injured 
glomerular endothelial cells [53, 54].
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In  addition  to  promoting  proliferation  and  survival,  VEGF  induces  the  migration  of 
endothelial  cells  and  other  cell  types,  including  hematopoietic  stem  cells,  monocytes, 
osteoblasts  and,  as  recently  shown,  branchiomotor  neurons  [55-59],  Upon  VEGF 
stimulation,  endothelial  cells  migrate  into  perivascular  areas,  a  process  that  requires 
cytoskeletal reorganization and localized degradation of the extracellular matrix.  VEGF 
forms  a  chemotactic  gradient  to  attract  endothelial  cells,  and  upregulates  or  activates 
proteolytic enzymes to promote tissue invasion. The chemotactic role of VEGF appears to 
be  evolutionarily  conserved.  In Drosophila,  VEGF  controls  the  migration  of VEGFR- 
expressing blood cells, indicating an ancestral role for this factor in hematopoiesis [60]. In 
a recent study, Ruhrberg et al. have shown that blood vessel tips extend along rising VEGF 
concentration gradients in the midline region of the developing mouse hindbrain [61, 62]. 
Disruption of these gradients clearly impaired the directed extension of vessel tip filopodia, 
resulting in vessel branching defects [61, 62]. VEGF is also a potent chemoattractant for 
monocytes,  a  cell  type  implicated  in  pathological  angiogenesis,  and  can  both  activate 
monocytes and induce monocyte chemotaxis across endothelial cell monolayers [58].
Endothelial  cells  accommodate  the  specific  needs  of  certain  surrounding  tissues  by 
displaying  specialized  characteristics,  and  VEGF  levels  likely  mediate  these  specific 
endothelial  phenotypes.  In  particular,  degrees  of  vascular  permeability  have  been 
correlated with differing levels of VEGF expression. The permeability of the blood-brain- 
barrier  endothelium  must  be  low  in  order to  ensure  a tight  barrier that  prevents  toxic 
substances from entering the brain. VEGF expression levels in the brain are dramatically 
decreased in the adult compared to levels during embryonic angiogenesis [63]. Conversely, 
the  vessels  of the  kidney  must  maintain  a  high  level  of permeability  to  facilitate  the
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exchange of metabolites, and VEGF and its receptors are highly expressed in this adult 
tissue [64]. In the kidney glomerulus, where fluid filtration occurs, and in endocrine organs, 
which secrete particles into the blood, endothelial cells are discontinuous and fenestrated 
[65]. Fenestrae are circular membrane pores, usually containing a diaphragm, that span the 
entire thickness of highly attenuated endothelia and thus provide a route for transcellular 
permeability  [66].  VEGF  promotes  the  formation  of fenestrae,  either  when  added  to 
cultured  endothelial  cells  or  when  injected  into  certain  tissues  [65,  67].  While  the 
molecular mechanisms for this process are almost completely unknown, the rapidness of 
the  induction  suggests  that  fenestrae  formation  relies  on  reorganization  of pre-existing 
cytoskeletal components rather than de novo gene transcription.
1.2.3  Regulation of VEGF expression
In  vitro,  several  mechanisms  have  been  shown  to  regulate  the  expression  of VEGF, 
including growth factors and cytokines, cellular transformation, and low oxygen tension 
[23, 68, 69]. Cytokines and growth factors that induce VEGF mRNA expression or VEGF 
release  in  cultured  cells  include  epidermal  growth  factor  (EGF),  transforming  growth 
factor-p (TGF-P), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF)- 
1  and stromal-derived factor (SDF)-l [70-74]. Certain pro-inflammatory cytokines, such as 
tumor  necrosis  factor-a  (TNF-a),  interleukin  (IL)-6  and  IL-lp,  induce  expression  of 
VEGF,  suggesting  a  role  for  VEGF  as  mediator  in  inflammatory  disorders  [75-77]. 
Although  these  pro-inflammatory  cytokines  lack  direct  angiogenic  effects,  many  can 
indirectly induce angiogenesis through upregulation of VEGF. In addition, some of these 
factors  are upregulated by VEGF,  suggesting autocrine and paracrine  loop  mechanisms
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that may potentiate VEGF effects. The relevance of these indirect angiogenic stimulants 
for normal and pathological angiogenesis has yet to be fully examined.
Certain transforming events can also modulate VEGF expression. The von Hippel-Lindau 
(VHL) tumor suppressor gene encodes the vHL protein, an inhibitor of hypoxia-regulated 
proteins.  Mutations  in  VHL  result  in  increased  expression  of  VEGF  in  cerebellar 
hemangioblastomas  and  human  renal  carcinomas  [78,  79].  VEGF  expression  is  also 
increased following loss of the wild-type tumor suppressor gene p53,  and as a result of 
mutation or overexpression of H-ras, v-src, or v-raf during transformation of fibroblasts or 
epithelial cells [80-82]. Because tumor growth usually depends on angiogenesis, genetic 
changes that favor VEGF expression promote rapid and sustained tissue growth.
The third type of signal that regulates VEGF expression, low oxygen tension or hypoxia, is 
the  most  important  inducer  of VEGF  gene  expression.  Indeed,  virtually  all  cell  types 
increase  VEGF  expression  under  hypoxic  conditions  [83,  84].  Hypoxia-induced 
upregulation of VEGF is a fundamental physiological mechanism to  adapt the vascular 
network  to  low  tissue  oxygenation  both  in  the  growing  and  physiologically  hypoxic 
embryo,  and  in  response  to  pathological  circumstances  in  the  adult  organism  such  as 
chronic hypoxia or ischemic insults [85,  86].  A well-characterized example of hypoxia- 
induced VEGF production in developmental organogenesis is the formation of the retinal 
vascular network.  As  astrocytes  and  other neuroglial  cells  migrate  away  from  existing 
blood vessels in the developing retina, they encounter increasingly hypoxic conditions and 
in response secrete increasing  levels  of VEGF.  The VEGF  concentration gradient  thus 
resulting  allows  new  blood  vessels  to  grow  toward  the  VEGF  source,  following  the
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migration of the astrocytes until the oxygen demand is accommodated [87]. Upregulation 
of VEGF under hypoxic conditions is achieved by activation of two transcription factors, 
hypoxia-inducible factor (HIF)-l and -2, and by an increase in VEGF mRNA stability [88- 
91].  The protein  levels of the HIF-la  subunit are downregulated in normoxic  cells by 
ubiquitination  and  proteasomal  degradation,  a  process  that  is  mediated  by  the  tumor 
suppressor vHL  [92].  When  activated  by  low  oxygen  tension,  HIF-1  accumulates  and 
translocates to the nucleus, where it binds to the hypoxia response element (HRE) located 
in the 5’  and 3’  untranslated region (UTR) of the VEGF gene, resulting in activation of 
VEGF gene transcription [85]. The important role of HIF-1 in mediating VEGF expression 
during embryonic development and tumor angiogenesis has been confirmed by targeted 
disruption of the HIF-la gene [93, 94].  Loss of the HIF-la gene in these mice reduces 
hypoxia-induced expression of VEGF. In addition to transcriptional control, VEGF levels 
under hypoxic conditions are increased via regulation of mRNA stability. This increased 
stabilization occurs when as yet unidentified proteins bind to the 3’  UTR of the VEGF 
mRNA, thereby preventing normal turnover of the VEGF transcript [95, 96].
1.3 Biochemical and biological properties of VEGF
1.3.1 VEGF gene structure and splice forms
VEGF-A  (henceforth  referred  to  as  VEGF)  is  the  most  prominent  member  of  the 
PDGF/VEGF  family  of growth  factors,  a  family that  includes  placental  growth  factor 
(P1GF), VEGF-B, VEGF-C, VEGF-D, the ORF virus-derived VEGF-E variants, and the 
recently identified VEGF-F  [97-99].  VEGFs are present in all vertebrate species with a 
high  degree  of  sequence  homology.  Homologues  have  been  found  in  invertebrates,
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including  Drosophila,  C.  elegans  and  jellyfish,  pointing  to  a  role  for  VEGF  in 
orchestrating elemental developmental functions [100-102]. The human VEGF gene spans 
approximately 14 kb and contains eight exons separated by seven introns [103,  104]. At 
least five isoforms of 121, 145, 165, 189 and 206 amino acids after signal peptide cleavage 
are produced from a single gene by alternative RNA splicing [103-107] (Figure  1.1). The 
corresponding  murine  splice products,  VEGF 120,  VEGF 144,  VEGF 164  and  VEGF 188 
(the mouse homolog of human VEGF206 has not been identified) contain one less amino 
acid  than  their  human  counterparts  but  are  thought  to  posses  the  same  biochemical 
properties  and  exert  similar  activities.  Recently,  a  subspecies  of  human  VEGF 165, 
VEGF 165b,  was  identified  in  a  PCR-screen  examining  the  differential  expression  of 
VEGF isoforms in renal carcinoma cells [108]. This variant, which contains an alternative 
exon 8, was found to be downregulated in malignant cells. It was further shown to inhibit 
VEGF-induced  proliferation  and  migration  in  vitro  as  well  as  angiogenesis  in  vivo, 
suggesting a role for this splice form as endogenous inhibitor of angiogenesis [108,  109]. 
Another RNA splice form, VEGF 162, was detected in a human ovarian carcinoma cell line 
[110]. The purified protein bound heparin with high affinity due to the presence of exon 
6A- and 6B-encoded peptides, and was mitogenic and angiogenic  [110], but its specific 
biological role remains unidentified.
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Figure 1.1 Exon structure of the splice variants of human VEGF. The eight exons of 
the human VEGF-A gene are alternatively spliced to produce at least five isoforms that 
differ  in  total  amino  acid  number.  The  length  of  some  individual  exon-encoded 
polypeptides  and the exon number from which they derive  are shown at the top  of the 
figure. 5’- and 3’-untranslated regions (UTR) are represented by diagonal lines and introns 
are represented by horizontal lines.  Introns and exons are not drawn to scale. The signal 
peptide cleavage site in the exon 2-encoded domain and other enzyme cleavage sites are 
marked  by  arrowheads.  Abbreviations:  a.a.,  amino  acids;  ex,  exon;  MMP,  matrix 
metalloproteinase;  uPA,  urokinase-type  plasminogen  activator;  Np,  neuropilin;  HSPGs, 
heparan sulfate proteoglycans. Courtesy of Y.S. Ng.
27Chapter 1 Introduction
1.3.2 VEGF protein structure
VEGF is a dimeric glycoprotein that belongs to the cysteine knot family of growth factors 
[111,  112].  Members  of this  family contain  eight  conserved  cysteine  residues  in  each 
monomer, forming the typical disulphide bonded knot motif that is thought to be a major 
determinant for the stability of these growth factors [111,  113]. In VEGF, two monomers 
are covalently linked by two interchain disulfide bridges between cysteine 51  and cysteine 
60 to form an antiparallel homodimer [114]. A hydrophobic signal sequence, essential for 
dimerization  and  secretion,  is  encoded  by  exon  1  and  four residues  of exon  2  and  is 
cleaved off during secretion [40, 41,  115]. All VEGF splice forms share the same amino 
(N)  -terminal  amino  acid  sequence  encoded  by  exons  1   to  5,  containing  high-affinity 
binding sites for the receptor tyrosine kinases VEGFR-1  and VEGFR-2. Crystal structure 
studies and site-directed mutagenesis have identified symmetrical  receptor binding  sites 
located at each pole of the VEGF homodimer [114, 116]. Binding to these poles appears to 
be important for receptor dimerization and  signaling  [117].  While  sharing the  same N- 
terminus, the VEGF transcripts all differ by the presence or absence of sequences encoded 
by exons  6  and  7.  This region  encodes two  heparin-binding  domains  (HBDs),  each of 
which confers the ability to bind heparin [118]. The HBD of VEGF 165  is located to the 
exon  7-encoded peptide  (Figure  1.2).  The  structure  of both  the N-  and  the  C-terminal 
binding  domains  of VEGF  have  been  solved  separately by  X-ray  crystallography  and 
NMR, respectively [116, 119]. In addition, the HBD structure has been characterized [119, 
120].
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Figure  1.2  Schematic  representation  of  VEGF165.  The  VEGF 165  isoform  is  a 
homodimeric protein with a 55-residue HBD  (VEGF111-165)  located in the C-terminal 
region of each monomer. This domain is defined by the plasmin cleavage site (arrow) in 
the exon 5-encoded domain and includes the C-terminal part of exon 5 as well as exon 7 
and 8 (dark-shaded regions). The amino acid sequence of the HBD is shown at the bottom. 
Intermolecular and intramolecular disulfide bridges are represented by lines. Adapted from 
W. Fairbrother et al. [119].
1.3.3  The HBD of VEGF165
Since the HBD plays such a critical role in determining VEGF isoform localization and 
function, it is important to understand the characteristics of this domain. The structure of 
the  VEGF 165  HBD  produced by plasmin  cleavage of the  full-length protein has  been 
determined by a group at Genentech [119,  120]. Neither the sequence nor structure of this 
55-residue C-terminal  fragment (VEGF111-165) bears any similarity to known heparin- 
binding proteins outside the VEGF family of growth factors, suggesting that the HBD has 
a novel fold [121]. This fragment binds heparin with the same affinity as the full-length 
isoform,  demonstrating  that  all  heparin-binding  activity  of  VEGF 164/165  is  indeed
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confined  to  this  domain  [118].  The  HBD  is  comprised  of clearly  defined  N-terminal 
(residues  1-29)  and  C-terminal  (residues  29-55)  subdomains,  each  containing  a  two- 
stranded, anti-parallel, P-sheet (residues 18-21, 26-29, and 42-44, 49-51) and two disulfide 
bonds (Cys 7-Cys 25, Cys 10-Cys 27, and Cys 29-48, Cys 36-50) which dominate the fold 
(Figure  1.3).  In addition,  a single  a-helix  (residues  33-38)  is  located in the C-terminal 
subdomain, where it is packed against the p-sheet. The charge of the overall highly basic 
domain  (pi  ~  11)  is  distributed  rather  unevenly  across  the  surface,  with  a  surplus  of 
positively or negatively charged  amino  acids  on  each  side  of the  domain.  It has  been 
suggested that an area with a high density of positively charged side chains on one side of 
the N-terminal subdomain (Lys 30, Arg 35, Arg 39, and Arg 46) may represent a major 
heparin-binding  site  [119].  However,  the  loop  region  at  the  interface  of  the  two 
subdomains  (residues  11-17)  and the relative  orientation of the  subdomains  within the 
HBD  remain poorly  defined.  The  increased  flexibility of this  domain compared  to  the 
remainder of the protein complicates accurate prediction of heparin-binding sites within 
the HBD.
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Figure  1.3  Structural  fold  of  the  VEGF165  HBD.  Stereo  ribbon  diagram  of  the 
VEGF 165 HBD with secondary structure elements. The cysteines shown are all involved 
in the formation of disulfide bonds. Charged residues are color coded, with basic residues 
depicted in blue and acidic residues depicted in red. Numbering of residues is according to 
the primary amino acid sequence shown in Figure  1.2. The diagram was produced using 
PyMOL (DeLano Scientific) based on published NMR data (PDB code:  1KMX).
1.3.4  The VEGF isoforms: extracellular distribution
Although at least five human VEGF iso forms have been identified to date, most VEGF- 
secreting cells appear to preferentially express VEGF121, VEGF 165 and VEGF 189. These 
variants  have  a  wide  tissue  distribution,  whereas  the  less  common  VEGF 145  and
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VEGF206 are only expressed in the female reproductive system  [122,  123].  The VEGF 
isoforms  have  distinct  biochemical  properties.  Perhaps  the  most  striking  feature  is  the 
differential binding affinity for heparin. In vivo, heparin affinity translates into the ability 
to interact with heparan sulfate and heparan sulfate proteoglycans (HSPGs) on cell surfaces 
and basement membranes, therefore representing a major determinant for the localization 
of the isoforms in the extracellular space [124]. VEGF121, the shortest isoform, lacks both 
the exon 6- and exon 7-encoded HBDs.  This isoform is freely released from cells upon 
secretion and can therefore diffuse relatively long distances. The larger isoforms VEGF 189 
and  VEGF206  are  highly basic  and  bind  heparin  strongly  due  to  the  presence  of two 
independent heparin-binding regions located in exon 6a and exon 7. Consequently, these 
proteins  are  almost  completely  sequestered  in  the  extracellular  matrix  and  on  the  cell 
surface  [124,  125].  VEGF145  binds  to  the  extracellular  matrix  but  shows  decreased 
heparin-binding activity relative to VEGF 189 because it lacks the exon 7-encoded peptide 
sequence  [106].  VEGF 165,  the prototypic  and  most  abundant  VEGF  isoform,  displays 
only a moderate affinity for heparin and differs from VEGF121 by the inclusion of a basic 
peptide encompassing 44 residues encoded by exon 7. This peptide also contains binding 
sites for neuropilin-1  and neuropilin-2 [126,  127]. The proportion of VEGF 165 associated 
with the extracellular matrix was reported to be 50-70%, which enables this isoform to act 
in a dual fashion, as both a soluble and a cell-bound factor [128-130].
Through production of both soluble and matrix-bound forms of VEGF, bioavailability and 
spatial distribution of this factor around endothelial cells can be controlled. Indeed, a finely 
balanced  VEGF  concentration  gradient consisting of isoforms  with differential  heparin- 
binding affinities seems to be necessary for proper blood vessel branching morphogenesis
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in the mouse hindbrain  [61].  It is important,  however,  that mechanisms exist to release 
VEGF from the extracellular matrix.
1.3.5 Processing of VEGF in the extracellular milieu
The  cell  surface-bound  and  extracellular  matrix-associated  isoforms  are  thought  to 
constitute a reservoir of growth factors, which can be released into the extracellular milieu 
as active proteins without the need to initiate gene transcription. This can occur either by 
displacing the isoform with heparin or HSPGs, by exposure to heparinases; or more rapidly, 
by specific proteases such as plasmin and urokinase-type plasminogen activator [124, 131]. 
Plasmin  cleavage  of  VEGF 165  and  VEGF 189  releases  a  homodimeric,  non-heparin- 
binding 34-kDa fragment that consists of amino acids  1-110 (VEGF 110).  Although this 
fragment contains the binding domains for VEGFR-1  and VEGFR-2, the endothelial cell 
mitogenic potential  of VEGF110  was  significantly less  than that  of VEGF 165  in  vitro 
[118].
Another example  for the mobilization  of cell-bound  VEGF by proteolytic  activity was 
reported in a study by Plouet et al. [131].  In this study, VEGF 189 was shown to 
undergo  a  maturation process  mediated by the  serine protease  urokinase.  Cleavage by 
urokinase was required to convert VEGF 189 from an inactive precursor state to a smaller, 
mature version, which was able to potently induce a mitogenic effect in vitro. By cleaving 
VEGF  within  the  exon  6-encoded  region,  urokinase  activity  is  thought  to  expose  the 
VEGFR-2-binding  site,  which  is  obscured  in  the  full-length  version.  Matrix 
metalloproteinases (MMPs) have also been implicated in the mobilization of extracellular
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matrix-bound VEGF. The degradation of the basement membrane and extracellular matrix 
catalyzed by MMPs, which allows endothelial cells to proliferate and migrate toward an 
angiogenic stimulus, also releases matrix-bound VEGF isoforms. Recently, it has become 
evident that MMPs can precisely cleave extracellular matrix-associated molecules, thereby 
liberating  bioactive  fragments  and  growth  factors  [132].  Immobilized  VEGF 165  and 
VEGF 189 can be cleaved intramolecularly by certain proteases of the metalloproteinase 
family,  and  the  unprocessed  and processed  forms  exert  different  activities  in  vascular 
morphogenesis [133].
1.4 The VEGF receptors
VEGF  family members  can bind to type  III tyrosine kinase receptors,  neuropilins,  and 
HSPGs (Figure 1.4). Cellular responses to VEGF are primarily mediated by the binding of 
this  factor  to  the  type  III  tyrosine  kinase  receptors  VEGFR-1  and  VEGFR-2,  to  the 
semaphorin receptor neuropilin-1, and to HSPGs.
1.4.1 The VEGF tyrosine kinase receptors
VEGFR-l  and VEGFR-2  have been identified  as high-affinity transmembrane  receptor 
tyrosine kinases for VEGF [134,  135]. The two receptors share a 44% amino acid identity 
and  both  contain  seven  extracellular  immunoglobulin-like  domains,  a  single 
transmembrane region, and a conserved intracellular tyrosine kinase sequence interrupted 
by a kinase-insert domain [136, 137]. VEGFR-3 (also known as Flt-4), the third member of 
this receptor family, is a receptor for VEGF-C and VEGF-D, but not for VEGF [138, 139].
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Figure 1.4 The cell-surface receptors for VEGF. The monomeric VEGF tyrosine kinase 
receptors  (VEGFR-1,  VEGFR-2  and  VEGFR-3),  membrane-associated  heparan  sulfate 
proteoglycans  and  the  non-tyrosine  kinase  receptors  neuropilin-1  and  neuropilin-2  are 
displayed with their characteristic structural features and identified ligands listed above. Ig- 
like domains 2 and 3 of VEGFR-1  and VEGFR-2 (shown in orange) have been shown to 
be important for high-affinity ligand binding, and domain 4 (shown in blue) is believed to 
mediate  receptor  dimerization  for  VEGFR-1.  Both  the  unprocessed  and  proteolytically 
processed (*) forms of VEGF-C and VEGF-D can bind to VEGFR-3. Only the processed 
forms of VEGF-C and -D bind to VEGFR-2,  but their binding affinity  is significantly 
weaker than that of VEGF-A for VEGFR-2. Ligands for heparan sulfate proteoglycans are 
thought to interact with specific sequences of sulfation within the heparan sulfate chains, 
which are attached to a core protein (shown in blue). Binding of the VEGF-B 186 splice 
form to neuropilin-1  is regulated by proteolytic processing (*).  VEGF-E  is a collective 
term for a group of VEGF-like proteins that are encoded by certain strains of the Orf virus. 
Some  members  of  this  group,  including  ORFVnzioVEGF,  ORFVN z2VEGF,  and 
ORFVdi701 VEGF,  were  shown  to  bind  to  neuropilin-1  with  varying  affinities  [357]. 
Adapted from Neufeld, G. et al. [68].
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1.4.1.1  VEGFR-2: the major signaling receptor
VEGFR-2,  also  known  as  Flk-1  or  KDR,  has  been  identified  as  a  major regulator of 
vasculogenesis  and  angiogenesis.  It  is  considered  to  be  the  most  important  signaling 
receptor for VEGF, mediating most of its biological activities in endothelial cells. Binding 
of  VEGF  induces  dimerization  of  the  monomeric  receptors,  which  results  in 
autophosphorylation at several specific tyrosine residues of the cytoplasmic domains. The 
mode of ligand binding is similar for both receptors. Two receptor monomers bind one 
VEGF dimer, in such a way that each receptor molecule binds to the pole of each monomer 
at opposite ends of the ligand homodimer, in which the monomers are arranged in a head- 
to-tail orientation [68,  116,  140]. The immunoglobulin domains 2 and 3 are necessary and 
sufficient for VEGF binding [116,  140-142].  Ligand-induced dimerization of VEGFR-2 
leads to efficient phosphorylation of tyrosine residues [135,  143,  144]. Upon activation of 
VEGFR-2, autophosphorylated tyrosines create binding sites for several Src homology-2 
(SH2) domain-containing proteins, such as PLC-y or Grb2, leading to the phosphorylation 
and activation of these proteins. This mechanism has been implicated in the activation of 
the Raf-l/MEK/ERK cascade,  a crucial  signaling pathway,  resulting  in  endothelial cell 
proliferation and angiogenesis [45, 46, 145].
Expression of VEGFR-2 has been detected in endothelial and other mature vascular cells, 
as well as in endothelial and hematopoetic precursor cells  [146,  147].  Mice deficient in 
Flk-1  (murine VEGFR-2) die between embryonic day (E) 8.5 and E9.5, exhibiting a lack 
of yolk  sac  blood  islands  and  organized  blood  vessels  [30],  a  phenotype  that  is  not 
surprising  given  that  the  proliferation  and  migration  of  hematopoietic/endothelial 
progenitor cells requires signaling through Flk-1 [148]. Certain tumorigenic cell types also
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express  VEGFR-2,  including human melanoma cells  and  cells  from  acute  and chronic 
forms of leukemia [149, 150]. Interestingly, VEGFR-2 expression has also been described 
in neural progenitor cells of the retina, in neurons of the superior cervical and dorsal root 
ganglia,  and  in  Schwann  cells  [151,  152].  These  findings  led  to  the  hypothesis  that 
VEGFR-2 may transmit neurotrophic and even neuroprotective signals [152].
1.4.1.2  VEGFR-1
The transmembrane receptor tyrosine kinase VEGFR-1, also known as Fit-1, was the first 
receptor identified for VEGF.  Ligands for this receptor also  include the related growth 
factors P1GF and VEGF-B. VEGFR-1  is expressed on vascular endothelium and in some 
non-endothelial cells, including hematopoietic stem cells, macrophages and monocytes [26, 
153, 154]. Inactivation of the VEGFR-1 gene in mice leads to death in utero between E8.5 
and E9.5, due to a failure of endothelial cells to organize in functional blood vessels. The 
lack of vessel formation in these animals has been linked to an abnormal increase in the 
number  of  endothelial  progenitors,  indicating  that  VEGFR-1  may  act  as  a  negative 
regulator of VEGF function during development [155]. In support of this view, activation 
of the VEGFR-1  kinase  in wild-type  endothelial  cells  does  not  appear to  cause  direct 
proliferative, migratory or permeability effects, and upregulation of putative downstream 
signaling  molecules  has  only  been  observed  in  heterologous  cell  types  or  in  cells 
overexpressing  this receptor [143,  156-160].  In  contrast to  the  critical  role  of tyrosine 
phosphorylation in VEGFR-2 function, deletion of the VEGFR-1 tyrosine kinase domain, 
with  the  ligand  binding  domain  unaffected,  was  compatible  with  normal  vascular 
development and angiogenesis  [161, 162]. These observations suggest a role for VEGFR- 
1  in controlling VEGF availability by sequestering excess VEGF. Such a ‘decoy’ function
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can also be performed by a truncated, soluble form of VEGFR-1  (sFlt-1), which has the 
same ligand binding affinity as the full-length version despite lacking the transmembrane 
and intracellular domains [163, 164].
While  VEGFR-1  tyrosine  kinase  activity  appears  to  be  expendable  for  developmental 
vascular development,  this activity is required  for other physiological  and pathological 
functions.  For example, chemotaxis of monocytes and macrophages in response to both 
VEGF and P1GF depends on the tyrosine kinase activity of this receptor [161,  165,  166], 
Both  cell  types  are  known  to  express  VEGFR-1  as  the  sole  VEGF  receptor.  Indeed, 
macrophage  migration  towards  VEGF  or  P1GF  was  strongly  suppressed  in  VEGFR-1 
tyrosine kinase-deficient (VEGFR-1/Tk'7 ') mice [161]. These data were complemented by a 
recent study in which P1GF signaling via VEGFR-1  was reported to activate monocytes, 
leading to production of inflammatory cytokines and chemokines including TNF-a, IL-1  (3  
and monocyte chemotactic protein (MCP-1) [167].
There  is  mounting  evidence  indicating  that  VEGFR-1-mediated  signaling  may  have  a 
significant role in pathological angiogenesis. In a recent study, Carmeliet et al. observed 
that P1GF binding to VEGFR-1 specifically enhanced VEGF-induced angiogenesis through 
VEGFR-2 in a mouse model of ischemia [163]. Furthermore, injection of an anti-VEGFR- 
1  antibody into tumor-bearing mice suppressed neovascularization of tumors to an extent 
similar to that of anti-VEGFR-2 treatment [168]. Autiero and coworkers found evidence 
for a new mechanism of VEGFR-1  activity,  in which P1GF can activate intermolecular 
cross-talk between VEGFR-1 and -2, thereby enhancing VEGF signaling through VEGFR- 
2.  According  to  this  study,  P1GF  -  but not VEGF  -  stimulates  the phosphorylation  of
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distinct VEGFR-1 tyrosine residues, resulting in transphosphorylation and activation of the 
VEGFR-2 kinase [169]. Interestingly, although P1GF and VEGF bind similar domains in 
VEGFR-1, each ligand induces a different pattern of gene expression and induces, at least 
in part, different biological responses [169-171].
The apparently contrasting activities of VEGFR-1, inhibition and enhancement of VEGF 
signaling  via  VEGFR-2,  may  be  partly  explained  by  correlations  between  VEGFR-1 
function and cell type, developmental stage or pathological condition. While under certain 
pathological circumstances in the adult organism VEGFR-1  can act as a positive signal 
transducer  and  mediator  of  angiogenesis,  its  function  in  embryonic  angiogenesis  is 
primarily the depletion of excess  ligand  [172].  Furthermore,  while the heparin binding 
isoform VEGF 165 binds to VEGFR-1  with higher affinity than does VEGF 121, it is not 
yet known whether this difference in binding  affinity translates into  distinct biological 
responses [118]. Another complication in elucidating VEGFR-1- and VEGFR-2-mediated 
signaling outcomes in response to VEGF  is the presence of further interaction partners 
such as the neuropilins and the HSPGs. Association with these species, either directly or 
indirectly through binding to VEGF, may potentially modulate VEGF receptor behavior.
1.4.2 Neuropilin-1: a VEGF isoform-specific receptor
Another VEGF receptor, which is expressed on endothelial and tumor cells, as well as on 
neurons  and  vascular  smooth  muscle  cells,  specifically  binds  to  the  exon  7-encoded 
heparin-binding domain of VEGF 165 and was found to be identical to neuropilin-1  [126, 
179,  180].  Neuropilin-1  is  a  single-spanning  transmembrane  protein  with  a  short
39Chapter 1 Introduction
cytoplasmic domain of about 40 amino acids and five extracellular domains, al/a2, bl/b2, 
and c. The al/a2 domains and the bl/b2 domains contain the binding sites for class-III 
semaphorins  and  VEGF 165,  respectively, and  the c  domain mediates  the  formation of 
functional homodimers and heterodimers with neuropilin-2 [173,  174]. Neuropilin-1  was 
originally characterized as a neuronal receptor for axon repellent factors belonging to the 
class-III  semaphorin  subfamily  [175,  176].  Both  neuropilin-1  and  neuropilin-2  control 
neuronal guidance at the growth cone of axons by forming ligand-independent complexes 
with  receptors  of the  plexin  family,  which  act  as  signal-transducers  in  response  to 
semaphorin binding [177,178].
The  discovery  of neuropilin-1  as  a  VEGF  receptor  was  intriguing,  as  it  substantiated 
previous observations in transgenic mice that indicated a role for this neuronal receptor in 
the vascular system. Overexpression of neuropilin-1 in mice causes excessive formation of 
dilated capillaries and blood vessels; ablation of the neuropilin-1 gene, on the other hand, 
results  in  insufficient  vascularization  of  the  yolk  sac  and  neural  tube,  as  well  as 
cardiovascular  defects,  leading  to  embryonic  death  at  El 0.5-El 2.5  [179,  180]. 
Morpholino-mediated  knock-down  of  neuropilin-1  in  zebrafish  embryos  results  in 
impaired blood cell circulation in the intersegmental vessels, similar to the defect caused 
by inhibition of the VEGFR-2 kinase in this organism [181]. These observations suggest 
that VEGFR-2 cannot sufficiently transduce VEGF signals in the absence of neuropilin-1. 
Neuropilin-1 does not appear to mediate VEGF signals independent of other receptors. No 
direct  effects  have  been  observed  after ligation  of neuropilin-1  to  VEGF 165  or  other 
VEGF-related neuropilin-1  ligands, including P1GF-2, VEGF-B and the VEGF-E variant 
VEGFnz2 [182-184]. Co-expression of neuropilin-1  and VEGFR-2, however, results in an 
enhanced VEGF-induced cell migratory response compared to cells expressing VEGFR-2
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alone [126]. Similarly, VEGF 165 is a more potent inducer of VEGFR-2 phosphorylation in 
HUVEC  than  is  non-neuropilin-binding  VEGF 121  [185].  The  role  of  neuropilin  in 
mediating  this  effect  was  confirmed  using  a  PIGF-derived  peptide  that  specifically 
competes  with  VEGF 165  for binding  to  neuropilin-1.  The  peptide  antagonized  VEGF 
signaling  via  VEGFR-2  in  an  isoform-specific  manner,  suggesting  that  the  ability  of 
VEGF 165 to bind to the VEGFR-2/neuropilin-l  complex may explain the difference in 
potency between VEGF 165 and VEGF 121 [185].
Surprisingly, the increased potency of VEGF 165 in the presence of neuropilin-1  does not 
seem  to  result  from  an  increase  in  binding  affinity  to  VEGFR-2,  but  rather  is  the 
consequence of increased complex formation between the two receptors [185]. Neuropilin- 
1  does not bind VEGFR-2 directly, but it can present VEGF to VEGFR-2. Since VEGFR-2 
and  neuropilin-1  binding  sites  are  distinct,  VEGF 165  can  bind  both  receptors 
simultaneously, allowing the formation of ligand-dependent receptor clusters [186,  187]. 
This hypothetical model will most likely have to be modified if cell-surface HSPGs are to 
be included in the equation, because all three components of this complex are themselves 
heparin-binding proteins [186,  188,  189].  In addition, neuropilin-1  binds VEGFR-1  and 
can  form  a  ligand-independent  complex  with  this  receptor  [186].  Neuropilin-1  may 
therefore  also  play  a  role  in  VEGFR-1-associated  biological  responses,  such  as  cell 
migration [59, 190].
Despite  numerous  biochemical  and  in  vivo  studies,  it  remains  unclear  how,  exactly, 
neuropilin-1  exerts  its  functional  role  during  vascular  development  and  in  the  adult 
organism.  The  vascular  defects  observed  in  neuropilin  null  mice  were  predominantly
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attributable  to  a  deficiency  in  VEGF-neuropilin-1  signaling,  as  the  deletion  of  the 
semaphorin binding domain of neuropilin-1  did not significantly alter the severity of the 
null mutant phenotype [191]. It remains to be determined whether the role of neuropilin-1 
on  endothelial  cells  is  simply  to  sequester  VEGF 165  and  amplify  signaling  through 
VEGFR-2, thus resulting in a synergistic increase in migratory and proliferative effects, or 
whether it is able to trigger distinct signaling pathways within the vascular cells that are 
specific for the VEGF 165 isoform.
1.4.3 HSPGs: low-affmity VEGF receptors
HSPGs are abundant, highly conserved components of the cell surface and extracellular 
matrix of all animal cells. These molecules play a critical role in modulating the activities 
of a wide range of growth factors, morphogens and chemokines, including VEGF [192]. 
HSPGs bind to certain VEGF isoforms with low affinity, but this interaction is critically 
important in determining VEGF isoform localization and function.
1.5 HSPGs as modulators of protein function
1.5.1 Structural characteristics of HSPGs
HSPGs  are  molecules  composed  of  repeated  sulfated  disaccharides,  which  constitute 
unique  glycosaminoglycan chains  covalently  linked to  a protein  core  [193].  The  most 
abundant glycosaminoglycan, heparan sulfate, is a repeat of alternating glucuronic acids 
and glucosamines, and is characterized by a high degree of modification of the sulfo and 
acetyl groups [194, 195]. The heparan sulfate chains are assembled in the Golgi apparatus
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by glycosyl transferases while attached to  a proteoglycan core protein. The membrane- 
bound core proteins are predominantly members of two major families of proteoglycans, 
the membrane-spanning syndecans and the glycosylphosphatidylinositol-linked glypicans 
(Figure  1.5).  Other proteoglycans,  namely perlecan,  agrin,  and collagen,  are  associated 
with  but  are  not  linked  to  the  cell  membrane  [194,  196].  Heparin,  also  a 
glycosaminoglycan, is a highly sulfated type of heparan sulfate and is almost exclusively 
produced by mast cells. It is structurally and chemically similar to heparan sulfate and is 
frequently used in biochemical studies as a heparan sulfate analogue [197, 198].
HSPGs are highly negatively charged molecules by virtue of densely packed sulfate and 
carboxylate groups on the heparan sulfate chains. An important and unique characteristic 
of heparan sulfate chains that determines binding affinity and specificity is the existence of 
spatially  discrete,  highly  sulfated  domains  (S-domains)  of  different  length  (2-8 
disaccharides) and varying patterns of 6-O-sulfation [199].
4
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Figure  1.5  Structure  of the  two  major  cell-surface  heparan  sulfate  proteoglycans 
(HSPGs).  Glypicans  (left)  have  a  large  globular  domain  and  are  linked  to  the  cell 
membrane by a glycosylphosphatidylinositol (GPI) anchor. The transmembrane syndecans 
(right) can carry several heparan sulfate (HS) attachment sites near their extracellular N- 
terminus,  whereas  those  in  glypicans  are  located  near the  C-terminus  close  to  the  cell 
membrane.  Both glypicans and syndecans can be proteolytically cleaved resulting in the 
release of the HSPG into the extracellular matrix. Adapted from Hacker, U. et al. [200].
These domains alternate with stretches of low sulfation, consisting mostly of unmodified 
N-acetylated  and  N-sulfated  disaccharides  [201]  (Figure  1.6).  Several  proteins  bind  to 
individual or multiple S-domains simultaneously, depending on their oligomeric state and 
the number and positioning of the heparin-binding sites [202-204]. Because many proteins 
that  bind  heparin  (and,  by  extrapolation,  heparan  sulfate)  are  basic  or  contain  basic 
domains, binding is expected to occur mainly via electrostatic interactions [205].  Indeed, 
heparin-binding sites in proteins are characterized by clusters of arginines and lysines that 
bind to the highly anionic structures on glycosaminoglycan chains in a rather non-specific 
manner.  However,  crystallographic  studies  of  heparin  complexes  with  antithrombin,
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annexin  V,  and  fibroblast  growth  factor (FGF)  have  demonstrated that  heparin-protein 
interactions depend on the presence of specific,  structurally defined  sequences on both 
binding partners to ensure the steric fit of the complex [206-208]. Cardin and Weintraub 
were the first to identify heparin-binding motifs or consensus sequences such as XBBXBX 
and XBBBXXBX (where B  stands  for a basic residue and X stands  for a hydropathic 
residue)  by  comparing  primary  protein  sequences  of  heparin-binding  proteins  [209]. 
Molecular modeling of these sequences in appropriate secondary structure conformations 
showed that basic residues are  located on the surface and the hydropathic residues are 
pointing back into the protein core. Some heparin-binding proteins include the sequences 
described by Cardin and Weintraub, but many others do not contain any of these motifs, 
suggesting that heparin-binding ability and  specificity might not primarily depend on  a 
linear pattern of amino  acids.  Indeed,  heparin-binding epitopes  can also  be  defined  by 
similar spatial motifs, in which basic residues that are distant in sequence but topologically 
close to each other form an optimal binding surface [210]. The affinity and specificity of 
the  interaction  can  be  further  enhanced  by  the  contributions  of hydrogen  bonds  and 
hydrophobic interactions. Further structural characterization of protein-glycosaminoglycan 
complexes  will  be  necessary  to  understand  more  fully  the  molecular  details  of these 
interactions.  These  studies  would  be  greatly  facilitated  by  technologies  that  allow the 
synthesis of size-defined, chemically homogeneous glycosaminoglycans, which are then 
used for x-ray crystallography and NMR spectroscopy [211,212].
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Figure 1.6 Heparan sulfate chain structure and heparan sulfate-binding proteins, (a)
Heparan sulfate (HS) chains are synthesized on the core protein by the sequential action of 
glycosyltransferases. The chain is attached to specific serin  residues through a common 
tetrasaccharide linker region  and consists of alternating disaccharide  units comprising  a 
hexuronic  acid  (glucuronic  acid,  GlcA,  or  iduronic  acid,  IdoA)  and  a  D-glucosamine 
(GlcNAc). N-sulfated glycosamines (GlcNSCb) may be O-sulfated at C3 (3-0 S), C6 (6-0 
S) or both, or may carry no sulfates.  Similarly, the N-acetylated glucosamines (GlcNAc) 
may be O-sulfated at C6 or unsulfated. Distinct domains of different charge densities are 
formed  during  biosynthesis  of  the  polymer  (micro-heterogeneity)  and  create  a  large 
potential  for structural  diversity,  (b)  An  incomplete  list of factors  that  bind  to  heparan 
sulfate (HS) and/or require heparan sulfate for activity.
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The complexity of possible interactions between HSPGs and proteins can be attributed to a 
variety  of  factors,  including  tissue-specific  differences  in  proteoglycan  expression, 
extensive variations in the sequence of disaccharide repeats, variety of sulfation patterns of 
the glycosaminoglycan chains,  and differences in proteoglycans size, ranging from 5-70 
kDa [213]. Despite this potentially immense sequence variety, it is expected that heparan 
sulfate uses a limited range of sequences to execute many of its activities [214]. Still, the 
sequence and structural heterogeneity determines the binding specificity for protein ligands. 
Indeed,  the biological  activity of many heparin-binding  growth  factors  is dependent on 
these  ‘fine  structures’  of HSPGs  [215].  For  example,  6-O-desulfated  heparin can bind 
FGF-2 but, unlike non-modified heparin, fails to promote mitogenic activity of FGF-2 in 
heparan sulfate-deficient fibroblasts, probably due to inefficient signaling via FGF receptor 
(FGFR)-l  [216]. This idea was supported by a structural analysis of the FGF-2-FGFR-1 
complex in the presence of a heparin fragment. In this structure, the 6-O-sulfate group was 
shown to make hydrogen bonds with both FGF-2  and its receptor [217, 218].  Although 
there is no agreement on a single, universal structure of the FGF-2-FGFR-heparin complex, 
this system remains one of the most well-studied examples of how heparin can control 
receptor-ligand engagement.
The structural components of heparin required for specific interaction with VEGF 165 are 
different from those used for binding to many other proteins [219]. Whereas FGF binding 
to FGFR-1  was maximally potentiated in the presence of a dodecasaccharide,  a heparin 
fragment with 22-24 sugars was required to potentiate VEGF receptor binding, suggesting 
that  this  fragment  can  occupy  both  HBDs  in  the  VEGF  homodimer  [220,  221]. 
Furthermore, competition binding assays using heparin derivatives revealed that both N-
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and  O-sulfation  of heparin  is  necessary  for  VEGF165  binding,  indicating  that  VEGF 
interacts with both S-domain and non-S-domain sequences in heparan sulfate [219, 222].
1.5.2 HSPG function
HSPGs bind to numerous factors to influence cell function (Figure  1.6b), and exert their 
effects  through  a  variety  of mechanisms,  including  localization  and  sequestration  of 
heparin-binding  growth  factors,  facilitation  of  growth  factor-receptor  binding,  and 
chemokine  oligomerization.  Genetic  studies  in  Drosophila  have  identified  specific 
functions  for  heparan  sulfates  in  establishing  gradients  of  signaling  factors  that  are 
involved in morphogenesis and differentiation during pattern formation, such as wingless 
(Wg), hedgehog (Hh) or Notch [223-227]. In mice, brain-selective disruption of EXT1, an 
enzyme  required  for  heparan  sulfate  biosynthesis,  revealed  a  critical  role  for  heparan 
sulfate  in  axon  guidance,  possibly due to  altered  function  of heparin-binding  guidance 
molecules  [228].  Several  mechanisms  have  been proposed  for the  role  of heparin  and 
heparan sulfates in growth factor regulation. It has been known for some time that heparin- 
bound  growth  factors  are  more  resistant  to  proteolytic  degradation  and  thermal 
denaturation.  Moreover,  heparin  has  the  potential  to  restore  bioactivity  to  damaged 
proteins. Notably, glypican-1 can act as an extracellular chaperone for VEGF 165 and can 
restore  its  receptor  binding  ability  after  VEGF  has  been  damaged  by  oxidation,  thus 
enhancing  its  efficacy  [229].  HSPGs  can  also  maintain  reservoirs  for  pro-  and  anti- 
angiogenic  factors,  including  FGF,  VEGF,  platelet-derived  growth  factor  (PDGF)  or 
thrombospondins,  thereby  prolonging  growth  factor  retention  time  and  receptor 
engagement.  During  blood  vessel  remodeling,  matrix-degrading  proteases  can  either
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release these factors to promote cell proliferation, or generate fragments from extracellular 
matrix proteins that are angiostatic [230-232].
More than a decade after the demonstration that heparan sulfate serves as an accessory 
molecule obligatory for the binding of FGF-2 to its receptor [233], and despite the progress 
that has been made in elucidating the various functions of HSPGs, the exact mechanism by 
which  individual  proteoglycans  facilitate  specific  protein-protein  interactions  remains 
poorly understood [234]. Two mechanistic models, which are complementary rather than 
mutually exclusive, can be used to explain the potentiating functions of heparan sulfates. 
Firstly, negatively charged heparan sulfate chains can capture growth factors with high 
association rates and restrict their diffusion from three dimensions to the two-dimensional 
mobility of the  HSPGs  on the cell  surface  [235].  This lateral  movement  increases  the 
frequency at which growth factors encounter unoccupied high-affinity signaling receptors. 
In  the  vicinity  of these  receptors,  the  ligand  rapidly  dissociates  from  the  low-affinity 
binding site(s) and binds to the signaling receptor. This structure may be further stabilized 
by the formation of a ternary complex with heparan sulfate, resulting in a more durable 
activation of the receptor tyrosine kinase [235, 236]. The second model for heparan sulfate 
function involves enhancing receptor dimerization. It has been shown that FGF receptor 
dimerization induced by multivalent binding of a FGF-heparin complex is necessary for 
receptor activation. Active heparan sulfate chains are usually long enough to accommodate 
more  than  one  FGF  monomer,  resulting  in  a  higher-order  structure  that  favors  FGF 
receptor dimerization and activation [237, 238].
Higher-order oligomers can also provide directional cues to guide the migration of cells in 
physiological and pathological settings. For example, the ability of certain chemokines to
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oligomerize on glycosaminoglycan chains to form chemokine gradients on cell surfaces 
was recently demonstrated to be important for the guidance of leukocytes in vivo [239]. 
During  an  inflammatory  response,  chemokine  gradients  are  established  and  stabilized 
through interactions with HSPGs. Leukocytes are then chemotactically attracted by these 
gradients and move toward the endothelium, where they bind to selectins and integrins 
before transmigrating into the underlying tissue [240]. HSPGs may also add another level 
of specificity to cell migration and signal transduction processes beyond that defined by 
the  interaction  of chemokines  with  their  G  protein-coupled  receptors  (GPCR),  when 
ligands specifically bind to certain types of glycosaminoglycans [241-243]. Whether these 
mechanisms are relevant to the modulation of VEGF activity remains to be investigated.
1.5.3 The modulation of VEGF behavior by heparan sulfates
HSPGs  control  various  aspects  of angiogenesis,  e.g.  by  modulating  FGF  activity,  as 
described above, and by influencing function of the different VEGF isoforms. The exact 
mechanisms by which heparin regulates the activity of heparin-binding VEGF isoforms 
has proved elusive, in part due to the potential complexity of interactions, since heparin 
can bind to all three VEGF receptors in addition to the ligand. Furthermore, the lack of 
crystal  or NMR  structures  of protein-heparin  complexes  has  made  it  difficult  to  gain 
insight into the structural specificity of the binding partners.
Endothelial cells predominantly express the membrane-bound glypican-1  and syndecans, 
as well as the extracellular matrix-associated perlecan [244-246]. Glypican-1 was the first 
native HSPG reported to bind to and modulate VEGF  activity [229].  Glypican-1  binds
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VEGF 165 through its heparan sulfate chains with some specificity; this interaction can be 
inhibited by excess amounts of heparin, but not by other HSPGs. Exogenous glypican-1 
also potentiates the binding of VEGF 165  and oxidized VEGF 165 to heparinase-digested 
human umbilical vein endothelial cells (HUVEC) and to soluble VEGFR-2, respectively 
[229].  In contrast, binding of VEGF121  to VEGFR-2  is not affected by removal of cell 
surface heparan sulfates, as detected by cross-linking to HUVEC, and neither glypican nor 
heparin can restore the receptor binding capability of VEGF121  treated with oxidizing 
reagents [247]. This function of glypican-1  may represent a mechanism to ensure VEGF 
activity by extending its half-life in situations where high levels of free radicals or other 
oxidizing agents are produced, such as wound healing, inflammation or hypoxia-induced 
angiogenesis [247].
An exact understanding of the effects of HSPGs on VEGF isoform activity is complicated 
by  the  fact  that  different  studies  have  yielded  seemingly  contradictory  results.  Not 
surprisingly, the observed regulatory effects of heparin or HSPGs on receptor binding and 
activation by VEGF are affected by several factors, including the experimental set-up, the 
cell and receptor types involved, and the concentration, type and sulfation level of HSPGs 
[248, 249]. Whereas heparin strongly potentiates 125I-VEGF165 binding to VEGFR-2 in a 
cell-free assay, the equivalent amount of heparin inhibited the binding to NIH-3T3  cells 
that overexpress VEGFR-2 [250]. Heparin did, however, augment VEGF binding to cells 
in which VEGFR-2 is endogenously expressed [248, 251]. In the case of VEGFR-1, both 
VEGF 121  and VEGF 165 binding are reduced by exogenous heparin [251, 252]. Ito et al. 
observed a dose-dependent decrease  in VEGF 165  binding to  porcine  aortic  endothelial 
cells (PAEC) transfected with VEGFR-1  in the presence of different batches of heparin
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[253]. Similar results were reported by Terman et al. [251]. These data suggest that heparin 
and  HSPGs  differentially  modulate  VEGF  binding  through  direct  interaction  with  the 
different receptor types. A heparin-binding peptide found in the extracellular domain of 
VEGFR-2  does not bind VEGF 165, but it potently inhibits VEGF binding to the receptor 
and blocks endothelial cell proliferation [189]. Possible outcomes of a direct interaction of 
heparin with this receptor include an increase in the number of available binding sites, an 
increase in VEGF stability, and/or changes in receptor conformation [118, 248, 251, 253]. 
In the presence of HSPGs, VEGF 165, VEGFR-2 and neuropilin-1  are thought to form an 
as-yet undefined signaling complex through intermediary heparan sulfate molecules [185, 
249]. It can be assumed that heparin and HSPGs play an important role in enabling VEGF 
isoform-specific signaling responses in endothelial cells by orchestrating the differential 
association of VEGF isoforms with the various receptor components.
1.6 The roles of heparin-binding VEGF isoforms
1.6.1 Physiological angiogenesis
The VEGF isoforms exert specific functions based on their differential distribution in the 
extracellular milieu, as demonstrated in a study investigating vascular branch formation 
and its underlying mechanisms [61]. Although VEGF 120 alone is able to support mouse 
embryonic  vasculogenesis  and  angiogenesis  to  a  certain  extent  [284],  the  balanced 
expression of both soluble and heparin-binding isoforms appears to be necessary to ensure 
proper vessel branching morphogenesis during vascular development in the hindbrain [61]. 
In the VEGF12 0 7120 mice, which lack heparin-binding isoforms, disruption of the naturally- 
occurring  chemotactic  VEGF  gradient  near  the  midline  region  resulted  in  defective
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migration of sprouting vessel tips, decreased branching complexity and enlarged capillaries. 
On  the  other  hand,  the  exclusive  expression  of the  VEGF 188  isoform  (VEGF1887188) 
promoted  excess  branching,  producing  small  caliber vessels.  Normal  vessel  parameters 
were fully restored in mice engineered to express VEGF120 and VEGF188 (VEGF1207188), 
indicating that VEGF 188 can compensate for the loss of VEGF 164 during development. 
Thus,  it  has  been  hypothesized  that the  balance  between  the  heparin-binding  and  non- 
heparin-binding  variants  determines  whether  vessels  will  undergo  branching 
morphogenesis or luminal growth [61].
The  longer  VEGF  isoforms  are  believed  to  provide  positional  cues  to  VEGFR-2- 
expressing  endothelial  tip  cell  filopodia due  to  their HBD-mediated  retention  near the 
VEGF-producing cells [61]. A similar role for the heparin-bound splice forms was found 
for the guidance of tip  cells  during retinal  angiogenesis  [62].  In  VEGF1 2 0  120 mice that 
survive until P9, the absence of the heparin-binding VEGF isoforms results in defective 
endothelial cell outgrowth and vessel remodeling [254]. Furthermore, VEGF 164 not only 
supports the migration of endothelial cells but also contributes to neuronal patterning in 
vivo by acting as a guidance cue for neuropilin-1-expressing motor neurons [59].
The ability of VEGF 188 and, to a lesser extent VEGF 164, to be sequestered locally may 
trigger  signaling  events  that  modulate  vessel  morphogenesis.  It  has  been  shown  that 
immobilized  VEGF 188  and  VEGF 164  remain  functional  and  serve  as  substrates  for 
endothelial cell adhesion and spreading through direct ligation with avp3 integrins in vitro 
[255]. To induce proliferation, however, VEGF188 must undergo enzymatic processing to 
unmask its VEGFR-2-binding domain, suggesting that different mechanisms are involved
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in proliferation and migration [131]. VEGF 188 activities may also be modulated by the 
neuropilins.  Binding  of the VEGF 188  to  neuropilin-1  /VEGFR-2  complexes  through  its 
exon-7-encoded sequence has yet to be verified, but this interaction may potentially induce 
a similar migratory response in endothelial cells to that observed for VEGF 165 [126, 256].
1.6.2  Pathological conditions
1.6.2.1  Tumors
Deregulated  VEGF  expression  contributes  to  the  development  of  solid  tumors  by 
promoting tumor angiogenesis [36, 257]. In addition, the extracellular processing of VEGF 
isoforms has been implicated in the angiogenic switch, a process that renders hyperplastic 
tissue tumorigenic [258]. The regulation of expression of the three primary VEGF isoforms 
(VEGF121, VEGF 165,  and VEGF 189) by tumor cells and the tumor-associated stroma, 
however,  remains poorly understood. Moreover,  the distinct pathophysiological roles of 
the  isoforms  appear  to  be  affected  significantly  by  the  microenvironment,  such  as 
expression  of  VEGF  receptors  and  extracellular  matrix  components,  at  the  different 
anatomical sites of these tumors [259].
Overexpression of individual VEGF isoforms increases the angiogenic potential of tumor 
cells  [260-262].  Various  studies  have  shown  that  soluble  VEGF  is  less  effective  than 
heparin-binding VEGF at supporting the neovascularization needed for tumor survival. For 
example, glioma cells transfected with VEGF121  fail to induce tumor progression when 
implanted in the sub-cutaneous space, whereas VEGF 165- and VEGF 189-overexpressing 
cells strongly augment neovascularization compared to parental cells [259]. VEGF 120 is
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incapable  of supporting  maximal  growth  of heterotypic  tumor  cells,  as  observed  in  a 
mouse  xenograft  model  using  transformed  embryonic  fibroblasts  expressing  individual 
isoforms on a VEGF nullizygous background [263]. In this seminal study, the diffusible 
VEGF 120 recruited peripheral vessels but was incapable of vascularizing the tumor itself. 
In  contrast,  the  high  local  concentration  of the  heparin-binding  VEGF 188  resulted  in 
highly vascularized tumors with a retarded growth rate, as these tumors failed to connect to 
the systemic vasculature. Only VEGF 164, with heparin-binding and diffusible properties, 
induced both  internal  and  external  tumor vascularization,  fully rescuing  growth  of the 
angiogenesis-deficient tumor [263]. Analogous results have been observed with isoform- 
specific  VEGF  transgenic  mice  [61,  254].  Interestingly,  tumors  that  form  following 
injection  of different combinations  of immortalized,  VEGF  isoform-specific  fibroblasts 
primarily contain VEGF 164-expressing fibroblasts, indicating that this isoform confers a 
growth advantage in certain tumors [263]. A similar alteration of VEGF protein expression 
patterns  in  favor of the  membrane-associated  isoforms  has  been  observed  in  lung  and 
colorectal  tumor  tissues  [264].  Finally,  VEGF165  and  VEGF188  expression  has  been 
associated with poorer outcomes  in osteosarcomas and colon cancer,  respectively [265, 
266]. Taken together, these data suggest that soluble VEGF may be needed in the stages of 
tumor development in which the tumor has to recruit systemic vessels to ensure its blood 
supply.  The heparin-binding forms appear to support the vascularization of the capillary 
bed within the tumor, inducing the formation of thin, highly branched and interconnected 
vessels [133, 263].
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1.6.2.2  Intraocular disease and the predominant role of the VEGF164/165 
isoform
Numerous  studies  suggest a causal role  for VEGF  activity in proliferative,  neovascular 
pathologies of the eye  [34, 267-269].  In diabetic retinopathy, retinopathy of prematurity 
(ROP),  and  the  wet  form  of  adult  macular  degeneration,  VEGF  not  only  causes 
uncontrolled  neovascular  growth  that  damages  the  retina,  but  also  promotes  vascular 
leakage of plasma proteins  and  vitreous  hemorrhages  that  eventually lead to  blindness 
[270].  During pathological proliferative retinopathy,  hypoxia-induced VEGF production 
by ischemic  retinal  cells  results  in  aberrant  vessel  growth  that  can  extend beyond  the 
retinal surface into the vitreous cavity [271]. Of the various isoforms, VEGF 164 appears to 
be  preferentially  involved  in  pathologic  retinal  neovascularization  and  selectively 
accumulates in the ischemic retina in a commonly used animal model of human ROP [272, 
273].  In this  model,  1-week  old  mice  are  exposed  to  75%  oxygen  for  a  5-day period 
followed  by  a  return  to  room  air.  Hypoxia-induced  upregulation  of VEGF  expression 
results in  abnormal  vessel  growth between P17  and  P21  and  is most prominent  at the 
leading  edge  of the  vascularized  retina  in  the  midperiphery  [274].  Inhibition  of the 
VEGF 164 isoform in this model has been shown to be as effective as pan-VEGF blockade 
in preventing neovascularization [273].
Recent evidence indicates that VEGF 164 is also the most pro-inflammatory iso form in the 
eye,  capable  of inducing  leukocyte  recruitment  (leukostasis)  to  the  limbal  and  retinal 
vascular  endothelium  [273,  275].  VEGF-induced  retinal  leukostasis  and  blood-retinal 
barrier  breakdown  is  mediated,  in  part,  through  upregulation  of intercellular  adhesion 
molecule-1   (ICAM-1) expression on the endothelium [276]. VEGF may also directly act
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on certain cells of the immune system, including monocytes, lymphocytes, and dendritic 
cells,  as  they  have  been  shown  to  express  active  VEGF  receptors  [166,  277].  On  an 
equimolar basis, VEGF 164 was reported to be approximately 1.5 times more potent than 
VEGF 120 in inducing retinal leukostasis, and about three times more potent in inducing 
corneal  inflammation  [275,  278].  The  significance  of this  isoform-specific  activity  is 
considerable as inflammatory cells not only contribute to blood-retinal barrier breakdown 
and  neovascularization,  but  also  produce  VEGF  themselves  [279].  In the  ROP  model, 
adherent  leukocytes  are  commonly  associated  with  pathological  neovascularization. 
Because  VEGF-induced  pathological  vessel  growth  is  frequently  preceded  by  an 
inflammatory response, it has been suggested that recruited leukocytes serve to mark the 
site of future neovascularization [273]. VEGF 165/164 expression also predominates over 
other isoforms in human diabetic  retinopathy and in an animal model of diabetes  [279, 
280].  Retinal inflammation and leakage in both early and established diabetes could be 
significantly reduced when VEGF 164 activity was blocked by an isoform-specific, RNA- 
based  aptamer  antagonist  [278].  This  finding  was  surprising,  given  that  the  abnormal 
wound-healing  response  of  diabetes  involves  a  complex  inflammatory  process  with 
changes in expression patterns of numerous factors [22].
Taken together,  these observations  suggest that VEGF 164  is  the major disease-causing 
isoform  in  models  of  neovascular  eye  disease.  The  above  mentioned  highlights  the 
importance  of understanding  the  specific  contributions  and the  interplay  of the  VEGF 
isoforms regarding their normal physiologic role and in vascular pathologies. In particular, 
the expression, distribution and function of the major isoforms (i.e VEGF121, VEGF 165 
and VEGF 189) in a spatial-temporal context must be better defined.
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were performed by Kazuaki Nishijima (Eyetech Research Center). Real-time quantitative 
PCR  was performed  and  analyzed by Michael  Gee  (Eyetech Research  Center).Circular 
dichroism  spectroscopy  was  performed  by  Indrajit  Giri  (OSI)  Eyetech.  The  PAE  cell- 
binding assay was performed by Andrea de Erkenez (Eyetech Research Center). Animal 
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2.1 Materials
2.1.1 Reagents
All chemicals were obtained from Sigma-Aldrich and Fluka, unless indicated otherwise. 
All  mammalian tissue  culture  media  and  related products  were purchased  from  Gibco 
(Invitrogen),  unless  stated  otherwise.  All  restriction  endonucleases  were  from  New 
England  Biolabs.  Oligonucleotides  were  provided  by  Cancer  Research  UK  (CRUK)
125 oligonucleotide synthesis  service or purchased  from  Proligo  or Invitrogen.  Human  I- 
VEGF and tritium-labeled heparin ([3H]-heparin) were obtained from GE Healthcare and 
Perkin Elmer,  respectively.  All protease inhibitors  were  obtained  from  Roche,  whereas 
heparinase I and III was obtained from Sigma-Aldrich. The expression vectors pPICZaC- 
VEGF120  and pPICZaC-VEGF164  were  used  for  expression  of full-length,  untagged 
VEGF 120 and VEGF 164 in Pichia pastoris and were a gift of Dr. M. Golding (CRUK).
2.1.2 Oligonucleotides
For subcloning of human VEGF111-165 (HBD) into pPICZaC expression vectors: 
VEGF-HBD (XhoD
5’- CCGCTCGAGAAGAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGC -3’ 
VEGF-HBD (XbaD
5’- GCT  CT  AG  ATT  AT  C  ACCGCCT  CGGCTT  GT C  AC  AT  CT  GC  AAGT -3’
For generating VEGF 164 HBD mutants:
164-R13/R14A
5’- TGTGAGCCTTGTTCAGAGGCGGCAAAGCATTTGTTTGTCC -3’
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164-A13R (R13A reverse)
5’- GAGCCTTGTTCAGAGCGGGCAAAGCATTTGTTTGTCC -3’
K26A
5’- GT  CC  AAG  AT  CCGC  AG  ACGT  GT  GC  AT  GTT  CCT  GC  AA -3’
164-K30A
5’- CGTGTAAATGTTCCTGCGCAAACACAGACTCG -3’
164-R35/R39A
5’- AAC  AC  AG  ACT  CGGCTT  GC  AAGGCGGC GC  AGCTT  G  AGTT  AAACG -3’ 
164-R46/R49A
5’- TGAGTT  AAACG  AAGCT  ACTT  GCGC  AT GT  G  AC  AAGCCG  AGG -3’ 
164-R49A
5’- AACGAACGT  ACTT  GCGC  AT GT  GAC  AAGCCG  AGG -3’
(Nucleotides in bold indicate mutations)
For sequencing of pPICZaC constructs:
Forward
5’AOX-l  5’- GACTGGTTCCAATTGACAAGC -3’
a-Factor  5’- T  ACT  ATT  GCC  AGC  ATT  GCT  GC -3’
Reverse
3’AOX-l 5’- GC  AAAT  GGC  ATT  CGT  AC  AT  CC -3’
PIC/BsmB I 5’- TCGAGGTACCGATCCGAGACG -3’
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For genotyping of VEGF1 2 0  1 8 8  mice:
VEGF120FOR  5’- C  AGT  CT  ATT  GCCT  CCT  G  ACCTT  C  AGGGT  C-3 ’
VEGF 12 ORE  V  5’- CTT  GCGT  CC  AC  ACCGT  C  AC  ATT  AAGT  C  AC-3 ’
VEGF120COM  5’- TTCAGAGCGGAGAAAGCATTTGTTTGTCCA-3’
VEGF188FOR  5’- GAT  C  AAACCT  C  ACC  AAAGCC  AGC  AC  AT  AG-3 ’
VEGF188REV  5’- TT  GT  C  AC  AT  CT GC  AAGT  ACGTT  CGTTT  AAC-3 ’
VEGF188COM  5’- GT  GGGT  AG  AG  AAAGG  AGG  AG  AAAAC  AAG-3 ’
Real-time PCR (Taqman) primers and probes (ABI, sequences not disclosed): 
human tissue factor  sequence reference: NM  001993 RefSeq, Exon3/4 (535bp)
human GAPDH  forward and reverse primer, probe (ABI 402869)
2.2  Methods
2.2.1 Bacterial culture
2.2.1.1 Preparation of electrocompetent bacteria
800 ml of LB medium inoculated with 5 ml of an ovemight-culture of XL-1 Blue bacteria 
(Stratagene)  was  grown  at  37  °C  with  shaking  to  an  O D 5 9 5   of 0.6.  The  culture  was 
incubated on ice for 30 min and centrifuged at 5,000 rpm  for 20 min at 4 °C using an 
Avanti JE centrifuge (Beckman Coulter) with a JA-10 rotor. The pellet was washed twice 
with 500 ml ice-cold water and once with 400 ml ice-cold  10% glycerol. The pellet was 
resuspended in  1   volume ice-cold  10% glycerol and tested for transformation efficiency.
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Preparations that gave >108  colonies/pg plasmid DNA in test transformations were stored 
at -80 °C.
2.2.1.2 Transformation of bacteria
50-500 pg DNA were added to 80 pi of competent cells in a 1  mm electroporation cuvette 
(Bio-Rad)  and  the  mixture  was  incubated  on  ice  for  10  min.  Transformations  were 
performed at 200 Q, 25 pF, and 1.8 kV. Bacteria were incubated with 400 pi SOC medium 
at 37 °C for 1   hr and then centrifuged at 3,500 rpm for 1   min in a microfuge. The pellet 
was resuspended in  100 pi LB medium, plated on agar plates containing the appropriate 
selection agent and incubated for up to 18 hr at 37 °C.
2.2.1.3 Cryopreservation of bacteria
Bacterial cultures were stored as 40% glycerol stocks at -80 °C.
2.2.2  Yeast techniques
2.2.2.1  Pichia pastor  is strains
Strain Genotype Phenotype
X-33 wild-type Mut+  (methanol utilization plus)
GS115 his4 His', Mut+
KM71H arg4 aoxl :: ARG4 Muts (methanol utilization slow), Arg+
SMD1168H pep4 Mut+, deficient in protease A
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2.2.2.2 Preparation of electrocompetent yeast cells
250 ml of YPD medium (1% (w/v) yeast extract; 2% (w/v) peptone; 2% (w/v) dextrose) 
was inoculated with 0.125 ml of a 3 ml overnight culture of the Pichia pastoris strain and 
incubated overnight at 30 °C to an OD6ooof 1.3-1.5. The cells were centrifuged at 1500 x g 
for 5 min at 4 °C and then resuspended with 250 ml of ice-cold, sterile water. This washing 
step was repeated with 125 ml of ice-cold water before resuspending the pellet in 10 ml of 
ice-cold,  1   M sorbitol. After centrifugation, the pellet was resuspended in 0.5 ml of ice- 
cold 1  M sorbitol for a final volume of approximately 0.75 ml. The cells were kept on ice 
and used within 3 hr.
2.2.2.3 Transformation of yeast cells
Plasmids  (10  pg)  were  linearized  to  completion  with  SacI  and  purified  by  phenol 
extraction. 80 pi of electrocompetent cells were mixed with 5-7 pg of the linearized DNA 
and transfered to an ice-cold, 2 mm electroporation cuvette (Bio-Rad). After incubation on 
ice for 5 min, the cells were pulsed at 200 Q, 25  pF,  and  1.5 kV using the Gene Pulser 
Xcell™ (Bio-Rad). 0.5 ml of ice-cold,  1   M sorbitol was immediately added to the cuvette 
before transfering the contents to a sterile  15  ml tube. The tube was incubated at 30 °C 
without shaking for 1  hr. 50 and 100 pi of culture were spread on separate, labeled YPDS 
agar (YPD;  1  M sorbitol, 2% (w/v) agar) plates containing  100 pg/ml, 200 pg/ml, or 500 
pg/ml zeocin. The plates were incubated for 3-5 days at 30 °C.
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2.2.2.4  Analysis of transformants for protein expression
Transformants were screened for high-secreting colonies using a modified colony blotting 
protocol [281]. A nitrocellulose filter (GE Healthcare) was placed over the colonies of the 
master plate for 1   min. The filter was carefully removed and placed upside-down onto a 
BMGY  agar  plate  (1%  (w/v)  yeast  extract;  2%  (w/v)  peptone;  100  mM  potassium 
phosphate,  pH  6;  1.34%  (v/v)  yeast  nitrogen  base;  4  x  10"5%  (v/v)  biotin;  1%  (v/v) 
glycerol; 2% (w/v) agar) and incubated overnight at 30 °C. To induce protein expression 
and secretion, the filter was then placed on a BMMY agar plate (1% (w/v) yeast extract; 
2% (w/v) peptone; 100 mM potassium phosphate, pH 6; 1.34% (v/v) yeast nitrogen base; 4 
x 10'5  % biotin; 0.5% methanol; 2% (w/v) agar) onto which 100 pi of BMMY medium had 
been spread out.  The plate was returned to  a 30 °C  incubator overnight.  The filter was 
transfered to a fresh BMMY agar plate and incubated again overnight. The nitrocellulose 
filter was removed and washed in tris-buffered saline (TBS; 20 mM Tris base and 150 mM 
NaCl,  pH  7.5)  to  remove  the  yeast  colonies.  Subsequently,  the  filter  was  blocked  in 
blocking  buffer  (PBSMT;  3.8  mM  sodium  phosphate  monobasic,  16.2  mM  sodium 
phosphate dibasic,  150 mM NaCl, pH 7.4, 5% (w/v) nonfat dry milk, 0.05% (v/v) Tween- 
20) for 2 hr and then incubated with a mouse monoclonal anti-VEGF antibody (C-l, Santa 
Cruz,  1:250  dilution)  in  blocking  buffer  for  1   hr.  The  filter  was  washed  with  PBST 
(phosphate-buffered saline (PBS) containing 0.05% Tween-20) for 20 min, incubated with 
blocking  buffer  containing  a  horseradish  peroxidase  (HRP)-conjugated  anti-mouse 
secondary antibody (GE Healthcare) and washed with PBST for 20 min. Immunoreactivity 
was  detected using  enhanced  chemiluminescence  (ECL,  GE  Healthcare).  Colonies  that 
showed the  strongest  signal  were  selected  for protein  expression.  Alternatively,  Pichia
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clones were tested for insertion of the gene of interest by direct PCR screening (Chapter 
2.2.4.8.3).
2.2.2.5 Determination of the Mut (methanol utilization) phenotype
o
All zeocin-resistent transformants in KM71H  are Mut  because the AOX1  gene,  which 
encodes one of the two methanol utilizing enzymes, is disrupted. Most of the transformants 
in X-33, GS115 or SMD1168H should have been Mut+. To exclude the possibility that the 
cross-over recombination occured in the 3’- AOX1  region of the Pichia genome, thereby 
disrupting the wild-type AOX1  gene and creating a Muts transformant, a replica-plating 
assay was used. Ten colonies were patched on an MDH (1.34% (v/v) yeast nitrogen base, 4 
x  10'5   %  (v/v)  biotin,  2%  (v/v)  dextrose,  0.004%  (v/v)  histidine)  plate  using  sterile 
toothpicks. The plate was incubated at 30 °C for 2 days. The patches were then replica- 
plated from the MDH plate onto fresh MMH (same as MDH, except 0.5% methanol was 
used instead of dextrose) and MDH plates. The replica plates were incubated at 30°C for 2 
days and growth on MDH and MMH plates was compared with the growth of Muts and 
Mut+ control patches in order to determine the phenotype.
2.2.2.6 Cryopreservation of yeast cells
A single colony of each strain or transformant was cultured at 30 °C overnight in YPD (1% 
(w/v)  yeast  extract,  2%  (w/v)  peptone,  2%  dextrose).  The  cells  were  harvested  and 
suspended in 20% glycerol at a final OD6ooof 30-50 (1.5-2.5 x  109  cells/ml). Cells were
frozen in liquid nitrogen and stored at -80°C. Using a sterile pipette tip, approximately 20
65Chapter 2 Materials and methods
pi of cells were taken from the frozen vial and were streaked out on YPD agar plates (for 
transformants, 100 pg/ml zeocin was added to the YPD medium) to obtain single colonies.
2.2.3  Tissue culture
2.2.3.1 Routine culture of mammalian cells
HUVEC  (Cascade Biologies)  were cultured in M200 media supplemented with  lx  low 
serum  growth  supplement  (Cascade  Biologies),  2mM  glutamine  and  lx 
penicillin/streptomycin  (Invitrogen).  PAE  cells  were  cultured  in  Ham’s  F12  medium 
supplemented with  10% FBS, 2 mM glutamine and  lx penicillin/streptomycin.  All cells 
were grown at 37 °C in an atmosphere of 5% CO2 / 95% air. All cell lines were trypsinized 
using a lx trypsin/EDTA solution (Invitrogen). Cells were thawed by diluting the contents 
of a vial in 9 volumes of medium, sedimenting the cells at 500x g and resuspending the 
pellet in the appropriate volume of complete medium.
2.2.3.2 Cryopreservation of mammalian cells
Cells were frozen in 10% DMSO, 20% fetal bovine serum (FBS), 70% complete medium 
and were stored in liquid nitrogen using standard procedures.
2.2.3.3 Tissue factor (TF) induction in HUVEC
HUVEC cells were seeded at 8x 104 cells per well in a 12-well plate in complete medium. 
24 hr later, the cells were serum-starved for 4 hr in M200 media containing 1% FBS and 
antibiotics.  The cells  were rinsed once with M200 media without  serum  before adding
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VEGF variants (0.3 pmol) in 1  ml of serum-free medium or medium without VEGF. After 
incubation at 37 °C for 1  hr, the cells were rinsed once with PBS and processed for RNA 
isolation. The RNA was used to test for tissue factor expression (chapter 2.2.5.5)
2.2.3.4  Binding of VEGF variants to PAE cells
PAE cells were seeded at 3.0 x 105  cells/well in 12-well dishes and were cultured for 24 hr. 
Cells were washed once with binding buffer (Ham’s F-12K medium containing 0.1% (w/v) 
bovine serum albumin (BSA), pH  7.5)  Binding of purified mouse VEGF variants  (7.14 
nM) to the cell surface was carried out in binding buffer for 30 min at 37 °C and 5% CO2. 
Unbound VEGF was removed with a pipette and the cells were washed three times with 
binding  buffer  before  bound  VEGF  was  enzymatically  dissociated  from  cell-surface 
heparan sulfate proteoglycans. To this end, heparinase I and III were prepared immediately 
before each experiment by dissolving  in 20  mM  Tris-HCl  (pH  7.5)  containing 50 mM 
NaCl, 4 mM CaCL, and 0.01% (w/v) BSA. The enzymes were added to the cells at a final 
concentration of 0.5 U/ml and the mixture was incubated for 1   hr at 37 °C and 5% CO2. 
The supernatant of each well was collected with a pipette and cells were washed one more 
time with binding buffer. The concentration of VEGF in the supernatant and the final wash 
was determined using the mouse VEGF Quantikine® ELISA kit (R&D) according to the 
instructions of the manufacturer.
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2.2.4 DNA techniques
2.2.4.1 Quantitation of DNA
DNA was diluted in an appropriate buffer and placed in a quartz cuvette with a path length 
of 1   cm, and the absorbance was read at 260 nm and 280 nm using a spectrophotometer. 
An OD26oof 1  corresponds to 50 pg/ml double-stranded or 33 pg/ml single-stranded DNA. 
The OD260/280 ratio was calculated to estimate the purity of the DNA preparation. A ratio of 
1.7-1.9 was considered acceptable.
2.2.4.2 Phenol/chloroform extraction
To  remove  proteins  from  DNA  preparations,  DNA  was  mixed  with  1   volume  of  a 
phenol/chloroform/isoamyl  alcohol  (25:24:1)  mixture,  vortexed  and  centrifuged  in  a 
microfuge at 14,000 rpm for 5 min at room temperature. The aqueous DNA solution was 
transfered to a fresh tube and residual phenol was removed by extracting the DNA with 1  
volume chloroform. The DNA was then precipitated with ethanol.
2.2.4.3 Ethanol precipitation of DNA
The salt concentration of the DNA was adjusted by adding  1/10 volume of 3  M sodium 
acetate (pH 5.2). 2.5 volumes of ice-cold, 100% ethanol were then added and the resulting 
solution mixed and centrifuged at maximum speed in a microfuge for 30 min at 4 °C. The 
DNA pellet was washed twice with 70% ethanol, air-dried and resuspended in TE buffer 
(lOmM Tris, pH 8.0, ImM EDTA) or water.
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2.2.4.4 Preparation of plasmid DNA
Plasmid DNA was prepared from overnight cultures of bacteria (1.5  ml  for DNA mini 
preparations,  50-80 ml  for DNA midi preparations) which were  grown at 37  °C  in LB 
medium containing Ampicillin (75 pg/ml) or Zeocin (25 pg/ml). DNA was purified using 
Qiagen  plasmid  mini  kits  or  QiaFilter  plasmid  midi  kits  (Qiagen)  according  to  the 
manufacturer’s instructions.
2.2.4.5 DNA agarose gel electrophoresis
Agarose gels were prepared by dissolving 0.7%-2% agarose in TAE buffer (40 mM Tris 
base, pH 8.0, 20 mM glacial acetic acid,  ImM EDTA). Ethidium bromide was added to a
TM
final concentration of 0.5 pg/ml. DNA samples were mixed with lOx BlueJuice  loading 
buffer (Invitrogen) and electrophoresed at 5-20 V/cm in running buffer (TAE). A 100 bp or 
1  kb DNA ladder (Invitrogen) was run in parallel for comparison.
2.2.4.6 Gel purification of DNA fragments
DNA fragments were excised from agarose gels and purified using a gel extraction and 
nucleotide removal kit (Qiagen).
2.2.4.7 Restriction enzyme digestion
For  small-scale  diagnostic  digests,  1   pg  of  DNA  was  incubated  in  the  appropriate 
restriction enzyme buffer with 5-10 U of restriction endonuclease in a total volume of 20 
pi. The reaction was incubated at the appropriate temperature for  1-2 hr. For large-scale
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preparative digests,  10-20 pg of DNA was mixed with the appropriate buffer and 20-40 U 
of  restriction  endonuclease  in  a  total  volume  of  100-150  pi,  and  incubated  at  the 
appropriate  temperature  for  3-6  hr.  Following  digestion,  enzymes  were  inactivated  by 
incubating at 65 °C for 20 min or by phenol/chloroform extraction.
2.2.4.8  Polymerase chain reaction (PCR)
2.2.4.8.1  Genotyping of VEGFI20/I88mice by PCR analysis
For each DNA sample, two PCR reactions were performed to screen for the deletion of 
exons 6 and  7 'VEGF 120)  and  the  presence of  exons  4-8  (VEGF 188),  respectively.
Reactions  were carried  out  in  the  appropriate buffer containing  150ng  genomic  DNA,
lOOpM of each primer (chapter 2.1.2),  lOmM dNTP, 0.75pl MgCE (50 mM), and 0.2pl 
Taq Polymerase in a total volume of 25pi using the following conditions:
VEGF120:
Segment 1   1  cycle  denaturation at 94°C for 90 sec
Segment 2  4 cycles  denaturation at 94°C for 1  min
annealing at 55°C for 45 sec 
extension at 72°C for 90 sec 
Segment 3  24 cycles  denaturation at 94°C for 1  min
annealing at 60°C  for 1  min
extension at 72°C for 1  min
Segment 4  1  cycle  extension at 72°C for 15 min
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VEGF188:
Segment 1  1 cycle  denaturation at 95 °C for 90 sec
Segment 2  27 cycles  denaturation at 95°C for 1 min
annealing at 62°C for 45 sec 
extension at 72°C for 90 sec 
Segment 3  1 cycle  extension at 72°C for 10 min
2.2.4.8.2  PCR-cloning of VEGF111-165 (HBD)
For subcloning of the cDNA encoding the C-terminal, 55-residue fragment of VEGF 165 
(HBD), primers were designed so that they were in frame with the Pichia a-factor signal 
peptide, which  is removed  proteolytically from the protein  in the yeast cell. The  reaction
was carried  out in the  appropriate buffer  containing  1   ng of VEGF 165  cDNA  encoding
pPICZaC-VEGF165 vector, 0.5 pM of each primer, 200 pM dNTP (Roche) and 5 U high- 
fidelity  Pfu  DNA  polymerase  (Stratagene).  The  PCR  amplification  was  performed  by 
using the hot-start method and the following cycling conditions:
Segment 1   1  cycle  denaturation at 95 °C for 1  min
Segment 2  30 cycles  denaturation at 95 °C for 1  min
annealing at 65 °C for 1  min
extension at 72 °C for 1  min
Segment 3  1  cycle  extension at 72 °C for 5 min
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The resulting PCR product was digested with Xhol and Xbal restriction endonucleases to 
generate  cohesive  ends  for the  subsequent  ligation  with  Xhol-  and  Xbal-digested  and 
purified pPICZaC expression vector (Invitrogen).
2.2.4.8.3 Direct PCR screening of Pichia clones
Pichia transformants were screened for the presence of the gene of interest using a PCR 
protocol by Linder et al. [282], A single yeast colony was suspended in 10 pi of water and 
the cells were lysed by adding 25 U of Lyticase. After  10 min at 30 °C the sample was 
frozen at -80  °C  for  10 min.  Three pi of the lysate containing the genomic  DNA, was 
mixed with 20 pmol primer  1   (5’- AOX1), 20 pmol primer 2  (3’- AOX1),  and  15  pi of 
Mega Mix Blue (Helena Biosciences). The resulting PCR products were visualized after 
gel electrophoresis. The cycling conditions for were as follows:
Segment 1   1  cycle  denaturation at 94 °C for 1  min
Segment 2  32  cycles  denaturation at 94 °C for 40 sec
annealing at 64 °C for 1  min 
extension at 72 °C for 1  min 
Segment 3  1  cycle  extension at 72 °C for 3 min
2.2.4.9  Cohesive-end ligation
Following digestion of vector and insert, the linearized vector was dephosphorylated with 
0.5 U/pg DNA of alkaline phosphatase (CIP, New England Biolabs) at 37 °C for 1   hr, to
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prevent recircularisation. Vector and insert were gel-extracted and precipitated. Ligations 
were performed using 200-300 ng total DNA and 400U T4 DNA ligase (New England 
Biolabs) in a final volume of 15  pi. The vector to insert molar ratios were  1:2,  1:6, and 
1:12. The reaction was carried out overnight at  16 °C.  1   pi of the ligation reaction was 
transformed into electrocompetent E. coli as described above.
2.2.4.10  Site-directed mutagenesis
In  vitro  site-directed  mutagenesis  was  performed  using  the  QuikChange™  multi  site- 
directed  mutagenesis  kit  (Stratagene).  Oligonucleotide  primers  containing  the  desired 
mutation flanked by unmodified nucleotide sequence were synthesized, then purified by 
HPLC and ethanol precipitation. Primers were designed to bind to adjacent sequences or to 
separate regions on the same strand of the template plasmid and were usually 32-43 bp in 
length with a minimum GC content of 40% and a melting temperature (Tin) of > 75 °C. 
The  primers  terminated  in  one  or  more  C  or  G  bases  at  the  3’-  end  and  were  5’- 
phosphorylated  for  better  mutagenesis  efficiency.  Reactions  were  carried  out  in  the 
appropriate  buffer in 25  pi  using  100  ng  of each primer,  50  ng  double-stranded DNA 
template,  1   pi  dNTP  mix,  and  1   pi  of Pfu  Turbo  DNA  polymerase  enzyme  blend 
(Stratagene). The following PCR conditions were used:
Segment 1   1  cycle  denaturation at 95 °C for 1  min
Segment 2  30 cycles  denaturation at 95 °C for 1  min
annealing at 55  °C for 1  min
extension at 65 °C for 2 min/kb of plasmid length
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The reaction was placed on ice for 2 min before adding  10 U of Dpnl-restriction enzyme 
for  1   hr at37°Cto digest the parental (nonmutated)  DNA template.  1.5  pi of the Dpnl- 
treated  DNA  was  transformed  into  XL 10-Gold  ultracompetent  cells  (Stratagene)  by 
incubating at 42 °C for 30 seconds. SOC medium (0.5% yeast extract, 2.0% tryptone,  10 
mM NaCl, 2.5 mM KC1, 10 mM MgCk , 20 mM MgSCL, 20 mM glucose) was added and 
the  tubes  were  incubated  at  37  °C  for  1   hr.  Different  amounts  of each  transformation 
reaction  were  spread  on  low  salt  LB  agar  plates  containing  25  pg/ml  Zeocin.  The 
mutagenesis efficiency of a control plasmid was determined as a positive control for each 
experiment.
2.2.4.11  DNA sequencing
Primers of 21  nucleotides in length were designed to amplify a region within the gene of 
interest or the vector sequence adjacent to the 5’  and 3’- end of the gene. Reactions were 
carried out in a volume of 20 pi containing 300-500 ng DNA, 3 pmol of primer and 8 pi of 
fluorochrome  labeling  mix  (Cancer  Research  UK)  using  a  thermal  cycler.  The  PCR 
conditions were as follows:
Segment 1   25 cycles  denaturation at 96 °C for 10 sec
annealing at 50 °C for 5 sec 
extension at 60 °C for 4 min
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Samples were ethanol-precipitated,  electrophoresed and visualized.  SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and visualization were performed by the Cancer Research 
UK Sequencing Service.  Alternatively,  sequencing was performed by ACGT, Inc.  DNA 
sequence analysis and alignment was performed using the software programs Mac  Vector 
(Accelrys) and Sequencher (Gene Codes Corporation).
2.2.5 RNA techniques
2.2.5.1 RNA isolation
Total RNA was isolated from cells using the RNeasy mini kit (Qiagen). 3-5 x 105  HUVEC 
were lysed in 350 pi RLT buffer (Qiagen). The lysate was passed through a QIAShredder 
spin column and then loaded on an RNeasy mini column. Further purification steps were 
carried  out  according  to  the  manufacturer’s  instructions.  RNA  was  eluted  in  water, 
visualized on an agarose gel, quantified and stored at -80 °C.
2.2.5.2 RNA quantitation
RNA solutions were placed in a quartz cuvette (1  cm path length) and the absorbance of 
the sample was determined at 260 nm and 280 nm using a spectrophotometer. An OD260 
value of 1, which corresponds to 40 pg/ml RNA, was used as a reference for calculations. 
An OD260/280 ratio of 1.9-2.1 indicated a pure preparation.
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2.2.5.3 RNA agarose gel electrophoresis
1.2% agarose gels were prepared in TBE buffer (45 mM Tris-borate, pH 8.0, ImM EDTA) 
containing ethidium bromide at a final concentration of 0.5 pg/ml. RNA was mixed with 
lOx  BlueJuice™  gel  loading  buffer  (Invitrogen)  and  electrophoresed  at  5-20  V/cm  in 
running buffer (TBE). Distinct ribosomal RNA bands with the 28S rRNA band of double 
intensity relative to the  18S rRNA band were an indication of intact RNA. Alternatively, 
RNA samples were loaded on an RNA 6000 Nano Chip (Agilent Technologies) and run on 
a Bioanalyzer 2100 (Agilent Technologies) according to the manufacturer’s instructions.
2.2.5.4 Reverse transcriptase PCR (RT-PCR)
Reverse transcription of RNA was performed using 100-200 ng RNA and TaqMan reverse 
transcription reagents (Applied Biosystems, ABI). The final concentration of the reaction 
was lx Taqman Reverse Transcriptase buffer, 5.5 mM MgC^, 500 pM  of dNTPs, 2.5 pM 
random hexamer primers,  0.4  U/pl  RNase inhibitor,  and  1.25  U/pl  Multiscribe  reverse 
transcriptase in a total volume of 60 pi. cDNA synthesis was carried out in a thermal cycler 
according to the following program:
Segment 1   1  cycle  25 °C for 10 min
Segment 2  1  cycle  42 °C for 60 min
Segment 3  1  cycle  95 °C for 5 min
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2.2.5.5  Real-time quantitative PCR (Taqman) for TF expression
Taqman cocktails were prepared using lx PCR master mix (Applied Biosystems, ABI), lx 
Tissue Factor Assay-on-Demand/FAM (ABI), and 2 pi of cDNA in a total volume of 10 pi. 
GAPDH served as the internal control for all reactions,  and was  amplified with human 
GAPDH  primers  and probe  (ABI),  using  lx  PCR  master  mix  (ABI),  10  pM  of each 
forward and reverse GAPDFI primer, and 20 pM of GAPDH probe in a total volume of 10 
pi. Reactions were loaded on a 384-well plate and run in the ABI Prism 7900HT System 
using the following cycling conditions:
Segment 1 1  cycle 50 °C for 2 min
Segment 2 1  cycle 95 °C for 10 min
Segment 3 40 cycles melting at 95 °C for 15 sec
annealing and extension at 60 °C for 1  min
Gene expression was analyzed using the SDS 7900HT software version 2.2 (ABI). Results 
were  quantified  using  the  comparative  threshold  (Ct)  method  [283].  Briefly,  relative 
expression levels were calculated in comparison to the non-treated control using arithmetic 
formulae.  The  amount  of target,  normalized  to  the  endogenous  GAPDH  housekeeping 
gene and relative to  the non-treated control,  was then given by 2'A A Q ,  representing the 
normalized expression of the target gene in the unknown sample, relative to the normalized 
expression of the non-treated sample.
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2.2.6 Protein techniques
2.2.6.1 Protein quantitation
Protein concentrations were determined using the bicinchoninic acid (BCA)-based protein 
assay (Pierce).  Samples and the BSA standards were diluted in sample diluent to a total 
volume of 25 pi and mixed each with the BCA working reagent (200 pi) in a 96-well plate. 
After incubation at 37  °C  for 30 min,  the absorption was measured  at  562  nm using a 
spectrophotometer.  Standard  curves  were  generated  based  on  the  absorbance  of BSA 
standards and were used to determine the protein concentrations of the samples.
2.2.6.2 Protein precipitation with trichloroacetic acid (TCA)
Protein samples were mixed with 0.1 volumes of 100% TCA, incubated on ice for 30 min 
and  centrifuged  at  14,000  rpm  for  15  min  at  4  °C  in  a  microfuge.  Supernatants  were 
completely  removed  and  pellets  washed  with  300  pi  acetone  (-20  °C),  dried  and 
resuspended in SDS-PAGE sample buffer.
2.2.6.3 Endotoxin detection
To determine the endotoxin levels in recombinant protein samples prior to animal injection, 
a Pyrosate test kit (Associates of Cape Cod) with a sensitivity of 0.25 endotoxin units (EU) 
per ml was used according to the instructions of the manufacturer. A positive control was 
run  in parallel.  The absence of clot formation  in the protein  samples  indicated that all 
samples contained less than 0.25 EU/ml.
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2.2.6.4  SDS-PAGE
Gels were poured at a thickness of 1-1.5 mm using the Bio-Rad Mini-PROTEAN® 3 Cell 
assembly  kit  or  the  Bio-Rad  Criterion™  Cell  system  and  solutions  from  National 
Diagnostics. The separating gel was prepared as follows:
Final
acrylamide
concentration
(%)
ProtoGel
(ml)
Resolving
buffer
(ml)
Deionised water 
(ml)
8 2.67 2.5 4.72
10 3.33 2.5 4.06
12 4 2.5 3.39
15 5 2.5 2.39
100 pi of 10% ammonium persulfate (APS) and  10 pi TEMED were added per 10 ml of 
gel solution to initiate polymerisation. The stacking gel was prepared by mixing  1.3  ml 
ProtoGel, 2.5 ml ProtoGel Stacking Buffer, 6.1 ml deionised water and adding 50 pi APS 
and  10 pi TEMED.  SDS  sample buffer was prepared as a 6x stock solution, containing 
0.35 M Tris-HCl (pH 6.8), 10% SDS, 0.6 M DTT, 30% glycerol, and 0.012% bromphenol 
blue. Protein samples were boiled in  lx SDS sample buffer at  100 °C for 5 min prior to 
loading.  For detection of protein dimers, proteins were denatured in SDS  sample buffer 
without dithiothreitol (DTT). Gels were run in Tris-glycine buffer (25 mM Tris, 250 mM
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glycine (pH 8.3), 0.1  % SDS) at  100-170 V. The gels were stained in Coomassie R-250 
using Imperial™ Protein Stain (Pierce)  for  1   hr and destained in water until bands were 
clearly visible.
2.2.6.5  Western blotting
Following electrophoretic separation, proteins were blotted onto nitrocellulose membranes 
(Hybond™, GE Healthcare) using a semi-dry blotter (Bio-Rad). Membranes and pieces of 
Whatman paper were soaked in transfer buffer (8ml 5x Tris-glycine buffer, 20 ml methanol, 
and  72ml  water).  The  gel  and  the  membrane  were  sandwiched  between  six  pieces  of 
Whatman paper,  with the membrane facing the anode of the electroblotter. The transfer 
was carried out at  120 mA per gel for  1   hr. Membranes were rinsed with PBS and then 
incubated in blocking buffer (5% non-fat dry milk in PBS with 0.05% Tween-20) for 2 hr 
at  room  temperature,  or  overnight  at  4  °C.  Blots  were  incubated  in  blocking  buffer 
containing  a primary  antibody  for  1-2  hr  at  room  temperature.  The  following  primary 
antibodies were used: mouse anti-VEGF (C-l,  1: 250, Santa Cruz Biotechnology), rat anti- 
VEGFi64 (1:  250,  R&D  Systems).  The  blots  were  washed with  PBS  containing  0.05% 
Tween-20  for 20  min,  and  incubated  with  a  horseradish  peroxidase  (HRP)-conjugated 
secondary antibody diluted in blocking buffer for 1  hr at room temperature. The following 
secondary antibodies were used: sheep anti-mouse IgG (1:1000, GE Healthcare), goat anti­
rat IgG (1:1000, GE Healthcare). Blots were washed for 20 min in PBS containing 0.05% 
Tween-20  and  processed  for  detection  of  immunoreactivity  using  enhanced 
chemiluminescence (ECL, GE Healthcare).
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2.2.6.6  Expression and purification of recombinant VEGF proteins
2.2.6.6.1 Secreted expression of recombinant VEGF proteins
Recombinant wild-type and mutant VEGF variants were produced in the methylotrophic 
yeast Pichia pastoris. Three ml of YPD medium containing 25pg/ml zeocin was inoculated 
with a single colony of Pichia pastoris transformants and cultured overnight at 30 °C in a 
shaking incubator. 800 pi of the saturated overnight culture was inoculated into 400 ml of 
BMGY growth medium and grown at 30 °C until the culture reached an ODeoo of around 3, 
which indicated that the cells were in log-phase growth. The cells were then harvested by 
centrifuging at 2500 x g for 5 min. To induce expression, pellets of transformants with a 
Muts phenotype  were  resuspended  in  100  ml  of BMMY  induction  medium  containing 
0.01%  Antifoam  204  (Sigma),  whereas  transformants  of  the  Mut+   phenotype  were 
resuspended to an OD6oo of 1   in the same medium. Cultures were grown at 29-30 °C for 
36-42 hr and methanol was added to a final concentration of 1% every 12 hr to maintain 
induction of gene expression. The cultures were centrifuged at 7000 rpm for 12 min at 4 °C 
and  the  supernatants  were  filtered  through  a  vacuum-driven,  0.22  pm  Durapore® 
membrane filter (Millipore) and kept on ice. The supernatants were analyzed for protein 
expression by SDS-PAGE and Coomassie staining.
2.2.6.6.2  Purification  of  recombinant  VEGF111-165  (HBD)  by  affinity 
chromatography
For purification of VEGF 111-165 (HBD), the cleared supernatant was first concentrated from 
150 ml to 5 ml using Vivaspin-20 centrifugation filter units with a 3 kDa molecular weight 
cut-off (Sartorius). The concentrate was equilibrated by adding two volumes of
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heparin-affinity chromatography binding buffer (20 mM Tris (pH  7.4),  150 mM NaCl), 
centrifuged at 10,000 rpm for 10 min in a microcentrifuge to remove any precipitates, and 
loaded automatically onto a preequilibrated,  1  ml HiTrap Heparin HP column (Amersham 
Biosciences)  at a flow rate of 0.5  ml/min using the AKTA FPLC™ system  (Amersham 
Biosciences).  The  column was  washed with  3  column volumes,  then bound  HBD  was 
eluted from the column using a step gradient (0.15  M -   1.5  M NaCl)  over  15  column 
volumes. The fractions containing the protein were pooled and analyzed by SDS-PAGE 
and Coomassie staining. Method programming as well as analysis and evaluation of runs 
were performed using the Unicom 4.1 Software (Amersham Biosciences).
2.2.6.6.3  Purification of recombinant VEGF proteins by Ni-NTA chromatography
For purification of recombinant VEGF 120,  VEGF 164 and VEGF 164 HBD mutants, the 
cleared  cell  supernatant was  first  concentrated  from  150  ml  to  3  ml  using  Vivacell-70 
ultracentrifugation  filter units with  a  30  kDa molecular weight  cut-off (Sartorius).  The 
concentrate  was  equilibrated  by  diluting  with  2  volumes  of Ni-NTA  chromatography 
binding buffer ((pH 7.4), 2.7 mM KC1, 2 mM KH2  P04,8 mM Na2 P04,300 mM NaCl, and 
complete protease inhibitor without EDTA (Roche)),  and incubated with 0.5  ml of pre­
equilibrated Ni-NTA agarose (Qiagen) for 60 min at 4 °C.  Ni-beads were centrifuged at 
1700 rpm for 3 min and washed twice with 5 ml of binding buffer. Proteins were eluted 
with elution buffer (PBS containing  150 mM NaCl and 40 mM imidazole) in  1   ml steps 
and analyzed by SDS-PAGE and Coomassie staining.
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2.2.6.6.4  Size-exclusion chromatography
Eluates  from  both  purification  procedures  were  concentrated  to  100-200  pi  using 
Centricon™ or Microcon™ centrifugal filter devices with the appropriate molecular weight 
cut-offs (Millipore). Concentrated proteins were centrifuged at 10,000 rpm for 10 min and 
then  loaded  automatically  onto  a  preequilibrated  Superdex  75  10/300  GL  column 
(Amersham  Biosciences)  using  an  AKTA  FPLC™ system  (Amersham  Biosciences)  for 
buffer exchange  and isolation of protein dimers.  Proteins were  eluted in  storage  buffer 
(PBS  or TBS)  at  a  flow  rate  of 0.3  ml/min  and  collected  in  1   ml  fractions  using  an 
automatic  fraction  collector  (Amersham  Biosciences).  Fractions  containing  dimeric 
proteins were concentrated and filter sterilized using Ultrafree®-MC sterile centrifugal 
filter units (Millipore). Protein concentrations were determined using a BCA protein assay 
(Pierce), then proteins were snap frozen in liquid nitrogen and stored in aliquots at -80 °C.
2.2.6.7  Analytical heparin-affinity chromatography
To  determine  the heparin-binding  affinity of VEGF  variants,  200  pi  of heparin-binding 
buffer (20 mM Tris, 100 mM NaCl, pH 7.4) containing 50 pg of protein was loaded onto a 
preequilibrated, 1  ml HiTrap Heparin HP column (Amersham Biosciences) at a flow rate of
TM
0.25 ml/min using the AKTA FPLC  system (Amersham Biosciences). Unbound material 
was  removed  and  the  column  was  washed  with  3  column  volumes  of binding  buffer. 
Proteins were then eluted with a linear salt gradient (100 mM - 1  M NaCl) over 15 column 
volumes at a flow rate of 0.5 ml/min. Alternatively, proteins were loaded in heparin-binding 
buffer containing 0.15 M NaCl and eluted with a salt gradient (0.15 M -  1.5 M NaCl) over 
11 column volumes. The columns were reconstituted by washing with binding buffer, then
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with H2O, and were finally stored in 20% ethanol. Conductivity, pH and UV absorbance 
(280  nm)  were  measured  at  4  °C.  All  fractions  were  subjected  to  trichloroacetic  acid 
precipitation. Protein pellets were diluted in SDS sample buffer, boiled, separated on a 12% 
SDS-PAGE  gel  and  analysed by Coomassie  staining.  Method  programming  as  well  as 
analysis and evaluation of runs were performed using the Unicom 4.1 Software (Amersham 
Biosciences).
2.2.6.$ Nitrocellulose filter trapping assay
As an additional heparin-binding screen, binding of VEGF 164 HBD mutants to heparin 
was assessed using a saturation binding assay in solution. 0.05 pM of [3H]-heparin (Perkin 
Elmer) was incubated in microcentrifuge tubes with increasing concentrations of VEGF 
mutant in binding buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% BSA) for 1  hr at 37 °C. 
Nitrocellulose  filters  (0.45  pm  pore  size,  Millipore)  were  preequilibrated  in  BSA-free 
binding buffer and were placed into separate pockets of a vacuum manifold (Millipore). 
The samples were transfered onto the filters and unbound [3H]-heparin was removed by 
applying vacuum and washing 3 times with  1   ml of BSA-free binding buffer. The filters 
were placed on Whatman paper for drying and then transfered to scintillation vials each 
containing 3 ml of scintillation liquid. The amount of [3H]-heparin retained by the filter as 
complexes was  determined by counting  in a  p-scintillation counter (Micro  Beta Trilux, 
Perkin  Elmer).  Saturation  and  competition  binding  analysis  were  performed  using 
GraphPad Prism 4 software (GraphPad).
84Chapter 2 Materials and methods
2.2.6.9 Competition binding assays with soluble VEGF receptors
96-well microtiter plates (Wallac HB Isoplate, Perkin Elmer) were coated with  100 pi of 
anti-human  IgG  (Fc -specific) antibodies (Calbiochem)  at  a concentration of 5  pg/ml  in 
PBS (pH 7.4) at 4 °C overnight. The wells were blocked 3x5 min with 300 pi of blocking 
buffer (Super Block, Pierce). The blocking buffer was removed and 100 pi of a solution 
containing  receptor/Fc chimeric  proteins  (R&D  systems)  in  binding  buffer  (PBS,  0.1% 
BSA, 0.02% Tween-20) at a final concentration of 400 pM (Flt-1/Fc), 2 nM (Flk-1/Fc), or 
1.8 nM (Np-1/Fc) was added to each well. After 90 min of incubation at room temperature, 
unbound receptors were removed by washing the plate 3  times with 200  pi of binding 
buffer.  Next,  0.01  pCi  (for  Flt-1)  or  0.02  j_iC 'i  (for  Flk-1  and  Np-1)  of  l25I-labeled 
VEGF 165 in binding buffer was added to the plate together with increasing concentrations 
of cold competitor in a final volume of 100  pi. Non-specific binding of  I-VEGF was 
assessed by adding 400 nM of VEGF 164 to the well. Binding to equilibrium was carried 
out at 37 °C for 2-3 hr, after which the plate was washed 3x with 200 pi of binding buffer. 
Binding  of 125I-VEGF  was  quantitated  in  a  p-scintillation  counter  (Micro  Beta Trilux, 
Perkin Elmer). Inhibitory concentrations 50% ( I C 5 0 )   values were calculated using the one- 
site competition binding analysis program of GraphPad Prism 4 (GraphPad Software).
2.2.7 Circular dichroism (CD) spectrophotometry
CD  spectra  of  VEGF 164  and  the  VEGF 164  HBD  mutants  K30A/R35A/R39A, 
R14A/R49A, and R13A/R14A/R49A were recorded in the wavelength range 198-260 nm 
with a Jasco J-810 spectropolarimeter (Jasco, UK) and a 0.1 cm path-length stain-free cell. 
The proteins were analyzed at a concentration of 0.15 mg/ml in TBS (10 mM Tris, pH 7.4,
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0.15  M NaCl) at room temperature.  Due to the absorbance of NaCl,  spectroscopic data 
below 200 nm were not used for structural interpretation.  The spectra were recorded in 
millidegrees of ellipticity (0). The solvent spectrum (TBS) was subtracted from the sample 
spectra and the subtracted spectra were converted to mean residue ellipticity (CD signal 
per ammo acid residue, [0\) in degrees x cm  x dmof  by the following equation:
[ ^Jinrw   0 \ M m rw  / 10 X  C  X 1
where c is the protein concentration in mg/ml, 1  is the cell path length in cm, and M m nv is 
the mean residue molecular weight of the VEGF 164 dimer. All measurements were done 
twice, with identical results.
2.2.8 Animal handling
All mice and rats examined were treated in accordance with the Association for Research 
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research.  Before  intravitreal  injection,  the  animals  were  anesthetized by  intramuscular 
injection of a mixture of ketamine and xylazine. A drop of Tropicamide® was administered 
to dilate the pupil of each eye to be injected and liquid tears were administered to prevent 
desiccation. Animals were sacrificed by CO2 narcosis.
2.2.9 Rat aortic ring assay for angiogenesis
Thoracic aortas were dissected from male Fisher rats (6-10 weeks) and placed into a dish 
containing  EB  medium  (Cambrex)  supplemented  with  2  mM  glutamine  and
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penicillin/streptomycin (100 pg/ml). The aortas were carefully cleaned of all surrounding 
adventitial tissues under a dissecting microscope and cut into 1  mm wide rings. Each of the 
rings was embedded in a rat collagen mix (2 mg/ml collagen I, 4 ml H2O, lx DMEM, 2.34 
mg/ml NaHCCE) in 4-well multidishes (Nunc) and the collagen gel was then overlaid with 
450 pi of EBM medium. The plates were incubated at 37 °C and 5% CO2 in a humidified 
atmosphere for 7 days and EBM medium was replaced every 48 hr with control medium or 
medium containing purified VEGF variants (4.4 nM). Rings that did not show any signs of 
vessel growth after 48 hr were discarded.
2.2.10 Generation of VEGF164-deficient (VEGF120/188) mice
VEGF 164-deficient (VEGF1 2 0 7 1 8 8 ) mice were generated by mating VEGF+/188 female mice 
and VEGF+/l20 male mice,  both  of which were produced via targeted mutagenesis  with 
Cre//oxP-mediated site-specific recombination in embryonic stem cells [254]. Genotyping 
was performed by PCR.
2.2.11 Mouse model of oxygen-induced proliferative retinopathy
120/188 Oxygen-induced proliferative retinopathy  (OIR)  was  induced  in  VEGF  mice  and 
wild-type litter mates using the protocol described by Smith et al.  [274]. P7 mice and their 
nursing mothers were exposed to 75% oxygen/25% nitrogen for 5 days to induce retinal 
vaso-obliteration and were then returned to room  air (21% oxygen).  Retinal  leukostasis 
was  observed  at  P14  and  retinal  neovascularization  was  observed  at  PI7,  using  the 
techniques described below. VEGF1 2 0 7 1 8 8  control mice of similar age were kept in room air.
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2.2.12 Animal injections
For analysis of leukocyte recruitment, a single injection of 2 pmol or 20 pmol of VEGF 164, 
inactivated  VEGF 164,  VEGF 120,  VEGF 164  HBD  mutants,  P1GF-1,  P1GF-2  (R&D 
Systems), or VEGF-E (Cellsciences) in 2.5 pi PBS was performed by inserting a 33-gauge 
needle (Ito Seisakusyo) into the vitreous of an anesthetized male Long Evans rat (200-225 
g, Charles River). For blocking experiments using purified HBD, various concentrations of 
recombinant HBD (2.5 pi) were injected intravitreally 2 min before injecting VEGF 164 (2 
pmol/2.5 pi). The dosage was determined based on a previous study describing leukostasis 
in  the  retinal  vasculature  after  VEGF  injection  [276].  Insertion  and  infusion  were 
performed  under  a  surgical  microscope.  At  24,  48,  and  72  hr  after  vitreal  injection, 
leukocyte recruitment was analyzed using acridine orange fluorography.
To assess the effect of VEGFR-1  neutralization on leukostasis, mice were randomized to 
receive  intraperitoneal  injections  of 0.3,  1.5,  or  3.0  mg/kg  anti-VEGFR-1  neutralizing 
antibody (R&D  Systems) 3  hr before intravitreal injection of VEGF 164  (2 pmol/0.8  pi) 
using a 3 3-gauge dual needle.  Control animals received an equivalent amount of a pre- 
immune, control goat IgG (R&D Systems). To test the effect of recombinant HBD on the 
OIR-induced inflammatory response, 2 nmol of purified and sterilized HBD,  5 mg/kg of 
anti-VEGF-neutralizing antibody (R&D  Systems)  and goat IgG control  (R&D  Systems) 
were injected systemically into the penetrial space of P12 OIR mice every 24 hr for 2 days, 
using a 33-gauge needle (Ito  Seisakusyo).  To examine leukostasis,  P14  OIR mice were 
perfused with FITC-coupled concanavalin A (Con A) from the heart as described below.Chapter 2 Materials and methods
2.2.13 Cell labeling
2.2.13.1 Immunohistochemistry of rat aortic ring vessels
After 7  days  in culture,  aortic  rings  were washed with  PBS  and  fixed  in  1   ml/well  of 
paraformaldehyde (10% (v/v) in PBS) for 1   hr at room temperature, followed by a triple 
wash (3  x  10 min)  with PBS  and blocking of non-specific binding  sites with blocking 
buffer (6% (v/v) goat serum in PBS containing 0.3% (v/v) Triton X-100) for 8 hr. Blood 
vessels  were  stained  with  biotinylated  isolectin  B4  (Sigma,  1:300  in  blocking  buffer) 
overnight  at  4  °C  followed  by  multiple  washes  (4  x  15  min)  in  blocking  buffer  and 
incubation  with  HRP-conjugated  Alexa  546  secondary  antibody  (Invitrogen,  1:250  in 
blocking buffer) for 2 hr at room temperature. Finally, rings were washed 4 x 20 min in 
blocking buffer and 2  x  20 min  in PBS.  Images of aortic  rings  were captured using  a 
DMIR epifluorescence microscope (Leica) equipped with a digital camera (Qimaging).
2.2.13.2 Platelet endothelial cell adhesion molecule (PECAM)-staining of 
retinal endothelial cells
Mice were killed  at P17  and frozen  sections  (10  pm-width)  were made  from  eye cups 
embedded in optimal cutting temperature compound (Sakura Finetek). Samples were fixed 
with 4% paraformaldehyde in PBS for 10 min, then incubated in methanol/FLCh for 15 min 
at 4 °C, washed with PBS, and incubated for 30 min in  10% normal goat serum.  Slides 
were incubated for 2 hr with biotinylated anti-mouse PECAM-1  antibody (0.5 mg/ml, BD 
Biosciences) and,  after washing with PBS,  incubated with avidin coupled to peroxidase 
(Vector Laboratories) for 30 min at room temperature. After a final wash for 10 min, slides 
were incubated with diaminobenzidine to give a brown reaction product and were mounted
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with Vectashield. The sections were examined under a microscope (DMRA2, Leica) and 
images were digitized using a 3CCD color video camera (ORCA-ER, Opelco).
2.2.13.3 Lectin labeling of retinal vasculature and adherent leukocytes in 
mice
C57BL/6J  male  mice  (20-22g,  Charles  River)  and  VEGF  transgenic  mice  were  deep- 
anesthetised with intramuscular xylazine hydrochloride and ketamine hydrochloride. The 
chest cavity was then carefully opened and a 22-gauge cannula introduced into the aorta. 
The  animals  were  perfused  with  500  ml  of  PBS  per  kg  of body  weight  to  remove 
erythrocytes and non-adherent leukocytes.  Perfusion with Con A coupled to  fluorescein 
isothiocyanate  (FITC,  40  pg/ml  in  PBS,  pH  7.4;  5  mg/kg  body  weight;  Vector 
Laboratories) was then performed to  label  adherent leukocytes and vascular endothelial 
cells,  followed  by  PBS  perfusion  to  remove  residual  unbound  lectin.  The  eyes  were 
enucleated and fixed with 4% paraformaldehyde for 1  hr before retinas were separated and 
flat mounted. Each retina was imaged with an epifluorescence microscope, and the total 
number of adherent leukocytes per retina was determined.
2.2.13.4 Labeling of macrophages with F4/80 immunofluorescence
Adherent  leukocytes  were  first labeled  in  vivo  with  FITC-coupled Con A as  described 
above. Eyes were removed and eye cups containing the retina were fixed overnight at 4 °C 
in  4%  paraformaldehyde.  Following  fixation,  eye  cups  were  permeabilized  with  0.5% 
Triton X-100  in PBS  for 24 hr and non-specific  binding was reduced by incubation  in 
blocking  buffer  (10%  goat  serum  in  PBS).  The  eye  cups  were  then  incubated  with  a
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purified rat anti-mouse antibody directed against F4/80 (1:250 dilution, eBiosciences) in 
blocking  buffer  for  2  hr  at  room  temperature,  washed  for  2  hr  in  wash  buffer  (PBS 
containing  0.1%  Triton  X-100)  and  incubated  with  Alexa  Fluor-488  goat  anti-rat  IgG 
secondary antibody (1:500 dilution, Molecular Probes) for 1  hr in blocking buffer. After a 
final  wash  for  3  hr,  retinas  were  flat  mounted  and  imaged  with  an  epifluorescence 
microscope.
2.2.13.5  Acridine orange leukocyte fluorography
Leukocyte  recruitment  in  the  retina  was  studied  in  vivo  by  acridine  orange  leukocyte
fluorography, using rats injected intravitreally with VEGF family member proteins and/or
purified HBD as described above. At 24, 48, and 72 hr after vitreal injection, animals were
injected intravenously with acridine orange, which causes leukocytes and endothelial cells
to  fluoresce through the noncovalent binding of the molecule to double-stranded DNA.
Immediately before fluorography, each rat was anesthetized and the pupil dilated with 1%
tropicamide.  Acridine orange (Sigma)  was  dissolved in  sterile  saline  (1  mg/ml),  and  3
mg/kg were injected through the tail vein catheter at a rate of 1  ml/min. Static leukocytes
in the capillary bed were observed in vivo 30 min later for 1   min by fundoscopy, using a
scanning  laser ophthalmoscope with an argon blue laser as  illumination source  and the
standard fluorescein angiography filter in the 40° field setting. Thirty min later, the fundus
was  again  observed  to  evaluate  retinal  leukostasis.  Images  were  recorded  on  a  digital
•  2 videotape. To evaluate retinal leukostasis, 8 areas of 200 pixel  each at a distance of 5 disc 
diameters  from  the  edge  of the  optic  disc  were  assessed  to  determine  the  number  of
'y
fluorescent dots in the retina. These numbers were converted to leukocytes/mm  by using
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the formula:  1  pixel = 3.2 pm2. Leukocytes were considered static if their position did not 
change for 3 min.
2.2.14 Morphometric analysis
2.2.14.1 Analysis of vessel outgrowth from aortic rings
To quantify blood vessel growth in the aortic ring assay, RGB images of the rings were 
converted to 8-bit grayscale images in Photoshop (Adobe) and blood vessels were traced in 
a new layer using a 9-point pencil tool. All images were traced by a masked researcher. 
The new image layer was then binarized and the traced lines skeletonized using the Image- 
J software (NIH). All white pixels in the skeletonized image were counted and expressed 
relative to the circumference of the aortic ring in order to normalize the total number of 
new blood vessels to the aortic ring size.
2.2.14.2 Analysis of vascular development and density in the retina
Vascular development was quantified by measuring the length of eight vessels from the 
optic nerve to the edge of the vascular area, each going in a different direction. The length 
of a vessel was then expressed as a percentage of the radius of the retina. The eight values 
were then analyzed statistically. To determine the vascular density of retinal flat mounts 
the total length of vessels in each of four different vascular areas (each 200 pixels2) were 
measured using NIH image. The vessel length was expressed in pixels  and the vascular 
density was expressed as a percentage by dividing the total vessel length by the area using 
NIH image.
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2.2.15 Statistical analysis
All  values  were  expressed  as  mean  ±  SEM  unless  otherwise  indicated.  For  statistical 
analysis of in  vivo  studies, the unpaired Student t-test was used when two groups were 
compared. Data were analyzed by using post-hoc comparison test (Bonferroni) when three 
or more groups were compared. Differences were considered statistically significant when 
P-values were <0.05.
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3.1 Introduction
The significance of the heparin-binding VEGF isoforms was emphasized by the finding 
that 50% of the mice engineered to express exclusively the non-heparin-binding VEGF 120 
die of postnatal angiogenesis defects shortly after birth [284]. On the other hand, mice that 
solely produce VEGF 164 appear normal and healthy [254]. VEGF 165, the major isoform 
in humans,  shows moderate affinity for heparin and neuropilin-1,  as a result of binding 
determinants  encoded by exon  7  [126].  It has  been  suggested that this region conveys 
distinct functions to VEGF 165 and the longer iso forms [61,  118]. However, the functional 
significance of the heparin- and neuropilin-1-binding abilities of VEGF 165 has remained 
elusive.
To better understand the role of heparin binding in the mouse homolog VEGF 164,1  started 
by identifying amino acid residues that are critically involved in mediating this function. 
To  this  end,  I  introduced  mutations  into  the  exon  7-encoded  domain  of  full-length 
VEGF 164  using  alanine-scanning  mutagenesis.  This  chapter  describes  the  mutagenesis 
approach  and the purification of wild-type  and mutant  VEGF  species,  as  well  as  their 
characterization with regard to heparin and neuropilin-1 binding.
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3.2 Results
3.2.1 Sequence alignment of the VEGF164 HBD
The  HBD  of VEGF 165  lacks  significant  sequence  homology  to  other heparin-binding 
proteins outside the VEGF family [121], indicating that VEGF-heparin binding occurs via 
binding regions distinct from the heparin-binding consensus sequences or motifs that exist 
in other proteins  [209].  The novelty of the HBD  and the highly basic  character of the 
domain  have  made  it  difficult  to  identify  critical  amino  acids  involved  in  heparin 
interaction.
Sequence alignment analysis of the VEGF 164 C-terminal region revealed a high degree of 
sequence homology among residues of the long VEGF isoforms and other members of the 
VEGF  family  of growth  factors  (Figure  3.1).  Sequence  homology  was  also  observed 
between  species  as  phylogenetically  distant  from  mammals  as  frog  and  zebrafish, 
suggesting that heparin binding may be an evolutionarily conserved function of VEGF. All 
eight cysteine residues involved in the formation of intra-chain disulfide bridges within the 
VEGF 165  HBD  are  conserved  among  all  variants  (Figure  3.1),  resembling  the  highly 
conserved cysteine knot motif in the VEGF/PDGF homology domain (VHD)  of VEGF 
[111]. Based on this cysteine homology, it is conceivable that the disulfide bond linkages 
are  the  same  among  these  variants,  raising  the  possibility  of  a  conserved  backbone 
structure.
96Chapter 3 In vitro mutagenesis of the heparin-binding domain of VEGF164
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Figure  3.1  Multiple  sequence  alignment  of the  VEGF164  C-terminal  region  with 
selected VEGF variants. Comparison of VEGF 164 exon 7- and  8-encoded amino acid 
sequence  (SWISS-PROT  accession  No.  Q00731-2)  with  corresponding  regions  of 
VEGF 165 (SWISS-PROT accession No. P15692), VEGF 188 (SWISS-PROT accession No. 
Q00731-1),  VEGF 189  (SWISS-PROT  accession  No.  P15692-2),  mouse  VEGF-B167 
(SWISS-PROT accession No.  P49766-2),  human VEGF-B167  (SWISS-PROT  accession 
No.  P49765-2),  Gallus  (chicken)  VEGF-A  (DDBJ/EMBL/GenBank  accession  No. 
AB011078), Xenopus (frog) VEGF 196 (SWISS-PROT accession No. 042572), and Danio 
(zebrafish) VEGF 165  (SWISS-PROT accession No.  073682-1).  The sequence alignment 
was generated using the Clustal W program and was further optimized manually. Amino 
acids that are identical are shaded in black and amino acids that are similar are shaded in 
grey. The asterisk (*) denotes a column with fully conserved amino acids (100% identity), 
whereas a period (.) denotes a column in which the molecular weight or the hydropathy of 
amino acids has been preserved in at least 50% of the aligned sequences. Residues that 
were subjected to mutagenesis in this study are highlighted in green.
3.2.2  Site-directed mutagenesis of the VEGF164 HBD
The  published  NMR  solution  structure  of  the  55-residue  HBD  of  human  VEGF 165 
provided the basis for a structure-guided mutagenesis approach [119]. The HBD contains 
the five C-terminal residues of exon 5 in addition to the peptide encoded by exons 7 and 8. 
Analysis of the solvent-accessible molecular surface of HBD revealed a marked polarity in
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surface charge distribution. The bulk of positively-charged amino acid residues are located 
on one side of the C-terminal subdomain. Basic residues in this region have been suggested 
to  be  likely  candidates  for  mediating  ionic  interactions  with  the  negatively-charged 
carboxy- and sulfo-groups of heparin [119]. To test this hypothesis,  I exchanged alanine 
for  six  solvent-exposed  arginines  and  two  lysines,  individually  or  in  double,  triple  or 
quadruple combinations (Table 3.1).
Mutant C-terminal HBD (11-55)
K30A
K35A/R39A
K30A/R35A/R39A
K30A/R35A/R39A/R49A
K26A
R46A/R49A
R13A/R14A
R14A/R49A
R13A/R14A/R49A
R13A/R14A/R46A/R49A
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
SERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
Table 3.1  VEGF164  HBD mutants  and  their  targeted  residues  within  the  primary 
amino  acid  sequence.  Residues highlighted  in blue were replaced with alanine by site- 
directed  mutagenesis.  Residues  1-10  of the  HBD  (1-55)  were  not  mutated  and  are  not 
shown. Both the VEGF 164 HBD and VEGF 165 HBD consist of 55 amino acids and the 
mutated residues share the same numbering in both proteins.
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The majority of these candidate amino acids can be grouped into three positively-charged 
clusters  located  on  the  same  side  of the  N-terminal  (R13,  R14)  and  the  C-terminal 
subdomain (K30, R35, R39, and R46, R49). Alanine mutagenesis was also applied to one 
lysine (K26) for control purposes. In total,  10 mutants were constructed (Figure 3.2). To 
generate  the  mouse  VEGF 164  HBD  mutants,  a  PCR-based  site-directed  mutagenesis 
approach was performed using the cDNA of full-length VEGF 164 as template.
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Figure 3.2  Structural  representation  of the VEGF165  HBD  and  illustration  of the 
amino acids mutated in this study. (A) Surface topology model of the VEGF 165 HBD 
(1-55) showing the distribution of electrostatic potential on the molecule surface. Charged 
residues  are  color  coded  with  basic  and  acidic  amino  acids  shown  in  blue  and  red, 
respectively. The structural model is shown at two angles rotated by 180° about the vertical 
axis. (B-K) Illustration of the mutated HBDs as ribbon diagram (left) and surface topology 
model  (right).  Lysine  and  arginine  residues  selected  for  mutagenesis  are  labeled  and 
highlighted  in  blue.  The  numbering  of amino  acids  is  based  on  the  primary  sequence 
shown  in  table  3.1.  (B)  K30A,  (C)  R35A/R39A,  (D)  K30A/R35A/R39A,  (E) 
K30A/R35A/R39A/R49A, (F) K26A, (G) R46A/R49A, (H) R13A/R14A, (I) R14A/R49A, 
(J)  R13A/R14A/R49A,  (K)  R13A/R14A/R46A/R49A.  Diagrams  were  generated  with 
PyMOL (DeLano Scientific, Inc.) based on the NMR solution structure (Protein Data Bank 
code:  1KMX).
3.2.3 Expression and purification of VEGF proteins
To produce recombinant wild-type (VEGF 120, VEGF 164,  and HBD)  and mutant VEGF 
proteins, the Pichia pastoris yeast expression system was chosen. This system allows the 
inducible secretion of proteins into the yeast culture medium with the additional advantage 
of high heterologous protein expression levels. Proteins produced in this organism do not 
require  refolding  and,  with  regard  to  posttranslational  modifications,  resemble  more 
closely those produced by higher eukaryotic organisms. All wild-type and mutant proteins 
appeared  to  be  released  into  the  medium  of transformed Pichia pastoris  cultures  after 
secretion, as resuspension of yeast pellets in high-salt buffer did not result in significantly 
higher protein yields (data not shown). The protein yield obtained from cell supernatants 
was estimated by SDS-PAGE and Coomassie staining and was found to be comparable to
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that of native VEGF 164, suggesting that the mutations did not significantly interfere with 
proper folding.
Proteins were purified from conditioned media by using two purification strategies. In the 
first, medium containing HBD was applied to a heparin-sepharose column and eluted with 
a step gradient of increasing NaCl concentration. The fragment eluted at 0.6-0.8 M NaCl. 
In  the  second  strategy,  VEGF 120,  VEGF 164  and  all  HBD  mutants  were  purified  by 
exploiting the nickel-binding  affinity of histidine residues located in the N-terminus of 
VEGF. To better refine comparison of the different VEGF variants in both in vitro and in 
vivo  studies,  dimeric  forms  were  separated  from  higher-order  oligomers  using  size- 
exclusion chromatography. The purity of all protein preparations was approximately 95%, 
as  estimated  by  SDS-PAGE  and  Coomassie  staining  (Figure  3.3).  The  identity  of 
VEGF 120 and VEGF 164 was confirmed by probing the purified proteins with a mouse 
monoclonal  antibody  raised  against  the  N-terminus  (Figure  3.3  B).  VEGF  immuno- 
positive bands were detected at  18 kDa and 23  kDa, the expected molecular weights of 
monomeric  VEGF 120  and  VEGF 164,  respectively.  Recombinant  HBD,  for  which  no 
antibody was available, runs as an approximately 7 kDa-protein under reducing conditions. 
The  ability  of  VEGF 120  and  VEGF 164  to  form  disulfide-linked  homodimers  is  a 
prerequisite for their bioactivity and was not compromised by heterologous expression or 
by the purification procedure, as dimerization of both proteins was preserved under non­
reducing conditions.
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Figure 3.3 Purification of recombinant VEGF wild-type variants. VEGF proteins were 
expressed in Pichia pastoris and purified by nickel-agarose chromatography (VEGF 120, 
VEGF 164)  or  heparin-affinity  chromatography  (HBD),  followed  by  size-exclusion 
chromatography. (A) Coomassie-stained SDS-PAGE gel of purified protein dimers and the 
HBD  monomer  (1  pg)  electrophoresed  under  reducing  (left)  and  non-reducing  (right) 
conditions. The aggregation of HBD monomers may have been a heating  artifact in the 
absence of DTT. (B) Western analysis of purified VEGF 120 and VEGF 164, which were 
probed with a monoclonal pan-VEGF antibody.
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VEGF 164 HBD mutants, too, were purified by nickel-agarose chromatography  As shown 
in Figure 3.4,  all  VEGF 164 HBD mutants  showed the  expected size on a non-reducing 
SDS-PAGE gel, demonstrating that the mutations within the heparin-binding domain did 
not interfere with the ability of these proteins to dimerize (Figure 3.4, top panel).  Under 
reducing  conditions,  all  mutants  except  K30A/R35A/R39A/R49A  and 
R13A/R14A/R46A/R49A  displayed  an  electrophoretic  mobility  similar  to  that  of 
VEGF164, which has a molecular size of approximately 23 kDa (Figure 3.4, bottom panel). 
The  slightly  decreased  mobility  of the  quadruple  mutants  indicates  either  a  decreased 
charge to  mass  ratio  of the  denatured proteins  compared to  native  VEGF  or mutation- 
related interference with the formation of the random-coil configuration necessary for size 
separation.
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Figure  3.4  Purification  of  recombinant  VEGF164  HBD  mutants.  VEGF 164  HBD 
mutant  proteins  were  expressed  in  Pichia  pastoris  and  purified  by  nickel-agarose 
chromatography  and  size-exclusion  chromatography.  Coomassie-staining  of  gels  after 
reducing  (lower panel)  and  non-reducing  (upper panel)  SDS-PAGE  of purified  protein 
dimers (1  pg) are shown in comparison to purified VEGF 120 and VEGF 164  (1  pg). The 
additional faint band observed with some mutants under reducing conditions is believed to 
be unglycosylated VEGF [124].
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3.2.4  Evaluation  of  the  bioactivity  of  the  VEGF164  HBD 
mutants
To determine whether the purified VEGF species exhibit biological activity in endothelial 
cells, HUVEC were stimulated with VEGF and the induction of tissue factor (TF) mRNA 
expression was determined. TF is a member of the cytokine-receptor super-family and the 
primary  cellular  initiator  of  the  blood  coagulation  cascade  [285].  It  has  also  been 
implicated  in  embryonic  blood  vessel  development  and  tumor-associated  angiogenesis 
[286, 287]. The protein is absent in vascular endothelial cells under normal conditions, but 
can be rapidly induced in response to various inflammatory and angiogenic stimuli, such as 
TNF-a, IL-1 and VEGF [288, 289]. VEGF-mediated induction of TF expression by VEGF 
depends  on  activity of VEGFR-2  [290].  This  assay  was  used  to  assess  VEGF  activity 
because  TF  induction  can  be  accurately  reproduced  and  does  not  require  labeling  or 
counting of cells.
Subconfluent HUVEC were treated with recombinant VEGF variants for 1  hr. The optimal 
VEGF concentration of 0.3  nM was determined in a dose-response experiment (data not 
shown). Compared to the buffer control, TF mRNA was induced 5.6-fold in response to 
VEGF 164, whereas VEGF 120 was slightly less potent,  causing a 3.9-fold induction. All 
VEGF 164 HBD mutants were active and their potency in stimulating TF gene expression 
was  comparable  to  that  of VEGF 164.  These  results  suggest  that  the  mutations  did  not 
significantly affect the ability of VEGF 164 to activate VEGF receptor-mediated signaling 
pathways leading to TF expression.
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Figure  3.5  VEGF164  HBD  mutants  induce  TF  inRNA  upregulation  in  HUVEC.
HUVEC were treated for  1   hr with medium containing PBS  or 0.3  pmol/ml of purified 
VEGF protein. Total RNA was isolated and reverse transcribed to yield cDNA, which was 
subjected to real-time PCR analysis using GAPDH as internal control. Levels of TF gene 
expression were determined using the comparative threshold method. The data represent 
the mean ± SEM of three independent experiments.
3.2.5 Qualitative analysis of heparin binding by VEGF164 HBD 
mutants
Next,  I  employed  heparin-sepharose  chromatography  as  a  method  for  screening  the 
heparin-binding  affinity  of the  mutants.  A  heparin-sepharose  column  was  loaded  with 
purified protein dimers and washed, then the bound proteins were eluted with a linear NaCl 
gradient. The relative affinities for heparin were assessed by determining the amount of
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salt required to  elute the proteins  from the  column.  As  expected,  VEGF 164 completely 
bound to the heparin column in the presence of 0.1 M NaCl (Figure 3.6). Binding of VEGF 
to  heparin  occurs  through  binding  determinants  located  in  the  HBD.  VEGF 120,  which 
lacks this domain, did not bind to the column and was found in the flow-through and wash 
fractions.  The  HBD  fragment  alone  exhibited  similar  heparin-binding  behavior  as 
VEGF 164,  resulting  in  a  similar  elution  profile.  These  data  confirm  that  the  heparin- 
binding  activity  of  VEGF 164  is  fully  mediated  by  its  C-terminal  domain.  Notably, 
VEGF 164 did not elute from the column in one distinct peak but rather over a wide range 
of the salt gradient (0.58 M -  1   M NaCl). This made it impossible to determine a specific 
salt  concentration  for each  protein  that  would  be  representative  for  its  heparin-binding 
affinity.  Instead,  the  concentration  of NaCl  in  the  elution  buffer  required  to  displace 
approximately 50% of the protein from the column was used as an indicator for its affinity.
With regard to their spatial arrangement, the basic amino acids K30, R35, R39, and R49 
are located in relatively close proximity to each other and may thus form a cluster that acts 
as  a  docking  site  for  heparin.  The  quadruple  mutant  K30A/R35A/R39A/R49A  and  the 
triple  mutant  K30A/R35A/R39A  presented  similar  elution  profiles.  In  both  cases  a 
significant  amount  of protein  was  found  in  the  wash  and  early  elution  fractions  and  a 
second portion of the sample bound more tightly to the column and eluted at 0.46-0.7 M 
(Figure  3.6).  A  similar pattern  was  also  observed with the  double  mutant  R35A/R39A, 
albeit to a lesser degree. Next, the binding of the single mutant K30A was investigated in 
order to determine the relative contribution of this residue to the heparin-binding activity 
observed  in  the  triple  and  quadruple  mutant.  The  elution  characteristics  of K30A  were 
comparable to those of VEGF 164  (Figure 3.6).  Therefore,  Lys30 does not appear to be
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critically involved in heparin interaction. Similar results were observed for Lys26 (Figure 
3.6), which is located on the backside of the N-terminal subdomain (Figure 3.2 F).
Arg46 and Arg49 form a basic cluster that is part of the two-stranded antiparallel p-sheet 
structure  within  the  HBD.  Targeting  of these  residues  resulted  in  a  slightly  decreased 
binding capacity of the protein, as shown in Figure 3.6. The NaCl concentration required to 
displace approximately 50% of this mutant from the column was approximately 0.82 M. 
Heparin binding was further impaired in the double mutant R13A/R14A (0.52 M NaCl). 
Argl3  and Argl4 are major components of a disordered and poorly-defined loop region 
adjacent  to  Arg46  and  Arg49,  and  the  combined  quadruple  mutant 
R13A/R14A/R46A/R49A  displayed  very  little  heparin-binding  activity.  Because  the 
replacement of four residues may have caused major alterations in the local structure, the 
number of mutations was reduced to three (R13A/R14A/R49A)  and two  (R14A/R49A). 
Both variants bound to the column and eluted in one peak. However, R14A/R49A (0.49 M 
NaCl) and R13A/R14A/R49A (0.4 M NaCl) showed a marked reduction in their ability to 
bind to heparin.
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Figure 3.6 Comparison of heparin-binding affinities of VEGF wild-type and mutant 
proteins. Purified protein dimers (50 pg) in binding buffer containing 0.1  M NaCl were 
applied to a heparin-sepharose affinity column. Flow through fractions were collected 
before  the  column  was  washed  with  three  column  volumes  of binding  buffer.  Bound 
proteins were eluted over 15 column volumes in a linear salt gradient (0.1-1  M NaCl) and 
1  ml fractions were collected. Eluted proteins were precipitated with trichloroacetic acid to 
concentrate samples and to eliminate buffer variability. The samples were separated on a 
12% SDS-PAGE gel and analyzed by Coomassie-staining.  Linear background correction 
of the images was performed for better contrast.
The low ionic strength of the binding buffer combined with the relatively shallow elution 
gradient  was  used  to  detect  subtle  changes  in  heparin  binding  activity  of the  different 
mutants.  However,  the  low  stringency  of these  conditions  not  only  resulted  in  higher 
sensitivity  but  may  have  also  been  responsible  for  the  prolonged  interaction  of some 
proteins  with  the matrix.  Avidity effects  resulting  from  multimerization  of the  dimeric 
proteins or non-specific solid-state interactions with the column matrix/resin are possible 
explanations  for  this  phenomenon.  To  avoid  these  potential  artifacts,  a  less-sensitive 
screening  of  selected  mutants  was  performed  by  increasing  the  ionic  strength  during 
binding (0.15 M) and the salt concentration increments in the elution phase from 0.06 M to 
0.12 M NaCl per 1  ml fraction. Under these conditions, the elution profiles of the indicated 
proteins were better-defined. As shown in Figure 3.7, VEGF 164 eluted at approximately 
0.9 M NaCl, a result similar to that from the previous experiment. As observed in the first 
assay,  K30A/R35A/R39A  contained  two  protein  fractions  which  differed  in  heparin 
binding. One fraction did not bind heparin whereas the other fraction bound to heparin as 
strongly as did VEGF 164. This differential binding behavior suggests the presence of a 
folded and misfolded protein population
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Figure 3.7  Comparison  of  heparin-binding  affinities  of  wild-type  VEGF164  and 
selected VEGF mutants at physiological salt concentration. Purified protein dimers (10 
pg) were injected onto a heparin-sepharose affinity column in the presence of 0.15 M NaCl. 
The column was washed and bound proteins were eluted over  11  column volumes  in a 
linear salt gradient (0.15-1.5 M NaCl) and  1   ml fractions were collected. Eluted proteins 
were  precipitated  with  trichloroacetic  acid  and  separated  on  a  12%  SDS-PAGE  gel. 
Western blotting was perfonned using a monoclonal pan-VEGF antibody,  and immuno- 
positive bands were visualized with a chemiluminescence system (ECL).
caused by the mutations.  Strikingly,  mutant R13A/R14A/R49A lost its ability to bind to 
the heparin-sepharose column at the physiological  salt concentration of this experiment, 
suggesting  that  the  binding  observed  in  the  previous  experiment  may  have  been  non­
specific.  Analysis  of the double mutant R14A/R49A revealed that heparin binding  was
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severely compromised,  as the majority of protein  was  found  in the  unbound  and  wash 
fractions. The small amount of R14A/R49A protein that did bind eluted gradually between 
0.15 M and 0.6 M of NaCl, suggesting that Argl3 contributes to the binding energy. Taken 
together,  these  results  indicate  the  presence  of  a  heparin-binding  site  containing  the 
residues Argl3, Argl4, and Arg49.
3.2.6  Analysis  of  VEGF164  HBD  mutant  structure  by  CD 
spectroscopy
To  confirm  that  the  marked  reduction  in  heparin  binding  by  mutant  R14A/R49A  and 
R13A/R14A/R49A was  not  a  function of major structural  changes,  secondary  structure 
analyses of these mutants and VEGF 164 were performed using CD spectroscopy in the far- 
ultraviolet spectral region (190-260 nm). Changes in the tertiary structure of VEGF could 
not be analyzed with this method due to the low absorption in the near-UV spectral region 
(250-350  nm).  The  method  is  based  on  the  differential  absorption  of  left-  and  right- 
circularly  polarized  light  by  the  protein  sample.  In  far-ultraviolet  CD,  the  spectra  are 
dominated by the  spatial  arrangements of amide groups.  Structural  elements such as a- 
helix, p-sheet and random-coil each give rise to a characteristic shape and magnitude of the 
CD spectrum, thus allowing the comparison of these elements between mutant and wild- 
type  protein  species  [291].  Figure  3.8  shows  that  the  nonnalized  far-UV  CD  spectrum 
obtained for the triple mutant R13A/R14A/R49A was essentially identical to that of wild- 
tvoe VEGF 164 (top panel). Both spectra were characterized by a negative trough near 210 
nm and a strong positive ellipticity at 2 0 0 nm, both of which are indicative of a high
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Figure 3.8  Secondary  structure  analysis  of  VEGF164  variants  by  far-UV  CD 
spectroscopy.  CD  spectra  (198-260  nm)  were  obtained  at  room  temperature  for  the 
VEGF 164  HBD mutants  R13A/R14A/R49A (top panel, pink line),  R14A/R49A (central 
panel,  red  line)  and  K30A/R35A/R39A  (bottom  panel,  green  line)  in  comparison  with 
VEGF 164 (black line). The solvent spectrum was subtracted from the sample spectra and 
the subtracted spectra were converted from millidegrees of ellipticity (0) to mean residue 
ellipticity  [#m rw]  (degrees  x  cm2 x  dmol*1 ).  The  molar  ellipticity  of  VEGF 164  has  a 
different magnitude in each panel due to nonnalization for protein concentration. Spectra 
were measured twice with identical results.
percentage of (3-sheet structures [292]. The qualitative analysis also revealed a significant, 
albeit  lower,  a-helical  content,  characterized  by  a  positive  band  at  192  nm  and  two 
negative bands at 208 nm and 222 nm. These results, although not quantitative due to the 
lack  of a  reference  CD  spectrum,  are  in  good  agreement  with  the  secondary  structure 
assignment derived from the solution structure of the VEGF (1-110) fragment and HBD 
(VEGF111-165)  [112,  119].  Concerning  mutant  R14A/R49A,  it  was  evident  that  the 
spectral shape and magnitude of this mutant is very similar to that of native VEGF, despite 
a slight shift of the curve between  198  nm and 210  nm  (Figure 3.8,  central panel).  To 
detennine whether the partial loss of heparin binding ability for mutant K30A/R35A/R39A 
resulted  from  structural  abnormalities,  fractions  2-4  (Figure  3.7)  were  collected,  pooled 
and subjected to  far-UV  CD  analysis.  As  shown  in the bottom panel  of Figure 3.8,  the 
mutant spectrum was very different from that of the wild-type. Computer-aided secondary 
structure  prediction  revealed  a  high  amount  of  random  coil  structures  and  a  marked 
reduction in a-helical content (Table 3.2).
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The  lack  of  significant  changes  in  secondary  structures  of  R14A/R49A  and 
R13A/R14A/R49A suggests that the impairment in heparin binding was not the result of a 
disrupted  backbone  structure.  In  contrast,  the  analysis  of  K30A/R35A/R39A  strongly 
supports the view that any heparin-binding deficiency of this mutant was caused by major 
conformational changes, suggesting that the exchange of residues in this mutant may have 
rendered the protein susceptible to misfolding. The analysis of mutants K.30A/R35A/R39A 
and K30A/R35A/R39A/R49A was therefore not further pursued.
Protein Alpha-heiix Beta-strand Random-coil
VEGF164 0.3 0.37 0.33
R13A/R14A/R49A 0.28 0.41 0.31
R14A/R49A 0.35 0.25 0.4
K30A/R35A/R39A 0.08 0.42 0.5
Table 3.2  Prediction of secondary structure content of VEGF164 variants based on 
far-UV CD data. Estimated percentages (shown as fractions) of helix, beta and random 
secondary structure of VEGF 164 and HBD mutant proteins. Calculations were performed 
using the K2d program [293] by submitting 41  CD values ranging from 200 nm to 240 nm 
obtained from spectra depicted in Figure 3.8.
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3.2.7  Quantitative  analysis  of the  heparin-binding  affinities  of 
selected VEGF164 HBD mutants
While  heparin-sepharose  chromatography  represents  a  valuable  screening  method,  this 
technique  is  incapable  of providing  dissociation  constants  (K<i)  and  is  biased  towards 
electrostatic interactions due to the high concentration of heparin in the column. To better 
assess  non-ionic  interactions,  such  as  hydrogen  bonding  and  hydrophobic  interactions, 
heparin-binding  affinities  of selected  mutants  were  determined  in  a  nitrocellulose  filter 
trapping  assay  [239].  This  assay  involves  incubation  of  tritium-labeled  heparin  with 
increasing_concentrations  of VEGF  in  solution.  Nitrocellulose  filters  are  then  used  to 
separate heparin-protein complexes from free molecules. The quantity of complex formed 
at  equilibrium  is  determined by measuring  the radioactivity retained  by the  filter.  This 
assay is thought to better reflect the overall binding capacity of a given protein [294].
The saturation binding curves for VEGF 164  and HBD mutants demonstrate that the Re­
value for VEGF 164 binding to heparin was 0.157 ±0.017 (mean ± SEM) pM (Figure 3.9), 
which  is  in good agreement  with the dissociation constant of 0.165  pM  reported  in the 
literature [295]. As indicated by heparin-affinity chromatography, the single mutant K26A 
showed slightly rednnerLaffinity (0.415 ± 0-08 pM) compared to VEGF164 (Figure 3.9). 
Binding of the two double mutants R13A/R14A (2.04 ±1.01 pM) and R46A/R49A (1.98 ± 
1.04  pM)  was  reduced  approximately  twelve-fold  compared  to  wild-type  VEGF 164 
(Figure 3.9). However, the large standard errors resulted in wide 95% confidence bands of 
the best fit curves, therefore the K <j values for these two mutants could not be accurately 
calculated.  Nonetheless,  this decrease in affinity was not observed in the column  assay,
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confirming the higher sensitivity of the filter trapping assay. Consistent with the previous 
assays,  the  quadruple  mutant  R13A/R14A/R46A/R49A  did  not  show  any  detectable 
binding to heparin. The residual binding activity observed in the previous assay is likely 
attributable to non-specific interactions.
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Figure 3.9 Binding of VEGF164 and HBD mutants to [3HJ-heparin. [3H]-heparin (0.05 
pM) was incubated with increasing amounts of VEGF variants in the presence of 0.15 M 
NaCl, and VEGF-heparin complexes were recovered using the nitrocellulose filter trapping 
assay  [239].  Bound  [3H]-heparin  was  quantified  in  a  liquid  scintillation  counter.  The 
GraphPad  Prism program was used to generate  a logarithmic  curve  fit  according to the 
one-site binding model and to calculate the dissociation constants. Mutants  R14A/R49A, 
R13A/R14A/R49A,  and  R13A/R14A/R46A/R49A  could  not  be  fitted.  Each  data  point 
represents  the  mean  ±  SEM  of three  independent  experiments,  with  each  experiment 
performed in triplicate.
119Chapter 3 In vitro mutagenesis of the heparin-bindina domain of VEGF 164
As expected from the column assay, binding of mutant R13A/R14A/R49A to [3H]-heparin 
was completely abolished in the presence of physiological salt concentration. Interestingly, 
the same effect was observed in mutant R14A/R49A.  In this case, the result differs from 
the  outcome  of  the  heparin  column  assay,  where  residual,  low-affinity  binding  was 
observed (Figure 3.7).
So  far,  this  mutational  analysis  has  identified  critical  amino  acids  residing  in  the  C- 
terminal subdomain (R46 and R49) and an adjacent loop region (R13, R14), and indicates 
that Argl4 and Arg49 constitute a w minimal'  heparin-binding site. The data also provide 
evidence  for  a  major  electrostatic  contribution  to  the  binding  energy  and  highlight  the 
importance of an appropriate spatial conformation of the residues to ensure optimal affinity 
and specificity of the interaction.
3.2.8 Binding of VEGF164 HBD mutants to neuropilin-1
The VEGF isofonn specific receptor neuropilin-1  binds to the exon 7-encoded region of 
VEGF 164  [126],  but  the  amino  acids  mediating  this  interaction  have  not  yet  been 
identified.  To  assess the  effect of the  HBD  mutations  on neuropilin-1  binding,  a plate- 
based  competition  binding  assay  was  performed  in  which  increasing  concentrations  of 
VEGF 164 dimers were mixed with l25I-VEGF165 and added to immobilized neuropilin-1. 
The binding of l2:)I-VEGF165 to neuropilin-1 was inhibited in a dose-dependent manner by 
VEGF 164
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R35A/R39A 0.710 ± 0.16 nM
K30A 0.621 ± 0.24 nM
K26A 0.318 ± 0.03 nM
R46A;R49A 3.080 ± 0.37 nM
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Figure 3.10  Competitive  binding  of  VEGF164  HBD  mutants  to  neuropilin-1.
Binding of 125I-VEGF165  to immobilized neuropilin-1/Fc was competed with  increasing 
concentrations  of  VEGF 164  or  VEGF 164  HBD  mutants.  Bound  ,25I-VEGF165  was 
quantified in a liquid scintillation counter.  (Top panel) The  IC50 for each VEGF variant 
shown on the histogram were derived from three independent experiments performed in 
triplicates. The binding data were used to calculate the percent specific binding. Inhibition 
binding  curves  were  generated  by  non-linear  regression  analysis  using  the  one-site 
competition binding model. Binding curves and IC50 ± SEM values (bottom panel) for all 
mutants were generated using the GraphPad Prism program.
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with a half-maximal inhibitory concentration (IC50) of 0.128 ± 0.02 (mean ± SEM) nM, 
indicating that binding to neuropilin-1 occurs with relatively high affinity in the absence of 
heparin  (Figure  3.11).  The  mutants  were  between  2.6-fold  (K26A)  and  120-fold 
(R13A/R14A/R46A/R49A) less effective in competing with  125I-VEGF165, compared to 
VEGF164.  Despite  this  reduction  in  binding  affinity,  all  mutants  were  able  to  bind 
neuropilin-1. These results suggest that the binding sites for heparin and neuropilin-1  in 
VEGF164 cannot be completely separated by site-directed mutagenesis, since the mutation 
of residues  that  mediate  heparin  binding  also  appears  to  affect  the  interaction  with 
neuropilin-1.
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3.3 Discussion
3.3.1 Characterization of the VEGF164 heparin-binding site.
In this part of the study,  I have  identified residues that contribute to the interaction of 
VEGF164  with  heparin  by  employing  two  in  vitro  heparin-binding  assays.  Relative 
heparin-binding affinities were differentially affected in all mutants. The degree of binding 
impairment  appeared  to  be  related  to  the  number  of substitutions  and,  therefore,  the 
decrease of the total electropositive charge. Minor conformational perturbations may have 
also contributed to reductions in affinity. For example, the 2.6 fold decrease in affinity of 
the K26A mutant relative to wild-type VEGF164 likely resulted from the substitution of 
lysine  with  the  smaller  alanine,  indirectly  affecting  the  ability of heparin  to  access  its 
binding groove. It is unlikely that Lys26 directly binds to heparin, as this basic residue is 
surrounded  by  negatively-charged  amino  acids,  which  have  a  repelling  rather  than 
attracting effect on heparin binding.
A  basic  cluster  containing  Lys30,  Arg35  and  Arg39  was  expected  to  contribute 
significantly to the interaction with heparin [119].  Although this VEGF species retained 
the ability to induce TF expression, the mutation of these residues clearly had a detrimental 
effect  on  the  secondary  structure  of  mutant  K30A/R35A/R39A,  as  demonstrated  by 
circular dichroism (CD) analysis. Arg35 takes part in the formation of a short a-helix that 
packs against the two-stranded P-sheet in the C-terminal subdomain [119]. The substitution 
of Arg35, together with Lys30 and Arg39, may have disrupted the integrity of the helix, 
which  is reflected by a  significant reduction  in  a-helical  content relative to  VEGF 164. 
Nevertheless,  mutant  K30A/R35A/R39A  partially  retained  heparin-binding  activity  at
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physiological salt concentration in the solid phase assay, indicating that this region does 
not  constitute  a  major  heparin-binding  site.  In  contrast,  mutants  R13A/R14A  and 
R14A/R49A  displayed  a  marked  decrease  in  heparin-binding  affinity.  The  binding  of 
R14A/R49A to soluble heparin in the presence of 0.15  M NaCl was reduced to  a level 
where Kd values were not measurable, and the triple mutant R13A/R14A/R49A failed to 
bind  heparin  at  physiological  salt  concentration  in  two  independent  in  vitro  heparin- 
binding  assays.  The  observed binding  at  low  salt  concentration  (0.1  M  NaCl)  and  its 
elution at 0.52 M NaCl may be explained by non-specific electrostatic interactions with the 
matrix under low-stringency conditions. The lack of binding at higher ionic strength might 
have been due to the saturation or shielding of these sites.
Taken  together,  these  data  suggest  the  existence  of  a  principal  heparin-binding  site 
consisting of Argl3, Argl4 and Arg49, with potential binding energy contributions from 
Arg46. Argl4 and Arg49 may constitute a ‘minimal’ binding site. The residues, although 
non-contiguous  in  sequence,  are  located  along  the  interface  of the  clearly  defined  N- 
terminal and C-terminal subdomain and form a continuous binding surface.  Support for 
this model comes from a recent publication presenting a refined NMR solution structure 
and a much-improved definition of the mutual  orientation of the  subdomains  [120].  In 
contrast to the original  structure  [119], the refinement revealed that the heparin-binding 
residues  (i.e.  Argl3,  Argl4  and  Arg49)  are  in  close  contact  with  each  other.  Spatial 
proximity of heparin-binding residues in the three-dimensional structure is characteristic 
for many heparin-binding proteins [296-299]. The nature of basic residues appears to be an 
important factor for this interaction. Arginines bind more tightly than lysines because they 
have a higher potential to form hydrogen bonds. In addition, the guanidinium group may
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form a stronger electrostatic interaction with the sulfate anion than the ammonium group 
[300], It should be mentioned that other residues may also contribute to the free binding 
energy by providing  non-electrostatic  interactions  with heparin  and  glycosaminoglycan 
chains, including hydrophobic contacts and hydrogen bonds.
3.3.2 Implications for neuropilin-1 binding by VEGF164
Based  on  the  results  from  the  competition  binding  assay,  it  was  concluded  that  the 
interaction  of VEGF 164  with  neuropilin-1  is  of high-affinity.  This  was  an  unexpected 
result,  considering  that  VEGF  is  thought  to  require  heparin  for  efficient  binding  to 
neuropilin-1  [301]. The finding is also in striking contrast to the low affinity of VEGF 165 
to  mouse neuropilin-1,  which has been reported  in  a binding  study using the BIAcore 
system  [186].  This discrepancy may be explained by a lower affinity of mouse and rat 
neuropilin-1  (used  in  this  study)  for  human  VEGF  compared  to  human  neuropilin-1, 
although this has not been confirmed. In light of these findings, the IC50 numbers obtained 
with this approach should be regarded as relative values rather than absolute values. The 
binding affinity of all  mutant VEGF proteins to  immobilized neuropilin-1  was reduced 
between 2.5-fold (K26A) and 115-fold (R13A/R14A/R46A/R49A) compared to VEGF 164, 
suggesting that the neuropilin-1 and the heparin-binding epitopes are overlapping. Still, all 
mutants retained significant neuropilin-binding activity.
Information regarding the requirements for VEGF binding to neuropilin-1  at a molecular 
level  is  mainly based  on  the  observation  that  VEGF  and  semaphorin  3A  compete  for 
neuropilin-1 binding at the bl domain. Since binding of semaphorin 3 A is mediated by its
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basic C-terminal tail, it has been hypothesized that competition between the two molecules 
results from binding of basic amino acids to a shared electronegative binding surface on 
neuropilin-1  [302,  303]. The data presented here suggest that electrostatic forces play a 
significant role, and that the neuropilin-1  -binding site of VEGF 164 may contain residues 
that also promote heparin binding. This hypothesis still agrees with the observation that 
heparin  potentiates  the  binding  of VEGF 165  to  the  bl/b2  domain  [173],  because  the 
heparin- and VEGF-binding sites of neuropilin-1 may be non-overlapping. In this context, 
it  would  be  interesting  to  investigate  whether  heparin  still  has  the  ability  to  increase 
neuropilin binding of the  heparin-binding-deficient  VEGF  mutants.  On the other hand, 
since the electropositive b2 domain of neuropilin-1   also contributes to the binding energy 
[173], the participation of non-basic residues cannot be ruled out.  Interestingly, a recent 
study  showed  that  neuropilin-1  is  able  to  bind  strongly to  the  heparin-binding  site  of 
several other proteins, including FGF-1, -2, -4, and -7 as well as FGFR-1  and hepatocyte 
growth  factor  (HGF)  [304].  The  authors  observed  that  these  interactions  could  be 
diminished by competition with heparin and concluded that binding may occur through a 
‘heparin mimetic’ site in neuropilin-1. This site might act as a scaffold for growth factor- 
receptor complexes and confer on certain proteins a general modulatory activity.  Such a 
heparin-mimicking  site might be non-specific  and interact with its binding partners  by 
means of charge-charge complementarity.  It is not known whether VEGF falls into this 
class of binding partners.
The  prediction  that  heparin  and  neuropilin-1  share  partially  overlapping  binding  sites 
within the exon 7-encoded domain implies that the generation of highly selective heparin-
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or  neuropilin-binding-deficient  mutants,  which  could  be  used  as  tools  to  dissect  the 
functions of the two binding properties of VEGF, may not be feasible.
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4.1 Introduction
In the previous chapter I described the design and production of VEGF 164 HBD mutant
forms and their characterization with respect to their heparin-  and neuropilin-1-binding
activity.  For the investigations into the biological implications of the VEGF 164 HBD,  I
  — ■
selected two mutants,  R14A/R49A and R13A/R14A/R49A to use as biochemical tools. 
The selection was made based on the following key experimental findings: both mutants 
lost their ability to bind heparin at physiological salt concentration in vitro: both displayed 
significant  binding  affinity  for  neuropilin-1;  and  both  retained  secondary-structure 
conformation and TF induction activity comparable to wild-type VEGF 164.
In  the  studies  described  in  this  chapter,  I  further  characterized  R14A/R49A  and 
R13A/R14A/R49A by assessing their interactions  with cell-associated  HSPGs  using  an 
assay  that  is  better  suited  to  simulate  the  in  vivo  heparin-binding  capacities  of these 
proteins than the heparin-sepharose column or the filter trapping assay.  In addition, the 
effects of the mutations in the C-terminus on binding to VEGFR-1  and VEGFR-2 were 
studied in a cell-free binding assay. Finally, the potencies of the mutants to stimulate blood 
vessel  growth  in  an  ex  vivo  model  of angiogenesis  in  comparison  to  VEGF 120  and 
VEGF 164 were also determined .
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4.2 Results
4.2.1  Binding  of  VEGF164  HBD  mutants  to  HSPGs  on  PAE 
cells
To further characterize the function of the mutants, I examined whether the loss of heparin 
binding  displayed  by R14A/R49A  and  R13A/R14A/R49A  translates  into  an  inability to 
interact  with  cell-associated  HSPGs.  For  this  experiment,  native  PAE  cells  were  used 
because these cells lack expression of VEGFR-1, VEGFR-2  and neuropilin-1  [143, 256]. 
The  amount  of  VEGF  bound  to  HSPGs  was  determined  by  assaying  the  VEGF 
concentration in the medium after enzymatic treatment of the cells with heparinase I  and 
III. VEGF 120, which lacks the HBD, was released from PAE cells by heparinase treatment 
at a significantly lower level than was wild-type VEGF 164 (1.67 ± 0.65 (mean ± SD) pM 
and 5.17 ± 0.81  pM,  respectively; Figure 4.1). The values obtained for the mutants were 
not significantly different from those of VEGF 120,  at  1.9 ±  1.27 pM (R14A/R49A)  and 
1.17 ± 0.42 pM  (R13A/R14A/R49A),  suggesting that these mutations are as effective at 
disrupting HSPG binding as is complete loss of the HBD.
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Figure  4.1  Interaction  of  R14A/R49A,  R13A/R14A/R49A  and  wild-type  VEGF 
isoforms with  cell-associated HSPGs.  Confluent porcine aortic  endothelial (PAE) cells 
were  incubated with purified  VEGF variants  (7.14  nM)  in binding buffer (pH  7.5)  and 
treated with heparinase I and III (0.5 U/ml). The supernatant containing dissociated VEGF 
(white bars)  and the  final  wash  fraction  (grey bars)  were  collected  and  the  amount  of 
VEGF in both fractions was measured in a mouse VEGF-specific ELISA. Average values 
with standard deviations derived from three independent experiments are shown. Statistical 
significance (*P<0.05) was detennined using the Bonferroni test.
4.2.2  Analysis of VEGFR-2 binding by VEGF164 HBD mutants
Next, I sought to establish whether the mutations in R14A/R49A and R13A/R14A/R49A 
have an impact on interactions with VEGFR-2.  To this end,  I assayed the ability of the 
mutants and wild-type isoforms to compete with l23I-VEGF165 for binding to immobilized 
VEGFR-2 using a microtiter plate format. This inhibition binding assay was preferred to a 
direct binding assay as it does not require labeling of the mutant proteins.
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Both mutant and wild-type VEGF variants were able to completely inhibit I25I-VEGF165 
binding to VEGFR-2 (Figure 4.2). Receptor binding by radiolabeled VEGF 165 was half- 
maximally displaced by VEGF 164 at a concentration of 0.081 ±0.016 (mean ± SEM) nM 
(IC50). The lack of the HBD had no significant effect on the binding affinity, as indicated 
by the IC50 value for VEGF 120 (0.071 ±0.013 nM). These data are in good agreement with 
those  reported  previously  for  the  human  VEGF  isoforms  [118].  As  expected,  receptor 
binding by the VEGF HBD mutants was not significantly affected (0.099 ± 0.013 nM and 
0.064 ± 0.013  nM  for R14A/R49A  and  R13A/R14A/R49A, respectively),  which further 
confirms that binding of VEGF to VEGFR-2 occurs independently of a functional HBD.
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Figure 4.2 Binding of R14A/R49A, R13A/R14A/R49A and wild-type VEGF isoforms 
to VEGFR-2. Competitive displacement of l23I-VEGF165 binding to immobilized mouse 
VEGFR-2/Fc with various concentrations of Pichia-derived VEGF 164 (black), VEGF 120 
(red),  R14A/R49A  (green),  and  R13A/R14A/R49A  (blue).  Specific  binding  was 
determined  by  subtracting  the  background  signal  (non-specific  signal  obtained  in  the 
presence  of 400  nM  of VEGF 164)  from  raw  signal  values.  Non-linear  regression  and 
analysis of binding parameters using the one-site competition model were performed with 
GraphPad  Prism  software.  Data (mean ±  SEM)  are representative of three  independent 
experiments performed in triplicates.
4.2.3  Analysis of VEGFR-1 binding by VEGF164 HBD mutants
VEGFR-1  binding  has  been  shown  to  differ  significantly  between  VEGF 165  and  the 
shorter isoform VEGF 121  [118].  Here, competition binding analysis demonstrated a 3.5- 
fold reduction in competitive binding activity of VEGF 120 compared to VEGF 164 (IC50:
0 . 0 7 7   ± 0 . 0 1 8   ( m e a n   ±  S F .M )   nM, and  0 . 0 2 2   ±   0 . 0 0 3   nM for  V E G F  1 2 0   and  V E G F  1 6 4 , 
respectively; Figure 4 . 3 ) .  The mutants R 1 4 A / R 4 9 A  and R 1 3 A / R 1 4 A / R 4 9 A ,  too,
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Figure 4.3 Binding of R14A/R49A, R13A/R14A/R49A, and wild-type VEGF isoforms 
to VEGFR-1. Competitive displacement of l25I-VEGF165 binding to immobilized mouse 
VEGFR-1/Fc  with  the  indicated  concentrations  of  Pichia-derived  VEGF 164  (black), 
VEGF 120  (red),  R14A/R49A  (green),  and  R13A/R14A/R49A  (blue).  Curve  fitting  and 
analysis of binding parameters were done as described in Figure 4.2. Data (mean ± SEM) 
are representative of three independent experiments performed in triplicates.
exhibited decreased binding to VEGFR-1, with IC50 values similar to those of VEGF 120 
(0.092  ±  0.024  nM  and  0.151  ±  0.049  nM  for  R14A/R49A  and  R13A/R14A/R49A, 
respectively). These results indicate that both the loss of the HBD and mutations within 
this  domain  negatively  affect  VEGFR-1  binding  by  VEGF,  with  the  triple  mutant 
exhibiting an approximately 7-fold reduction in potency compared with VEGF 164.  The 
VEGF receptor binding assays were performed in the absence of heparin; thus,  charged 
residues  important  for  heparin  binding  appear  to  be  directly  contributing  to  the  high 
affinity interaction with VEGFR-1.
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4.2.4 Characterization of VEGF164 HBD mutants in an ex vivo 
model of angiogenesis
Next,  the  potential  of the  double  and  the  triple  mutant  to  promote  angiogenesis  was 
assessed in  a rat  aortic  ring organ culture model.  Rat  aortic  rings  can be  stimulated to 
generate  microvessel  outgrowth  and  formation  of  a  network  composed  of  branching 
endothelial  tubes  [305,  306].  The  assay recapitulates  many of the  in  vivo  processes  of 
angiogenesis,  including  cell  proliferation,  migration  and  lumen  formation.  It  also 
recapitulates the in vivo process of vessel formation in that non-endothelial cells, including 
fibroblasts,  smooth muscle cells  and pericytes,  also contribute to the differentiation  and 
maturation of the microvasculature, and is therefore well  suited to assess the angiogenic 
potency of VEGF variants [307, 308].  Segments of the aorta were embedded in collagen 
and equimolar amounts of VEGF120, VEGF164, R14A/R49A or R13A/R14A/R49A were 
added to the cultures every 48 hr. After 7 days in culture, branching microvessel networks 
extended mostly from the edges of the rings and were surrounded by elongated, fibroblast- 
like cells (Figure 4.4 A). Treatment with either VEGF120 or VEGF164 induced a 3.5-fold 
or  3.6-fold  increase  in  total  micro  vessel  length,  respectively,  compared  to  PBS-treated 
rings  (Figure 4.4  B).  The R14A/R49A and R13A/R14A/R49A mutants were  5-fold and 
4.6-fold  more  potent  than PBS,  respectively,  at promoting  sprouting  angiogenesis.  The 
HBD  mutants  therefore  exhibited  a  comparable,  if  not  more  potent,  activity  to  that 
observed for VEGF 120 and VEGF 164. No gross differences in sprout morphology were
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Figure 4.4 Potency of recombinant VEGF164 HBD mutants and wild-type isoforms at 
stimulating  angiogenesis  ex vivo.  Freshly prepared rat aortic  rings  were embedded in 
collagen and incubated with serum-free medium in the presence or absence of the indicated 
VEGF  variants  (4.4  nM)  for  seven  days.  Microvessel  sprouts  were  visualized  using 
fluorescently labeled isolectin B. (A, left panels) Representative images of aorta explants 
captured using epifluorescence microscopy (lOx). Fibroblast-like cells were present but are 
not visible in these images.  (A, right panels) RGB  images were converted to grayscale 
images  and blood vessels were traced for quantification using Photoshop  (Adobe).  (B) 
Quantification  of  microvascular  outgrowth.  The  total  length  of  traced  vessels  was 
determined from the images obtained at day 7  (n = total number of rings taken from 4 
animals, * P< 0.001).
detected when rings from different treatment groups were compared (Figure 4.4 A). These 
data demonstrate that heparin-binding activity of VEGF 164 is not required for stimulation 
of ex vivo angiogenesis in this assay.
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4.3 Discussion
4.3.1 Differential binding of VEGF variants to HSPGs in vitro
This study has shown that the lack of heparin-binding of VEGF 120 and the VEGF 164 
HBD mutants observed in the previous chapter, correlated with a significant reduction in 
PAE cell-surface binding activity compared to VEGF 164. Moreover, the lack of heparin- 
binding residues  in  the  mutants  had the  same  effect  as  complete  loss  of the  HBD  in 
VEGF 120, indicating that association with these cells was mediated by a native HBD. This 
interaction  was  dependent  on  heparan  sulfate  proteoglycans,  as  shown  by  heparinase 
treatment to digest HS chains, and did not depend on the presence of VEGF receptors. 
Thus, the increased binding of VEGF 164 in this assay reinforces a mechanism whereby 
VEGF is stored on the cell-surface and can be rapidly released from this site to initiate 
blood vessel growth and sprouting.
The interstitial matrix that is being produced by cultured endothelial cells also contains 
binding partners  that act to  sequester VEGF.  In this  extracellular matrix  compartment, 
VEGF  not  only  binds  to  HSPGs  directly,  but  also  indirectly  through  other  ECM 
components,  such as fibronectin,  suggesting additional mechanisms for the retention of 
VEGF 164 by PAE  cells  [309,  310].  Fibronectin-binding activity at neutral pH has  also 
been shown for VEGF121  [311], which may explain the residual binding of this isoform 
and the heparin-binding-deficient mutants observed in the assay, as this interaction does 
not appear to be mediated by the HBD. Overall, these findings represent an indication of 
the differential ability of the VEGF variants to recognize and interact with matrix- and cell- 
surface-associated HS chains in vivo.
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4.3.2  Mutations  in  the  VEGF164  HBD  affect  binding  of 
VEGFR-1 and VEGFR-2 differently
Because of the cardinal role of the two major VEGF receptors in VEGF biology, I resorted 
to a competition binding assay to gauge the receptor-binding potential of the VEGF 164 
HBD mutants. These assays were conducted in the absence of heparin, therefore all effects 
regarding  receptor  binding  affinities  are  due  directly  to  changes  in  ligand-receptor 
interaction. The finding that binding of R14A/R49A and R13A/R14A/R49A to VEGFR-2 
was not compromised supports previous data suggesting that the VEGF C-terminal domain 
is not directly involved in receptor binding [118]. The HBD has, however, been implicated 
in control of endothelial cell proliferation, a response mediated by VEGFR-2  signaling. 
Keyt and colleagues noted that loss of the HBD in VEGF121 was associated with a 100- 
fold  reduced  potency  in  endothelial  cell  proliferation  [118].  In  my  hands,  VEGF 120 
showed no decrease in binding to VEGFR-2.  Moreover, in the TF induction assay, but not 
in the aortic ring assay, VEGF 120 was only slightly diminished in its potency compared 
with VEGF 164.  These data are consistent with a more recent report demonstrating that 
VEGF 120 and VEGF 164 have similar potency in endothelial cell proliferation assays [61] 
Thus, it is possible that the recombinant VEGF121  protein used by Keyt et al  had lost 
some of its activity during bacterial expression and subsequent refolding.
Unlike  VEGFR-2,  VEGFR-1  is  bound  by  soluble  VEGF 120  and  the  heparin-binding 
VEGF 164 with different affinities, though the variation observed in my experiment was 
less  dramatic  than  the  16-fold  difference  reported  by  Keyt  et  al.  [118]  (for the  same 
potential reason as mentioned above). The increased affinity of VEGF 164 for VEGFR-1 
compared to VEGF 120 has been linked to the presence of the HBD in VEGF 164  [118,
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312]. The loss of wild-type affinity for this receptor in the double and triple mutant further 
supports this theory. Although the HBD peptide does not directly interact with VEGFR-1 
[118],  its  conformation  within  VEGF 164  appears  to  enhance  receptor  binding.  It  is 
conceivable  that  this  domain  is  folded  in  such  a  way  that  it  contributes  directly  or 
indirectly to the binding energy of the VEGFR-1-VEGF interaction, but not to the binding 
energy in the VEGFR-2-VEGF complex.
4.3.3  Heparin-binding-deficient  VEGF164  mutants  are  potent 
stimulators of ex vivo angiogenesis
Blood vessel growth in the aortic ring assay approximates in vivo angiogenesis in that it 
involves  microvascular  sprouting,  branching  and  capillary  tube  formation  [305]. 
Measurement of total vessel length demonstrated that R14A/R49A and R13A/R14A/R49A 
possess an angiogenic activity similar to that of native VEGF 164. The slightly enhanced 
potency  of  the  mutants,  although  not  significant,  could  be  indicative  of  differential 
bioavailability  of the  VEGF  variants  in  the  extracellular  environment.  Whereas  some 
VEGF 164 may be sequestered in the matrix  in an inactive form,  requiring cleavage of 
extracellular  matrix  components  for  release  from  these  stores  [258],  heparin-binding- 
deficient mutants may be more freely available for interaction with their receptors.
In  view  of the  decreased  VEGFR-1  binding  activity  of the  HBD  mutants,  these  data 
underline  the  considerable  experimental  evidence  which  shows  that  the  growth  and 
proliferative  signals  are  predominantly  mediated  by  VEGFR-2  [143,  160,  312]. 
Furthermore,  the  fact  that  both  mutants  exhibited  significant  reduction  in  binding  to
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heparan sulfate on endothelial cells implies that this activity of VEGF 164 is not essential 
for VEGFR-2-mediated  functions  such  as  TF  induction,  VEGFR-2  binding,  and  vessel 
growth  from  ex  vivo  aortic  tissue.  These  findings  agree  with  observations  that  neither 
exogenous heparin nor cell surface-associated heparan sulfates are necessary for VEGF 165 
binding to cell surface-expressed VEGFR-2, and that heparin-binding ability of VEGF 165 
may only be required under conditions in which oxidative damage occurs [247]. Similarly 
VEGF-E, a VEGFR-2 specific ligand which lacks the HBD and only weakly interacts with 
neuropilin-1, promoted migration and sprouting of endothelial cells in HUVEC spheroids, 
and stimulated angiogenesis in vivo as potently as did VEGF 165  [313]. These results do 
not  imply  that  heparin  binding  has  no  role  in  vessel  growth.  Indeed,  heparin-binding 
functions of VEGF are required for guiding developing vessels where precise and directed 
branching morphogenesis  is critical  [61].  Rather,  these  findings  emphasize the need  for 
more detailed  studies  examining  the  function of VEGF-heparin  interactions  at  different 
stages during vessel development.
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5.1 Introduction
To investigate the effects of the VEGF 164 HBD mutants on vessel growth in vivo, I chose 
to  study  angiogenesis  in  the  context  of the  eye.  The  mouse  or  rat  retina provides  an 
excellent model tissue for studying angiogenesis as the progress of blood vessel growth 
can be monitored by angiography or fundoscopy and the entire retinal vasculature can be 
viewed  in  flat-mounted  retinal  preparations.  The  sequence  of  vascularization  during 
postnatal development is well-characterized, and several murine models of retinopathies 
have been developed.
VEGF and its receptors are constitutively expressed in the retina of the normal eye [314, 
315].  Blood vessels  in the adult eye  are relatively resistant to neovascular stimuli,  but 
when  the  retina  is  made  hypoxic  or  ischemic,  VEGF  levels  increase  and  induce 
physiological vascular development or pathological neovascularization [87, 271]. Similarly, 
when  VEGF  levels  are  increased  experimentally by  intraocular  injection  or transgenic 
overexpression,  this  stimulus  triggers  the  pathological  neovascularization  observed  in 
ischemic  retinopathies  [316-318].  Pathological,  but  not  physiological,  retinal 
neovascularization is characterized by increased levels of the VEGF 164 iso form [273]. The 
highly regulated expression pattern of the VEGF isoforms in normal development appears 
to be disrupted in certain disease conditions, leading to inflammation-associated invasion 
of retinal blood vessels into the vitreous. Both in vitro data and experiments using mouse 
models of diabetes demonstrated that VEGF 164 is more potent than VEGF 120 at inducing 
retinal and corneal inflammation [273, 275]. This isoform-specific inflammatory response 
is  causally  linked  to  the  pathogenesis  of  vascular  leakage  and  blood-retinal  barrier
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breakdown  [278].  The  ‘pathological’  activity  of VEGF164  in  the  eye  has  not  been 
investigated in greater detail, nor have the mechanisms underlying this isoform-specific 
effect been elucidated. Using genetically modified mice and the HBD mutants, I conducted 
in vivo structure-function studies testing the hypothesis that the heparin-binding function of 
VEGF 164 is responsible for heightened inflammation in the retina and thereby contributes 
to the pathological role of the VEGF 164 isoform in retinal neovascularization.
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5.2 Results
5.2.1  Characterization  of  retinal  neovascularization  in 
VEGF120 188 mice in a model of ischemic retinopathy
To further investigate the importance of VEGF 164 in ocular disease, VEGF 164-deficient 
mice  (VEGF  )  were  analyzed  in  a model  of OIR,  in  which  the  process  of retinal 
neovascularization  can  be  recapitulated  experimentally  [254,  274,  284].  In  this  model, 
newborn mice on day P7 are exposed to an environment containing 75% oxygen for 5 days 
(Figure 5.1). During this time vessel regression occurs, most likely through apoptosis of
PO P6 P7 P11 P12  P17
Room air 
1
Hyperoxia
1
i
Room air 
(Relative hypoxia)
Normal vessel 
growth
Retinal vessel 
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I
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Figure  5.1  Timeline  of  vessel  formation  in  a  mouse  model  of  oxygen-induced 
retinopathy (OIR).  Schematic representation of the protocol  developed by Smith et al. 
[274]. Experimental mice are exposed to a hyperoxic environment (75% O2) on postnatal 
day 7 (P7) for a 5-day-period. The vessels respond by undergoing severe vasoconstriction. 
When normal oxygen is restored (PI2), relative hypoxia triggers an ischemic condition in 
the retina,  where tufts of vessels grow through the  internal  limiting membrane  into the 
vitreous (from P14 onward). The hypoxia-induced neovascular response normally peaks at 
P17.
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endothelial cells following cessation of VEGF production by neuroglial cells. After return 
to  room  air  for  an  additional  5  days  (relative  hypoxia),  prominent  retinal 
neovascularization  caused  by  increased  VEGF  production  is  observed  in  100%  of the 
animals between P17 and P21.
To determine whether lack of VEGF 164 alters the retinal neovascular phenotype observed 
in the OIR model, retinal flat mounts of VEGF1 2 0  1 8 8  littermates were examined at P12 and 
PI7. Figure 5.2 shows the vaso-obliteration in the retina at the end of the hyperoxic phase 
at P12 in wild-type and VEGF120/188 mice (A and B). At this time point (P12), the avascular, 
non-perfused area in the centre of the retina surrounding the optical nerve disc was similar 
in both wild-type (4.98 ± 0.52  (mean ± SEM) mm2) and mutant mice (4.7 ± 0.32 mm2; 
Figure  5.3  E,  left  panel).  Upon  return  to  normoxic  conditions,  physiological 
revascularization  extended parallel  to  the  retinal  surface  towards  the  optic  nerve.  New 
vessel growth occurred predominantly in the mid-periphery, at the junction of the perfused 
and  the  non-perfused  areas  of the  retina.  At  PI7,  the  extent  of revascularization  was 
significantly (P<0.01) higher in VEGF1 2 0  1 8 8  retinas than in wild-type retinas (30.7 ± 1.3% 
vs. 22.9 ± 1.9%; Figure 5.2 C-E).
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Figure 5.2 Retinal neovascularization in wild-type and VEGF120/188 mice in the OIR
model. Wild-type and VEGF 164-deficient (VEGF120,188) mice were treated according to 
the timeline described in Figure 5.1. Mice were perfused with FITC-coupled Con A lectin 
at P12 and PI7, then retinal whole mounts were examined by fluorescence microscopy. 
(A-D) Panels show representative images of each time point. At the end of the hyperoxic 
period (PI2), obliteration of the central retinal vasculature resulted in an avascular area of 
similar  size  in  both  animals.  At  PI7,  the  extent  of physiological  neovascularization
i on/i sq (revascularization)  was  greater  in  VEGF  mice  than  in  wild-type  mice.  (E)  The 
avascular  area  at  P12  was  measured  using  NIH  Image.  The  revascularized  area  was 
expressed as a percentage of the whole retinal surface and quantified using the following 
formula: (vascularized area at P17 -  vascularized area at P12)/total retinal area at PI7. N 
indicates number of animals analyzed and data are expressed as mean ± SEM. Scale bar, 
200 pm.
The pathological neovascular response in the oxygen-injured retinas develops similarly to 
the physiological revascularization but is characterized by the formation of neovascular 
tufts within the superficial capillary network between PI7 and P21.  In wild-type retinas 
subjected to OIR conditions, extensive tuft formation was observed at PI7 in the vascular 
region adjacent to  the central  avascular zone (Figure  5.3  A,  arrows).  This process  was
1  9n/| oo  #
almost completely suppressed in retinas of VEGF  mice (Figure 5.3 B), demonstrating 
the  importance  of VEGF 164  for pathological  vessel  growth.  To  further  confirm  these 
observations, serial cross sections of eyes were prepared and retinal neovascularization was 
analyzed  by  immunohistology.  Normal  revascularization  was  observed  in  both  animal 
genotypes,  with blood vessels branching out from the retinal  surface toward the deeper 
layers (inner plexiform layer and inner nuclear layer, Figure 5.3 C and D). Wild-type OIR 
mice  showed  a  robust  neovascular  response,  with  vessels  breaking  through  the  inner 
limiting membrane and extending into the vitreous cavity (Figure 5.3 C, arrows).
148Chapter 5 In vivo functional analysis of the VEGF 164 heparin-binding domain
Wild-type P17  VEGF120/188  P17
1 ? n /i 8   si Figure 5.3  VEGF  mice with  ischemic  retinopathy  show  no  significant signs  of
•   1  9 A / 1  8 8 pathologic  neovascularization.  Wild-type  and  VEGF164-deficient  (VEGF  )  mice 
were treated according to the timeline described in Figure 5.1  and euthanized on day PI7. 
(A and B) Fluorescein angiography of retinal flat mounts and magnification of the leading 
edge of the growing vasculature. Arrows indicate neovascular tufts in the superficial layer
1  AA/ I OO
of wild-type retinas, which are absent in the retinas of VEGF  mice. (C and D) Eyes of 
PI7  animals were enucleated and cut  in  sections.  Blood vessels  in tissue sections  were 
immunostained with an anti-PEC  AM antibody.  Tuft formation (arrows)  can be seen just 
anterior to the inner limiting membrane (ILM)  of wild-type, but not mutant,  retinas.  V, 
vitreous;  ILM,  inner limiting membrane;  IPL,  inner plexiform layer;  INL,  inner nuclear 
layer; ONL, outer nuclear layer. Scale bar, 25 pm.
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120/188 In  contrast,  VEGF  mice  showed  little  or no  tuft  formation  on  the  retinal  surface 
(Figure 5.3 D).
5.2.2  VEGF120/188  mice  display  normal  physiological
neovascularization
To  exclude  the  possibility  that  the  lack  of pathological  vessel  growth  in  VEGF 164- 
deficient mice is the result of a decreased angiogenic capacity, I examined the process of 
vascular  outgrowth  during  retinal  development  in  these  mice.  Figure  5.4  shows  the 
physiological retinal vascularization of wild-type and VEGF1 2 0  1 8 8  mice at P5 (Figure 5.4 A 
and B) and P10 (Figure 5.4 C and D) as monitored by perfusion-labeling and imaging of 
flat mount preparations. The outgrowth of retinal capillaries of VEGF1 2 0  1 8 8  mice reached 
51.3 ±  1.1  (mean ±  SEM) % of the retinal radius at P5, whereas that of wild-type mice 
reached 49.5 ± 2 % (Figure 5.4 E, left panel). There was no significant difference in mean 
vascular density between wild-type (28.4 ± 0.3%) and VEGF1 2 0 7 1 8 8  retinas (28.8 ± 0.4%) at 
P5 (Figure 5.4 E, right panel). These findings complement previous data showing vascular 
retinal development in these mice at P10 [273]. At P10, the superficial vessels had already 
reached  the  edge  of the  retina  and  the  extensive  vascular  network  in  the  VEGF 164- 
deficient retina was essentially indistinguishable from that of the wild-type mice (Figure 
5.4 C and D).  In addition, no significant difference was observed in the formation of the 
deep vascular plexus between the two mouse strains (Figure 5.4 C and D, arrowheads).
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Figure 5.4 Retinal vascular development in VEGF wild-type and VEGF120/188 mice 
(A-D) VEGF wild-type and VEGF12 0  1 8 8  mice were perfused with FITC-coupled Con A 
lectin at P5  and  P10.  The  retinal  vasculature  was  then  visualized  in retinal  flat-mount 
preparations  by  fluorescence  microscopy.  Arrowheads  indicate  areas  where  superficial 
vessels branch out to form the deep vascular plexus. (E) Vascular development at P5 (left 
panel) was quantified by measuring the length of eight vessels, each going in a different 
direction. The length of these vessels was expressed as a percentage of the radius of the 
retina.  Vascular density  (right panel)  was  determined by measuring  the  total  length of 
vessels in 4 different areas (each 200 pixel2 ) and was expressed as a percentage of the total 
area using NIH  image.  Data are  expressed as means ± SEM of 12  eyes  (n=6  animals). 
Scale bar: 200 pm.
Taken together, these data demonstrate that VEGF 164 deficiency has no significant effect 
on physiological neovascularization and suggest that the pathological phenotype observed 
in OIR wild-type mice is VEGF 164 isoform-specific.
5.2.3  VEGF164  is  responsible  for  increased  leukostasis  in  the 
hypoxic retina
Ishida  et  al.  [273]  demonstrated  that  hypoxia-induced  VEGF  expression  leads  to  the 
recruitment  of leukocytes to  sites  of pathological  retinal  neovascularization  in  rats.  To
further explore the role of VEGF 164 as a critical stimulus for leukocyte stasis in retinal
120/188  •  • neovascularization, I analyzed leukostasis in VEGF 164-deficient (VEGF  ) mice using 
the OIR model. Leukocyte adhesion was examined in lectin-perfused retinas after 48 hr of 
relative hypoxia (PI4).
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*  120/188  In wild-type and VEGF  control mice, the number of adherent leukocytes per retina
was  17.4  ± 2.1  (mean ±  SEM)  and  25.4  ± 2.2,  respectively (Figure  5.5  A,  B  and  F).
Quantitative analysis of leukostasis in wild-type mice subjected to OIR conditions revealed
a 4^3-fold increase in leukocyte adhesion over baseline levels. Only a 1.4-fold increase was
observed in VEGF 164-deficient OIR mice, suggesting that VEGF 164 is responsible for the
induction  and  amplification  of  leukostasis  in  this  model  (Figure  5.5  F).  Adherent
leukocytes were predominantly found in the revascularizing retina at the leading edge of
the vascular zone.  Interestingly,  during  the progression  of retinal  neovascularization  in
wild-type  OIR  mice,  leukocytes  were  frequently  found  associated  with  vascular  tufts
(Figure 5.5 E).
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Figure  5.5  Retinal  leukocyte  adhesion  in  wild-type  and  VEGF120/188  mice  with 
ischemic retinopathy. (A and B) Few leukocytes (arrows) adhere to the retinal vasculature
1  ?n/1 ft#
of wild-type and VEGF  mice under normal conditions. On the indicated days, OIR 
mice  and  non-OIR  control  mice  were  perfused  with  PBS  to  remove  non-adherent 
leukocytes, then perfused with FITC-coupled Con A lectin to identify adherent leukocytes 
in the retinal vasculature. Retinas were flat-mounted and images were captured using an 
epifluorescence  microscope.  Note  that  control  animals  had  already undergone  vascular 
pruning by PI4, leaving behind a less dense and smaller-caliber vasculature than that of the 
experimental group in which this process was delayed. (C and D) 48 hr after the return to 
room air, leukocyte adhesion in ischemic wild-type mice was significantly higher than in
•   •   i  ?n/i k r ischemic  VEGF  mice.  (E)  Leukocytes  adhering to  vascular tufts in ischemic  wild- 
type mice  during progression  of retinal  neovascularization  (PI7).  (F)  Quantification  of 
total leukocyte adhesion per retina at PI4.  N indicates the number of animals.  Data are 
expressed as mean ± SEM. Scale bar, 10 pm.
5.2.4 Characterization  of  heparin-binding-deficient  VEGF164 
mutant activity in a leukocyte recruitment assay
Intraocular administration of VEGF 164 induces a specific inflammatory response that is 
stronger than that resulting from VEGF 120 injection  [275,  278].  This is not surprising, 
given  the  particular  requirement  for  VEGF 164  in  pathological  neovascularization.  To 
assess  whether  the  HBD  is  responsible  for  this  inflammatory  effect,  the  mutants 
R14A/R49A  and  R13A/R14A/R49A  were  tested  for  their  ability  to  induce  leukocyte 
adhesion to the retinal endothelium. Equimolar concentrations of purified, sterilized VEGF 
variants were administered intravitreally into rats, and leukocyte accumulation in the retina 
was analyzed after 24, 48, and 72 hr by in vivo leukocyte fluorography.
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As shown in Figure 5.6 A, VEGF164-induced leukostasis in the retinal microvasculature 
peaked at 48 hr after injection (52.6 ± 8.3 (mean ± SEM) leukocytes/mm2 retinal surface 
area) and was 3-fold higher than that induced by VEGF 120 (17.7 ± 2.7 leukocytes/mm2). 
When  compared  with  control  mice  injected  with  inactivated  VEGF 164,  these  findings 
indicate that the effect was specific and directly caused by active VEGF. These data are 
comparable with results reported previously in which VEGF 164 induced a 1.9-fold greater 
increase in leukostasis than did VEGF 120 [278]. In contrast, the VEGF 164 FIBD mutants 
R14A/R49A and R13A/R14A/R49A were increasingly less effective at inducing leukocyte 
recruitment  to  the  retinal  capillary  bed  compared  to  VEGF 164.  Only  31.9  ±  5.1 
leukocytes/mm  and  13.1  ±  1.6 leukocytes/mm  were counted 48 hr after injection of the 
double mutant and the triple mutant, respectively (Figure 5.6 A, F and G).
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Figure  5.6  Leukocyte  recruitment  to  the  rat  retinal  vasculature  after  intravitreal 
injection  of  wild-type  and  mutant  VEGF  variants.  (A)  Time  course  of  leukocyte 
dynamics after intravitreal injection of 2 pmol of purified, Pichia-dQrived VEGF variants. 
The dosage was determined based on a previous report describing leukostasis in the retina 
after VEGF  injection  [276].  VEGF 164  inactivated by  boiling  for  10  min  served  as  a 
control. Leukocytes were labeled by injecting acridine orange intravenously 30 min before 
scanning laser ophthalmoscopy. To evaluate retinal leukostasis, the number of fluorescent 
dots within 8 areas (each 200 pixel2) at a distance of 5 disc diameters from the edge of the 
optic disc was counted.  These numbers were converted to  leukocytes/mm2  by using the 
formula:  1  pixel = 3.2 pm2. At least 6 eyes were counted per time point and VEGF variant. 
(B-L) Representative acridine orange leukocyte fluorography images of the eye fundus 48 
hr after intravitreal  injection of 2 pmol (B-G)  or 20 pmol  (H-L)  VEGF  (Rats were not 
injected with 20 pmol of K26A). Adherent leukocytes appear as white dots (arrows). No 
increase in leukostasis was observed in 20 pmol vs. 2 pmol injected eyes.  Scale bar:  500 
pm.
Next,  I  determined  whether  the  reduced  potency  of the  two  mutants  with  respect  to 
leukostasis was specifically associated with alterations in the region implicated in heparin 
binding.  The  single  mutant  K26A  was  used  for  comparison,  since  binding  studies 
described in chapter 3  indicated that Lys26 is not part of the heparin-binding site. K26A 
retained  wild-type potency 48  hr  after  injection  of 2  pmol  (51  ±  7.9  leukocytes/mm2; 
Figure  5.6A),  suggesting  that  Argl3,  Argl4  and  Arg49  constitute  residues  that  are 
important for mediating the pro-inflammatory activity of VEGF 164. The reduced ability of 
the mutants to induce leukostasis was observed even after injecting 20 pmol of protein 
(Figure 5.6 K and L).
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To identify the type of infiltrating leukocytes in the retinal  vasculature,  weight-matched 
mice  were  perfused  with  FITC-labeled  Con  A  24  hr  after  intravitreal  injection  of 
VEGF 164,  allowing  visualization  of  the  retinal  vasculature  and  leukocytes.  Double­
labeling  with  the  pan-macrophage  marker  F4/80,  followed  by  superimposition  of the 
images  from  Con  A  perfusion,  identified  the  majority  of the  lectin-stained  leukocytes 
inside  blood vessels  as  F4/80-positive  monocytes/macrophages  (Figure  5.7,  right panel, 
arrows).  The  F4/80-negative  leukocyte  population  infiltrating  the  retinal  vessels  likely 
consists of neutrophils and lymphocytes.
B l & W j
Figure 5.7 Identity of endothelium-associated leukocytes in the retina after VEGF164 
injection.  Mice were  injected  intravitreally with VEGF 164  (2  pmol)  and perfused with 
FITC-coupled Con A lectin (green fluorescence, left panel) 24 hr later. Retinal flat mounts 
were probed with an anti-F4/80 antibody (red fluorescence, middle panel). Arrows indicate 
F4/80/lectin-positive  macrophages/monocytes,  whereas  F4/80-negative  leukocytes  are 
marked by arrowheads in the superimposed image (right panel).  Scale bar: 50 pm.
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5.2.5  Analysis  of  VEGF  receptor  involvement  in  VEGF164- 
induced leukostasis
In  an  attempt  to  examine  the  involvement  of individual  VEGF  receptors  in  mediating 
VEGF164-induced  leukostasis,  rat  eyes  were  injected  with  VEGF  receptor-selective 
ligands  of the  VEGF  family  of  growth  factors.  Both  VEGFR-1-specific  P1GF-1  and 
VEGFR-2-specific  VEGF-E  exhibited  only  a  weak  stimulatory  effect  on  leukocyte 
recruitment,  which  was  comparable  to  that  of  VEGF120  (Figure  5.8  A).  A  ten-fold 
increase in the injected dose (20 pmol) of either ligand did not result in an increase  in 
leukocyte accumulation (data not shown). Since VEGF-E and VEGF have been shown to 
bind VEGFR-2 with similar affinity, resulting in receptor phosphorylation and subsequent 
activation of signaling processes [313], these results suggest that the activation of VEGFR- 
2 alone is not sufficient to elicit a potent inflammatory response in the retina. In contrast to 
P1GF-1, mouse P1GF-2 displayed similar kinetics to, and was as potent as, VEGF 164 in 
inducing leukostasis (55 6 ± 7.3 (mean ± SEM) leukocytes/mm2 at 48 hr). P1GF-2 is bound 
by VEGFR-1  and the neuropilins, and is the only P1GF splice form able to interact with 
heparin [127]. No macroscopic signs of inflammatory reactions, such as corneal opacity, 
were detected,  indicating that the retinal  inflammatory response induced by P1GF-2 was 
direct.
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Figure 5.8 Induction  of retinal leukostasis  by VEGF  receptor-selective ligands. (A)
Time course of leukostasis after intravitreal injection of 2 pmol of PIGF-1  (human), P1GF- 
2 (mouse) or VEGF-E (ORF-virus) into rats. Values for VEGF 164 (inactivated), VEGF 120 
and VEGF164 are shown for comparison. Analysis and quantification of leukostasis was 
conducted as described in Figure 5.6. Bars represent mean values ± SEM. At least 5 eyes 
were analyzed in each group. (B-D) Representative acridine orange leukocyte fluorography 
images of the retinal vasculature at 48 hr after injection. Leukocytes appear as white dots. 
Scale bar: 500 pm.
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Because  the  different  potencies  of  the  P1GF  isoforms  with  respect  to  their  pro- 
inflammatory  activities  may  result  from  species-  and/or  isoform-specific  differences  in 
their affinities for VEGFR-1, competition binding assays were conducted to assess relative
p c
binding  affinities  for  VEGFR-1.  In  this  assay,  I-VEGF165  was  used  because 
radiolabeled P1GF was not available. As shown in Figure 5.9, the ability of mouse PIGF-2 
to  compete  with  125I-VEGF165  for  binding  to  VEGFR-1  was  comparable  to  that  of 
VEGF 164 and independent of the species origin of the receptor. The IC50 values for P1GF- 
2 were 0.11 ± 0.02 (mean ± SEM) nM, and 0.11 ± 0.02 nM for binding to human VEGFR- 
1,  and  mouse  VEGFR-1,  respectively.  PIGF-1  on  the  other  hand,  displayed  a  weaker 
affinity for the human form of the receptor (0.88 ± 0.37 nM), and was approximately 100 
times less potent than PIGF-2 in competing with VEGF 165 for binding to mouse VEGFR- 
1   (9.9 ±5.6 nM), which shares a high degree of sequence homology with the rat receptor 
[319]. Thus, the difference in VEGFR-1-binding affinity may account for the differential 
potency of PIGF-1 and PIGF-2 in the leukocyte recruitment assay.
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Figure 5.9 Characterization of PIGF-1 and PIGF-2 binding to immobilized VEGFR-1.
Competitive displacement of l25I-VEGF165  binding to immobilized human (h) VEGFR- 
1/FC  (left panel) and mouse (m) VEGFR-1/FC  (right panel) in the presence or absence of 
increasing concentrations of PIGF-1, mouse PIGF-2 or VEGF 164 was carried out in a 96- 
well microtiter plate.  Curve fitting and analysis of binding parameters using the one-site 
competition  model  were  performed  with  GraphPad  software.  Specific  binding  was 
determined  by  subtracting  the  background  signal  (non-specific  signal  obtained  in  the 
presence of 400 nM VEGF 164) from raw signal values. Data points (means ± SEM) are 
from triplicate wells and are representative of three independent experiments.
Previous studies have demonstrated that P1GF and VEGFR-1  are involved in a variety of 
inflammatory conditions [167,  168, 320], and that comeal inflammation after VEGF pellet 
implantation  was  suppressed  by  selectively  blocking  VEGFR-1  activity  [275].  In 
combination with the finding that both VEGF 164 HBD mutants show decreased VEGFR- 
1-binding  affinity,  the  data  presented  here  further  point  to  a  role  for  VEGFR-1  in 
VEGF164-induced retinal leukostasis. To test this hypothesis in mice, VEGFR-1 mediated 
responses  were blocked  in  vivo using  a mouse-specific  VEGFR-1  neutralizing antibody
163Chapter 5___________In vivo functional analysis of the VEGF 164 heparin-binding domain
[275]. Mice exhibited a different time course of leukostasis than rats (Figure 5.6) in that 
leukocyte  recruitment  peaked  at  24  hr,  as  determined  in  a  dose-response  experiment 
(Figure 5.10).  Injection of 4 pmol VEGF 164 caused retinal hemorrhage and non-specific 
leukocyte infiltration at 24 hr which was not observed after injecting 2 pmol VEGF 164 
(data not shown). An injection dose of 2 pmol  and a time point of 24 hr was therefore 
considered optimal.
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Figure  5.10  Time  course  and  dose-response  curve  of VEGF-induced  leukostasis  in 
mice. C57BL/6J male mice received intravitreal injections of 1, 2, or 4 pmol of VEGF 164, 
and  were perfusion-labeled  with  FITC-coupled  Con  A  immediately,  24  or 48  hr later. 
Retinal flat mounts were imaged with an epifluorescence microscope and the total number 
of adherent leukocytes per retina was determined. At least 5 eyes were analyzed in each 
group. Data points are represented as mean ± SEM.
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Weight-matched  mice  received  intraperitoneal  injections  of  the  antibody  3  hr  before 
intravitreal injection of VEGF 164. Systemic administration of the anti-VEGFR-1 antibody 
was necessary, as injection of the goat IgG control antibody into the mouse or rat vitreous 
induced  an  immune  response  in the eye.  Neither control  IgG  nor neutralizing  antibody 
caused local inflammation when injected into the mouse peritoneum. As shown in Figure 
5.11,  the VEGFR-1-blocking  antibody  suppressed VEGF164-induced retinal  leukostasis 
by  51%  compared  to  control  IgG  (28.5  ±  4.3  (mean  ±  SEM)  vs.  57.7  ±  9.5 
leukocytes/retina) when administered at a concentration of 1.5 mg/kg. A dose of 3 mg/kg 
of anti-VEGFR-1   did not further reduce the number of leukocytes recruited to the retinal 
vessels  (29.2  ±  4.2  leukocytes/retina).  These  findings  support  a  role  for  VEGFR-1  in 
VEGF164-induced  leukostasis,  but  given  that  VEGFR-1  blockade  did  not  completely 
abrogate leukostasis, it is likely that VEGF 164 exerts its pro-inflammatory activity in the 
eye by activating multiple pathways.
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Figure  5.11  Suppression  of  VEGF164-induced  retinal  leukostasis  by  blocking 
VEGFR-1  activity.  Mice received intraperitoneal injections of 0.3,  1.5, or 3 mg/kg of a 
goat anti-mouse VEGFR-1  neutralizing antibody (anti-VEGFR-1) or pre-immune control 
goat IgG (control IgG, 3 mg/kg) 3 hr before intravitreal injection of VEGF 164 (2 pmol) or 
PBS. The dosage of anti-VEGFR-1  antibody was based on similar experiments reported 
previously [275]. 24 hr after VEGF injection, adherent leukocytes in the retinal vasculature 
were imaged by perfusion-labeling with FITC-coupled Con A lectin. The total number of 
static leukocytes per retina was determined using an epifluorescence microscope. Numbers 
inside bars represent the number of eyes analyzed. Data are represented as mean ± SEM.
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5.2.6  Recombinant  VEGF164  HBD  inhibits  VEGF164-induced 
leukostasis
The results presented above indicate that the VEGF C-terminal domain either directly or 
indirectly mediates the pro-inflammatory activity of VEGF 164. To examine whether this 
region by itself can induce inflammation, the HBD of VEGF 164 was expressed in the yeast 
Pichia Pastoris as a recombinant fragment and injected into rats. As shown in Figure 5.12 
A,  intravitreal  injection  of 2,  10  or  50  pmol  of the  purified  peptide  did  not  increase 
leukostasis  significantly  above  the  control  level  shown  in  Figure  5.6  A  (inactivated 
VEGF164,  7.6  ±  2.1  (mean  ±  SEM)  leukocytes/mm2).  This  strongly  suggests  that  the 
VEGF HBD cannot exert its pro-inflammatory potential  independently of the N-terminal 
VEGFR-binding domain, but only within the context of the full-length protein.
Since  the  recombinant  HBD  lacks  the  ability to  induce  leukostasis,  it  may  be  able  to 
interfere with the pro-inflammatory activity of VEGF. To investigate this possibility, 2, 10 
or 50 pmol of recombinant HBD was injected intravitreally 2 min before VEGF 164 using 
an injection-delay technique that does not require removal of the needle between the two 
injections.  HBD  potently inhibited VEGF164-induced  leukocyte  adhesion to  the  retinal 
microvasculature in a dose-dependent manner (Figure 5.12 A and C-E). A 25-fold molar 
excess  of  the  HBD  monomer  (50  pmol)  over  the  VEGF  dimer  (2  pmol)  reduced 
VEGF164-induced  leukostasis  to  background  levels  (8.8  ±  2.13  (mean  ±  SEM) 
leukocytes/mm2 vs.  7.1  ± 2.6 leukocytes/mm2). These data suggest that the VEGF HBD 
might act as an  antiinflam m atory agent in  vivo  hv interfering with VEGF 164 activity in 
the eye.
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Figure  5.12  Inhibition  of VEGF164-induced  leukostasis  by  recombinant  HBD.  (A)
Purified HBD was injected intravitreally into rats at different concentrations either alone or 
2 min prior to injection of VEGF 164 (2 pmol). Leukostasis was evaluated after 48 hr by 
acridine orange leukocyte fluorography and scanning laser ophthalmoscopy as described in 
Figure 5.6. Numbers inside bars represent the number of eyes analyzed for each condition. 
Data  are  represented  as  mean  ±  SEM.  (B-E)  Representative  fluorescein  angiography 
images of the eye fundus show leukocytes (arrows) associated with the microvasculature. 
Scale bar: 500 pm.
5.2.7  Effect  of  recombinant  HBD  on  hypoxia-induced 
leukostasis in the mouse OIR model
Finally,  I  examined whether recombinant HBD  is  able to  reduce leukocyte recruitment
caused by hypoxia-induced upregulation of VEGF 164 in the eye [273]. As shown earlier,
•  120/188 leukocyte adhesion in the OIR model was elevated in wild-type but not m VEGF 
mice. To test the effect of the HBD on leukostasis in this model, wild-type mouse pups 
were taken out of the oxygen chamber on P12 and injected intraperitoneally with 2 nmol of 
the VEGF HBD at P12  and PI3  (hypoxic phase).  In parallel,  control groups received 5 
mg/kg of anti-VEGF neutralizing antibody or 5 mg/kg of a goat IgG control. Inflammatory 
cell recruitment to retinal vessels was visualized and quantified at PI4.
As  summarized in  Figure  5.13,  P14  mice  in the non-OIR  control  group  exhibited  low 
levels of leukostasis in the retina (16.1 ±2 (mean ± SEM) leukocytes/retina). The number 
of leukocytes was increased 4.3-fold (70 ± 4.8 leukocytes/retina) in OIR mice injected with 
IgG  from  non-immunized  goats,  which  served  as  an  isotype  control  for  the  VEGF 
neutralizing antibody.
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Figure  5.13  Suppression  of retinal  leukostasis  by  recombinant  HBD  in  mice  with 
oxygen-induced retinopathy. Oxygen-induced retinopathy (OIR) in mice was induced as 
described. The following injections were performed intravenously at P12  and PI3:  total 
goat IgG control (5 mg/kg), goat anti-mouse VEGF neutralizing antibody (5 mg/kg), and 
purified  HBD  (2  nmol).  Adherent  leukocytes  inside  retinal  vessels  were  visualized by 
perfusion of P14 mouse pups with FITC-coupled Con A lectin and quantified. Note that 
the total number of retinal vessels in OIR mice is lower than in non-OIR mice due to vessel 
regression during the hyperoxic phase. Numbers inside the columns represent number of 
eyes analyzed. Data are presented as mean values ± SEM.
These  levels  are  similar to  those  obtained  in  non-injected  OIR  mice  (Figure  5.5)  and 
demonstrate  that  the  control  antibody  has  no  effect  on  leukocyte  behaviour.  The 
administration  of  an  anti-VEGF  neutralizing  antibody  further  reduced  disease-related 
inflammation in the mouse retina compared to the IgG control by a total of 81% (12.8 ±
1.5 leukocytes/retina).  Strikingly, when OIR mice were injected with recombinant HBD
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and analyzed at 48 hr,  a reduction of leukocyte adhesion by 55% compared to the OIR 
control was observed  (31.8  ±  5.7  leukocytes/retina).  Due to  the elevated mortality rate 
among the OIR mouse pups, only one dose of HBD was tested in this experiment.
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5.3 Discussion
The  functional  importance  of the heparin-binding  forms  of VEGF  has  been  studied  by 
several groups using a variety of strategies, such as overexpression of single isoforms in 
cell  lines and tumors, proteolytic  removal  of the C-terminal domain and, most recently, 
transgenic  expression  of  only  one  isoform  in  mice  by  ‘knock-in’  mutation  of  the 
endogenous gene [118,  124, 254, 260, 263, 284]. Here, by combining in vitro and in vivo 
analysis using biochemical tools, I have shown that the heparin-binding domain mediates 
VEGF164-induced  retinal  leukostasis  and  is  critical  for  promoting  the  inflammatory 
activities of VEGF 164 in ocular pathology.
5.3.1  The  differential  requirement  of  VEGF164  in  retinal 
vascular  development  and  in  the  response  of  the  retina  to 
ischemia
Hypoxia-induced  VEGF  governs  both  retinal  vascular  development  and  pathological 
retinal  neovascularization  [321].  The  importance  of  the  VEGF 164  isoform  for  the 
pathogenesis of retinal neovascular diseases has been demonstrated in a number of studies 
[273,  275,  278].  Similar  observations  were made  here  by  studying  VEGF 164-deficient 
mice  in  a  well-characterized  mouse  model  of proliferative  retinopathy.  The  loss-of- 
function phenotype of these mice can be best summarized as a lack of neovascular tufts 
and a vastly reduced ability to recruit leukocytes to the ischemic retina. The absence of the 
pathological  phenotype  in  VEGF 164-deficient  mice  is  unlikely  to  be  the  result  of  a 
decrease  in  total  VEGF  expression  levels  compared  to  those  in  wild-type  mice,  since
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VEGF transcription levels in VEGF1 2 0  1 2 °, VEGF1 8 8  1 8 8  and VEGF+ + mice are comparable 
[254, 284]. Although other factors may contribute to the pathologic phenotype described 
here,  VEGF  appears to  be the only endothelial  cell  mitogen that  is  upregulated  in the 
hypoxic retina [322], Previously published VEGF isoform expression data are consistent 
with a major role of VEGF 164 in oxygen-induced retinopathies.  In the rat OIR model, 
repeated cycles of hyperoxic and hypoxic episodes were shown to result in significantly 
elevated  VEGF 164  mRNA  levels  relative  to  other isoforms,  and  this upregulation was 
maintained  through  the  time  of  maximal  neovascularization  [272,  273].  Whereas 
angiopathic changes were not analyzed in the present study, Tolentino et al.  showed that 
intravitreal  delivery  of VEGF 165  into  non-human  primates  stimulates  aberrant  blood 
vessel formation. The newly formed vessels showed features of proliferative retinopathy, 
including  vessel  dilation  and  tortuousity  as  well  as  preretinal  neovascularization 
originating from superficial veins and venules [323].
In contrast to the tightly regulated expression of VEGF 164 during development, hypoxic 
conditions  result  in  exaggerated  VEGF 164  levels  sufficient  to  generate  the  observed 
pathologic phenotype. Here, the inflammatory response observed in the OIR model could 
be  similarly reproduced by intravitreal  injections  of VEGF 164  into  normal  rats.  Using 
scanning laser ophthalmoscopy, a technique that allows the observation and quantification 
of leukocyte dynamics in vivo, a reliable and dramatic increase in leukocyte adhesion was 
observed after intravitreal delivery of Pichia-derived VEGF 164. VEGF 120 did not exert
1  70/1 this  effect.  Taken together with the observations made  in  VEGF  transgenic  mice, 
these data suggest that VEGF 164 is both required and sufficient for induction of retinal 
inflammation.  Because  inflammatory cells  clearly play  an  important role  in promoting
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neovascularization  [324,  325],  these  data  further  substantiate  the  essential  role  of the 
VEGF 164 iso form in pathological angiogenesis.  I therefore expect that the R14A/R49A 
and R13A/R14A/R49A mutants would be less potent than wild-type VEGF 164 at inducing 
pathological  neovascularization.  It would also be interesting to see whether injection of 
HBD in the OIR model will have a normalizing effect on aberrant blood vessel growth in 
addition to its anti-inflammatory effect.
Physiological  vascular  development  of the  retina  does  not  appear  to  be  a  VEGF 164- 
dependent process as development of superficial and deep retinal capillary beds were not 
compromised in VEGF 164-deficient mice. This observation supports previous data [273] 
and suggests that VEGF 164 function in normal vessel development can be replaced by the 
simultaneous expression of soluble (VEGF 120) and cell-associated (VEGF 188) isoforms. 
While VEGF 164 may not be required  for normal vascular development of the retina,  a 
recent  study showed that the retinal  vasculature  of mice  solely expressing  this  isoform 
(VEGF164/164) developed normally [254]. These findings may appear contradictory at first 
glance,  but they  suggest  a certain degree  of functional  redundancy between  the  VEGF 
variants  in  normal  retinal  angiogenesis.  The  observation  that  anti-VEGFR-2  antibody 
treatment does not affect developmental vessel morphology and growth also indicates that 
interaction  of VEGF  with  this  receptor  is  not  an  absolute  requirement  for  vascular 
development  in the  neonatal  retina  [326].  Normal  retinal  vascularization  is  likely to be 
more complex than pathological angiogenesis, and may require hypoxia-dependent and - 
independent stimuli and/or stimuli derived from non-endothelial cells, such as neuroglia, 
pericytes, and the retinal pigment epithelium [22].
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5.3.2  VEGF164  HBD  encodes  determinants  that  enhance  its 
pro-inflammatory properties
The results presented here reinforce the presence of HBD-encoded determinants that are 
indispensable  for  promoting  VEGF-induced  leukostasis.  The  leukostasis-inducing 
activities of the two VEGF 164 HBD mutants were not only severely impaired but also 
correlated with their respective heparin-binding potential, suggesting that binding to cell- 
associated  glycosaminoglycans  is  essential  for  this  function.  Two  major 
glycosaminoglycans,  heparan-sulfate  and  chondroitin-sulfate,  are  expressed  in  distinct 
spatiotemporal  patterns  in the retina during postnatal  development  and  in the  adult  rat 
[327]. Heparan sulfate is consistently found in the ganglion cell layer at the vitreoretinal 
interface  and in the inner nuclear layer  [328,  329].  In  the ganglion  cell  layer,  heparan 
sulfate  chains  are  likely  components  of the  basal  lamina  and/or  the  cell  surface  of 
endothelial cells in the superficial retinal vessels.
Upon injection, VEGF 164 is expected to penetrate the vitreoretinal membrane because of 
its low molecular weight and diffuse into the ganglion cell  layer, where it may interact 
with HSPGs on the superficial vasculature [330, 331]. Low-affinity binding of VEGF by 
HSPGs,  rather  than  the  less  abundant  high-affinity  signaling  receptors,  may  result  in 
increased levels of VEGF around the endothelium that would be available to  stimulate 
target  cells.  Compared  to  wild-type  VEGF 164,  which  binds  to  HSPGs,  the  mutants 
R14A/R49A and R13A/R14A/R49A may therefore be more rapidly cleared from the retina. 
Efforts to determine the diffusion rate of the VEGF variants after injection by comparing 
their  concentrations  in  the  vitreous  humor  and  the  retina  failed  due  to  difficulties  in
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separating these intimately attached compartments. Future work will seek to address the 
anatomical  distribution  of these  VEGF  variants  within the  retina  and the  type  of cells 
involved.
Recombinant HBD potently inhibited  VEGF164-induced leukostasis in a concentration- 
dependent manner but did not exert a visible effect on leukocyte recruitment when injected 
alone.  Thus,  it  appears  that  the  receptor-binding  domain  and  the  HBD  of VEGF 164 
represent two domains that act interdependently to amplify leukostasis and inflammation- 
driven  neovascularization  in  the  retina.  Given  the  complexity  of interactions  between 
VEGF  and  its  receptors  in  the presence  of heparin-like molecules,  one  could  imagine 
several mechanisms that could explain the enhanced activity of VEGF 164 relative to its 
HBD  alone.  In  addition to  facilitating  the  retention  of VEGF 164  on  cell  surfaces,  the 
interaction  with  glycosaminoglycans  of certain  chain  length  and  subtype  may  lead  to 
quantitative  and  qualitative  differences  in  receptor  engagement  and  signaling  output. 
Although it is not clear whether VEGF is able to oligomerize on glycosaminoglycans, the 
formation of such oligomeric structures may result in the activation of receptor-mediated 
and  specific  ‘pro-inflammatory’  signal  transduction  pathways.  In  this  model,  reduced 
activity of the  mutants  would  be  explained  by  the  inability of the  glycosaminoglycan 
chains to link the mutants into higher-order oligomers, due to the lack of heparin-binding 
epitopes.  It  follows,  then,  that recombinant  HBD  would  antagonize  VEGF164-induced 
leukostasis by competing with VEGF for binding to heparan-sulfate proteoglycans and/or 
neuropilin-1, without engaging signaling receptors. The importance of oligomerization for 
in  vivo  function  of certain  chemokines  has  been  demonstrated  by  analyzing  heparin- 
binding-deficient versions of RANTES/CCL5, MIP-lp/CCL4,  and MCP-1/CCL2. These
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mutants,  which  did  not  form  glycosaminoglycan-associated  oligomeric  complexes, 
activated receptors but were unable to induce inflammatory cell recruitment in a peritoneal 
recruitment assay [239, 332].
The type of proteoglycan involved, too, might influence signaling events. For example, the 
two cell-surface  HSPGs  syndecan and  glypican  are  equally capable  of forming ternary 
complexes  with  FGF-2  and  FGFR-1.  Yet  only  glypican-1,  which  is  also  known  to 
modulate the binding of VEGF 165 to VEGFR-2, is able to sensitize brain endothelial cells 
to FGF-2-induced mitogenesis [229, 333]. HSPG-mediated association of VEGF 164 with 
VEGF receptors may also  induce biologically relevant changes in auto-phosphorylation 
patterns  of  intracellular  receptor  domains  as  has  been  shown  for  FGF-2.  While  not 
essential for receptor dimerization and kinase activation, heparan sulfate is required for the 
phosphorylation of specific receptor substrates in response to FGF-2  [334, 335].  Similar 
roles  for  HSPGs  in  VEGF  signaling,  particularly with  regard  to  the pro-inflammatory 
activity of VEGF 164, have yet to be investigated.
Other mechanisms that may be operative in the generation of VEGF-induced leukostasis 
are  the  expression  or  translocation  of  endothelial  cell  adhesion  molecules,  including 
ICAM-1, VCAM-1, E-selectin, or P-selectin, and chemokines such as MCP-1, IL-8, and 
MIP-la  [276,  336-342].  A comparison of VEGF120  with VEGF164  demonstrated that 
VEGF 164  more  potently  induces  both  expression  of ICAM-1  and  translocation  of P- 
selectin to the surface of cultured HUVEC [275, 336, 338]. In vivo, VEGF 164 is known to 
induce ICAM-1  expression in the murine retinal vasculature [343] and increased levels of 
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during  experimental  diabetes,  where  the  VEGF 164  isoform  accounts  for  80%  of total 
VEGF  [279,  344].  ICAM interacts  with  activated CDlla-CD18  (LFA-1)  and  CD 11b- 
CD18 (Mac-1) integrins on rolling leukocytes which then firmly bind to the endothelium 
before transmigrating into the underlying tissue [345], indicating that increased leukocyte 
adhesiveness secondary to ICAM-1  upregulation may in part be responsible for the pro- 
inflammatory activity of VEGF 164.
Recent in vitro  data  suggest  a pivotal  role  for VEGFR-2  in  mediating VEGF-induced 
ICAM-1  expression  [275,  336].  VEGFR-2  expression  in  rodents  during  normal 
development has mostly been detected in the neural retina outside the microvasculature 
and, to a lower degree, in retinal vessels [151, 346, 347]. After hyperoxic insult, VEGFR-2 
immuno-reactivity is strongly elevated in intravitreal neovascular growth correlating with 
the high proliferative activity associated with this condition [326, 346]. While VEGFR-2 - 
mediated upregulation of adhesion molecules may play a role in VEGF164-induced retinal 
leukostasis,  the  reduced  ability  of VEGF-E  (isolate  D1701)  and  the  HBD  mutants  to 
induce leukocyte recruitment in  vivo  suggests that  activation of VEGFR-2  alone is not 
sufficient. Given the fact that VEGF 164 and mutant R13A/R14A/R49A are equally active 
in stimulating VEGFR-2-driven processes, such as endothelial cell proliferative pathways 
in  vitro  and  microvessel  growth  ex  vivo,  it  is  possible  that  the  HBD-dependent  pro- 
inflammatory pathway  induced  by  VEGF 164  is  distinct  and  different  from  its  HBD- 
independent  mitogenic  pathway.  Therefore,  the  increased  capacity  of  the  VEGF 164 
isoform to induce leukostasis does not originate from an elevated proliferative activity of 
VEGF 164.
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Because recombinant HBD does not interact with VEGFR-1 and VEGFR-2 directly [118], 
competition of HBD with VEGF 164  for binding to heparan sulfate and/or neuropilin-1 
may also have indirectly limited its access to one or both of the VEGF receptors.  The 
blockade of VEGF-neuropilin-1  interaction may impede VEGFR-2 downstream signaling 
by interfering with receptor coupling and/or the formation of a ternary complex [126, 187]. 
A similar mechanism has been proposed by Soker et al., who showed that a GST-fusion 
protein corresponding to the amino acid sequence of VEGF exon 7 and 8 not only inhibited 
cross-linking of 1251-VEGF165  to  neuropilin-1,  but also to  VEGFR-2,  without directly 
binding to VEGFR-2 [348]. Reports about an involvement of neuropilins in inflammation 
are limited. VEGF 165 may contribute to neutrophil adhesion to activated endothelial cells 
by inducing the translocation of P-Selectin to the endothelial cell surface primarily through 
activation of VEGFR-2. Binding of VEGF 165 to neuropilin-1 is thought to potentiate this 
effect as compared to VEGF121  [338]. In the eye, high transcript levels and a strong co­
localization of neuropilin-1  with VEGFR-2  mRNA can be  detected in neovascularized 
vessels  and  fibrovascular  tissue  in  two  mouse  models  of  proliferative  retinopathy 
suggesting a role for neuropilin-1  in regulating vascular density [280, 349]. On the other 
hand, a role for neuropilin-1 in retinal leukostasis may be difficult to reconcile with the fact 
that the adult quiescent retina expresses very low levels of neuropilin-1 [349]. Furthermore, 
mutant  R13A/R14A/R49A  was  inactive  in  the  leukocyte  recruitment  assay,  despite 
retaining  considerable binding affinity for neuropilin-1  in  vitro.  In the  current  study,  a 
PlGF-2-derived peptide that blocks VEGF binding to neuropilin-1  [185] was used in vivo 
to assess the role of neuropilin-1  in VEGF-induced leukostasis but yielded inconclusive 
results because it was found to also inhibit VEGF binding to heparin (data not shown). 
Further studies regarding the functional aspects of neuropilin-1  binding by VEGF in the
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eye as well as a possible involvement of neuropilin-2 in this process using more selective 
receptor antagonists are warranted.
The findings presented in this chapter are consistent with a significant role for VEGFR-1 
in VEGF-induced leukocyte recruitment and are in line with previous reports showing anti­
inflammatory effects of anti-VEGFR-1  treatment in  a variety of tissues  other than the 
retina [168, 275, 350]. In the present study, retinal leukostasis induced by VEGF164 was 
maximally reduced by 51% after systemic administration of an anti-VEGFR-1 neutralizing 
antibody. The incomplete inhibition of leukocyte infiltration may be partially attributed to 
the limited access of the antibody to the retinal tissue but also indicates the involvement of 
other  pathways  activated  by  VEGF.  While  the  latter  is  likely  the  case,  it  begs  an 
explanation for the apparently contradictory finding that both VEGF 164 and VEGFR-1 - 
selective  P1GF-2  exhibit  a  similar  dose-response profile  in  the  leukostasis  assay.  This 
discrepancy may be  explained by the  reported ability of P1GF-2  to  activate VEGFR-1 
differently than VEGF,  resulting in the  expression of distinct downstream target  genes 
[169]. P1GF-2 may also recruit a different subset of leukocytes.
VEGFR-1 is constitutively expressed in the normal retina, where it is associated with both 
microvascular and non-vascular structures in the inner nuclear layer as well as the ganglion 
cell  layer  and the  basement  membrane-rich  inner limiting  membrane  [315,  351,  352]. 
VEGFR-1  expression has been detected in arteries and veins and has been shown to be 
stimulated by hypoxia-inducible factors in vitro [254, 353]. Using the mouse OIR model, 
Carmeliet et al. reported that expression of membrane-bound VEGFR-1  was significantly 
upregulated in retinal vessels during ischemia [163], thus providing further support for an
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involvement of VEGFR-1 in mediating the inflammatory response in the hypoxic eye and 
after VEGF  injection.  VEGF  may  act  as  a  chemoattractant  for  inflammatory  cells  by 
ligating  and  stimulating  VEGFR-1,  which  is  expressed  on  the  monocyte/macrophage 
subpopulation  [154,  165].  Indeed,  immunostaining  of  retinal  flat  mounts  using  the 
macrophage marker F4/80  indicated  that the majority of leukocytes  that  adhere  to  the 
vessels  after VEGF  injection  are  of the  monocyte/macrophage  lineage.  Elevated  local 
VEGF  concentrations  thus  provide  recruitment  signals  for  differentiated  Fit-1+  
inflammatory cells to home to  future or ongoing inflammation.  During the recruitment 
process, monocytes/macrophages become activated and secrete more VEGF and other pro- 
inflammatory factors,  as  well  as  integrins  which  in  turn  further promote  inflammation 
[354-356]. The migration of monocytes in response to VEGF has been shown to require a 
functional VEGFR-1  tyrosine kinase domain [161]. Whether stimulation of this receptor 
subunit triggers  a  signaling  cascade that results in de novo  synthesis of gene products 
which are linked to the migratory activity of these cells has yet to be demonstrated.
From this discussion, it follows that the selective recruitment of leukocytes to VEGF 164 
may  lie  in  the  greater  affinity  of VEGF 164  for  VEGFR-1  compared  to  VEGF 120, 
R14A/R49A  and  R13A/R14A/R49A.  More  importantly,  the  examination  of  heparin- 
binding-deficient mutants suggests that, irrespective of the exact mechanism, the ability of 
VEGF 164  to  bind  to  HSPGs  in  addition  to  VEGFR-1  is  essential  for  its  leukostasis- 
inducing  activity.  By  binding  to  these  low-affinity  receptors  on  endothelial  cells, 
VEGF 164 may provide matrix- or cell-surface-associated guidance cues that facilitate the 
recruitment and retention of VEGFR-1-positive monocytes to the vessel-wall endothelium. 
The non-heparin binding VEGF forms would be unable to provide such cues because of
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their increased diffusibility. Interestingly, VEGF121  is able to cross-link to VEGFR-2 on 
HUVE cells but, unlike VEGF 164, not to VEGFR-1  [247]. This effect may be due to a 
lack of a heparin-binding domain which may be required to crosslink with the receptor via 
cell  surface HSPGs. In  vivo,  VEGFR-1  activation by VEGF 120  or HBD  mutants may 
therefore only be transient and insufficient to reach a critical threshold level necessary to 
elicit a certain effect. Lasting VEGFR-1  stimulation able to overcome the weak intrinsic 
kinase activity [143] may not be attained until the VEGF/VEGFR-1 complex is stabilized 
by  heparan  sulfate.  VEGF164-induced  VEGFR-1  signaling  thus  sustained  can  be 
quantitatively or qualitatively different leading to specific yet unknown effects on gene 
expression in endothelial cells or monocytes relevant to leukostasis.
Given the above discussion, it is becoming clear that the interaction of VEGF with HSPGs 
represents  a  significant  component  of  VEGF  biology.  With  regard  to  therapeutic 
intervention, interference with heparin binding of VEGF 164/165 may create a viable anti­
inflammatory strategy. Agents that specifically target the subdomain within VEGF that has 
been shown here to amplify inflammation and disease progression in the eye may prove 
beneficial  for  patients  with  ocular  vascular  disease  in  which  VEGF 165  expression 
predominates.  Possible  ways  of  intervention  can  be  the  inhibition  of  VEGF-binding 
epitopes on glycosaminoglycans by peptide derivatives, or the blockade of residues within 
the VEGF HBD by small molecule inhibitors and selective glycosaminoglycan mimetics. 
These alternative approaches may have the benefit of avoiding side effects resulting from 
pan-VEGF  inhibition  used  in  classical  anti-VEGF  therapies;  a  feature  that  may  be 
desirable considering the role of VEGF in survival and homeostasis.
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In conclusion,  I  have  shown here evidence indicating that the VEGF 164  HBD  and  its 
association with heparin-like molecules are required for mediating the pro-inflammatory 
potential of this isoform.  This finding is  surprising  as  glycosaminoglycans are obligate 
binding  partners  of  several  growth  factors  implicated  in  developmental  rather  than 
pathological processes. Although a link between VEGFR-1 and VEGF-induced leukostasis 
has been established in this study, contributions from other receptor systems, such as the 
neuropilins or VEGFR-2,  are  likely and need to  be investigated  in more detail.  Future 
studies will also have to address whether heparin binding is relevant to other inflammatory 
disorders related to VEGF. The present data also provide new insights into the mechanisms 
regulating the activity of VEGF in ocular disease.
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